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Executive summary/Abstract 
BACKGROUND 
Youth drug use is a severe problem worldwide. This review focuses on Cognitive-
Behavioural Therapy (CBT) as a treatment for young people who misuse non-opioid 
drugs, such as cannabis, amphetamines, ecstasy and cocaine, which are strongly 
associated with a range of health and social problems. CBT is an individualized and 
multicomponent intervention that combines behavioural and cognitive therapy. 
While behavioural therapy mainly focuses on external settings and observable 
behaviour, cognitive therapy is concerned with internal cognitive processes. The 
primary focus of CBT is to reduce users’ positive expectations about drug use, to 
enhance their self-confidence to resist drugs, and to improve their skills for 
problem-solving and for coping with daily life stressors.  
OBJECTIVES 
The objective of this review is to assess the effectiveness of CBT for young people 
(aged 13-21) in outpatient treatment for non-opioid drug use and to explore any 
factors that may moderate outcomes. 
SEARCH STRATEGY 
An extensive search strategy was used to identify qualifying studies. A wide range of 
electronic bibliographic databases were searched along with government and policy 
databanks, grey literature databases, citations in other reviews and in the included 
primary studies, hand searches of relevant journals, and Internet searches using 
Google. We also corresponded with researchers in the CBT field. No language or 
date restrictions were applied to the searches. 
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SELECTION CRITERIA 
Studies were required to meet several criteria to be eligible for inclusion. Studies 
must: 
 
 have involved CBT treatment for young people aged 13-21 years enrolled in 
outpatient treatment for non-opioid drug use; 
 have used experimental, quasi-randomised or non-randomised controlled 
designs; 
 not have focused exclusively on treating mental disorders; and 
 have had CBT as the primary intervention. 
 
DATA COLLECTION AND ANALYSIS 
The literature search yielded a total of 18,514 references, of which 394 were deemed 
potentially relevant and retrieved for eligibility determination. Of these, 360 did not 
fulfil the screening criteria and were excluded. Four records were unobtainable. A 
total of seven unique studies, reported in 17 papers, were included in the review. 
 
Meta-analysis was used to examine the effects of CBT on drug use reduction, social 
and family functioning, school problems, treatment retention and criminal activity 
compared to a group of other interventions (Adolescent Community Reinforcement 
Approach (ACRA), Chestnut Bloomington Outpatient (CBOP) (+Assertive 
Continuing Care (ACC)), Drugs Harm Psychoeducation curriculum  (DHPE), 
Functional Family Therapy (FFT), Interactional Therapy (IT), Multidimensional 
Family Therapy  (MDFT), and Psychoeducational Therapy (PET)). 
RESULTS 
Our main objective was to evaluate the current evidence on the effect of CBT on 
abstinence and drug use reduction for young people in outpatient treatment for non-
opioid drug use. Seven randomised trials, involving 953 participants, were included 
in this review. Each of the seven included studies compared CBT to another 
intervention. We analysed the effects in the short term (from the start of treatment 
to up to 6 months thereafter), medium term (from 6 months to less than 12 months 
after the start of treatment), and long term (12 months or more after the start of 
treatment). 
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We analysed CBT that was delivered with an add-on component such as 
motivational interviewing (four studies) separately from CBT that was delivered 
without an add-on component (three studies). 
 
Based on meta-analysis of data from the four included studies analysing CBT with 
an add-on component, there was no evidence of a relative effect of CBT for the 
reduction of youth drug use frequency compared to other interventions (ACRA, 
CBOP (+ACC), DHPE, FFT and MDFT). The random effects standardized mean 
difference was -0.14 (95% CI -0.64, 0.36) for the short term based on four studies, -
0.06 (95% CI -0.44, 0.32) for the medium term based on four studies and -0.15 (95% 
CI -0.36, 0.06) for the long term based on two studies.  
 
Based on meta-analysis of data from the four included studies analysing CBT 
without an add-on component, there was no evidence of a relative effect of CBT for 
the reduction of youth drug use frequency compared to other interventions (IT, 
MDFT, and PET ). The random effects standardized mean difference was -0.13 (95% 
CI -0.68, 0.42) for the short term based on two studies, -0.08 (95% CI -0.48, 0.31) 
for the medium term based on three studies and 0.02 (95% CI -0.48, 0.52) for the 
long term based on two studies.  
 
Thus, the available data does not support the hypothesis that there is a drug use 
reduction effect from using CBT with young drug users compared to other 
interventions (ACRA, CBOP (+ACC), DHPE, FFT, IT, MDFT, and PET ). 
 
Statistically significant heterogeneity was present in the short term. In the medium 
term statistically significant heterogeneity was present between studies analysing 
CBT with an add-on component. In the analysis of studies without an add-on 
component there was no statistically significant heterogeneity in the medium term. 
Due to the low power of detecting heterogeneity with only two studies included in 
the analysis, this result should be interpreted with caution. There was no 
heterogeneity between studies in the long term; however, with only two studies 
included in the analyses the power to detect heterogeneity was low. 
 
The primary outcome measured as recovery could only be analysed in the long term.  
The meta-analysis of CBT with an add-on component was inconclusive as the eight 
different comparison combinations analysed showed different results. Only one 
study analysing CBT without an add-on component provided data on recovery 
status. The reported effect was not statistically significant. 
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Several sensitivity analyses were performed with respect to analysis method, risk of 
bias, and intervention characteristics. None of the results from these sensitivity 
analyses changed the overall conclusions. 
 
No statistically significant differences between CBT, with or without an add-on 
component, and the comparison interventions (ACRA, CBOP (+ACC), DHPE, FFT, 
IT, MDFT, and PET ) were found for the secondary outcomes of psychological 
problems, family problems, school problems, risk behaviour (related to crime) and 
retention. No studies reported on other adverse effects, such as suicide or overdoses.  
 
AUTHORS’ CONCLUSIONS  
Based on the seven studies included in this review, there was no evidence that CBT 
interventions perform better or worse than the comparison interventions (ACRA, 
CBOP (+ACC), DHPE, FFT, IT, MDFT, and PET ) with respect to reduction in young 
people’s drug use.  
The evidence drawn from this systematic review is based on seven included studies 
analysed in two separate analyses, depending on whether the intervention was CBT 
with an add-on component such as motivational interviewing (four studies) or CBT 
without an add-on component (three studies). The seven studies are very different in 
terms of their findings regarding the effects of CBT interventions compared to other 
interventions (ACRA, CBOP (+ACC), DHPE, FFT, IT, MDFT, and PET ) on young 
people’s drug use. Therefore, the overall conclusion regarding the effect of CBT 
interventions compared to these other interventions on drug use reduction for young 
people aged 13 to 21 years should be interpreted with caution. The conclusions that 
can be drawn would be more convincing if more studies were available.
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1 Background 
1.1  DESCRIPTION OF THE CONDITION 
Youth drug use1 that persists beyond curious experimentation is a severe problem 
worldwide (United Nations Office of Drugs and Crime [UNODC], 2010). Drugs such 
as cannabis, amphetamines, ecstasy and cocaine, referred to in this review as non-
opioids2, are widely available and used among young people in western countries 
(European Monitoring Centre for Drugs and Drug Addition [EMCDDA], 2010; 
Substance Abuse and Mental Health Services Administration [SAMHSA], 2010). 
Non-opiates such as amphetamines, cocaine, ecstasy and cannabis, characterised by 
young people as social drugs, are often taken in recreational settings such as dance 
clubs and at music events. For young people, these non-opiates are often associated 
with “pleasure” and experimental drug taking (Østergaard & Bastholm Andrade, 
2011; Järvinen & Ravn, 2011). However, non-opioid drug use, like the use of other 
drugs, is strongly associated with a broad range of health and social problems 
including delinquency, poor scholastic attainment and suicide (Deas & Thomas, 
2001; Essau, 2006; Rowe & Liddle, 2006; Shelton, Taylor, Bonner & van den Bree, 
2009). 
 
The 2009 US National Survey on Drug Use estimated that 21.8 million (8.7 percent) 
people in the US aged 12 or older had used drugs during the past month. The most 
commonly used drug was marijuana: in 2009, 16.7 million people aged 12 or older 
(6.6 percent) used marijuana in the past year. In the same year, 1.6 million people 
aged 12 or older (0.7 percent) used cocaine, 760,000 (0.3 percent) used ecstasy, and 
502,000 (0.2 percent) used methamphetamine. The highest rate of drug use in the 
US was found among persons aged 18 to 20 years. In this age group, 22.2 percent 
used drugs, while the rate was 10 percent among 12 to 17 year olds (SAMHSA, 
2010)3. 
 
The European Monitoring Report estimated that 19.5 million (30.9 percent) of 
Europeans aged 15-24 years have used cannabis at some point in their life, with the 
highest prevalence in the Czech Republic, France, Denmark and Germany 
                                                          
1The terms use, abuse and dependence are used interchangeably throughout the review and refer to an addiction 
stage of non-medical usage. 
2Use of ketamine, nitrous oxide and inhalants, e.g. glue and petrol will not be considered in this review. 
3Statistics on drug use are mainly based upon subjective measures such as self-reported survey data and surrogate 
indices. 
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(EMCDDA, 2010). Within the month preceding the survey, 5.5 million (8.4 percent) 
young people in Europe aged 15-24 years had used cannabis. Synthetic drugs were 
the second-most used drug (EMCDDA, 2010). In 2009, 2.5 million (1.7 percent) of 
European 15-34 year-olds used ecstasy, 1.5 million (1.2 percent) used 
amphetamines, and 3 million (2.3 percent) used cocaine (EMCDDA, 2010). 
 
Non-opioid substances are associated with varying patterns of behaviour and the 
potential for addiction (Kosten, Sofuoglu, & Gardner, 2008; Rawson & Ling, 2008; 
Weaver & Schnoll, 2008). While for some young people drug use is controlled and 
part of developmental experimentation that will not constitute a clinical problem, a 
proportion of these users will advance to more serious levels of drug use that will 
require treatment at some point in the future (Järvinen & Ravn, 2011; Labouvie & 
White, 2002; Shelder & Block, 1990; Yamaguchi & Kandel, 1984).  
 
The treatment needs of young people differ from those of adults because of their 
unique stage of psychological and physical development, and researchers thus 
advocate distinct interventions for this population (Holmbeck, O’Mahar, Abad, 
Colder & Updegrove, 2006; Knudsen, 2009). Kendall (2006) argues that it is not 
enough to encourage young people to gain insight into their drug taking and ask 
them to consider changes to address their occasional problematic drug use without 
providing them with opportunities to practice new coping skills intended to 
compensate for cognitive limitations and distortions closely linked to their 
developmental stage. Other researchers concur with the need for practice-oriented 
and targeted treatment interventions that are developmentally appropriate for this 
population (Weisz & Hawley, 2002; Holmbeck et al., 2006, Shirk & Karver, 2006). 
Cognitive-Behavioural Therapy (CBT) interventions include a variety of such 
practical elements. As a structured yet flexible, individualized and multicomponent 
intervention, CBT is adaptable and can be tailored to deal with the challenges 
associated with specific substances and the individual needs of young people. 
 
The focus of this review is on young people enrolled in treatment for drug use, 
regardless of how their problems are labelled. Enrolment of a young person in 
treatment denotes that the degree of drug use has caused that person or a significant 
other close to him/her (parent, teacher, social worker, etc.) to seek out treatment. 
This review will focus on CBT delivered as an outpatient treatment4. In order to 
avoid duplication of effort, this review will focus primarily on non-opioid drug use5. 
                                                          
4A Cochrane review in progress will evaluate CBT for substance abuse in young offenders (Campbell, Macdonald, 
Minozzi, Gardner, & Taylor, 2010).  
5A Cochrane review evaluated psychosocial treatments for opiate abuse and dependence (Mayet, Farrell, Ferri, 
Amato, & Davoli, 2010), another will evaluate psychosocial treatments for drug and alcohol abusing adolescents 
(Minozzi, Amato, Vecchi, & Davoli, 2011), and another psychosocial interventions for benzodiazepine harmful use, 
abuse or dependence (Darker, Sweeney, Barry, & Farrell, 2012).  
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1.2  DESCRIPTION OF THE INTERVENTION 
In CBT interventions, drug use is perceived as a complex, multi-determined, 
cognitive and behavioural pattern influenced by several domains, including family 
history, environmental genetic factors, and comorbid psychopathologies that all play 
a contributing role in the development of and/or perpetuation of drug use (Carroll, 
2008). The primary focus of CBT is on reducing users’ positive expectations about 
drug use, enhancing their self-confidence to resist drugs, and improving their 
problem-solving skills and skills for coping with daily life stressors (Moos, 2007; 
Kaminer, Burleson, Blitz, Sussman & Rounsaville, 1998a). 
 
CBT aims to address the learned association between drug-related cues or stimuli 
and drug use by understanding and changing undesirable cognitive and behavioural 
patterns (Carroll, 2008; Shirk & Karver, 2006). CBT combines behavioural and 
cognitive therapy; while behavioural therapy mainly focuses on external settings 
and observable behaviour, cognitive therapy is concerned with internal cognitive 
processes. 
 
Behavioural therapy 
Behavioural therapy was developed from the ideas of classical and operant 
conditioning (Poulsen, 2006; McGuire, 2000). In classical conditioning, behaviour 
is believed to be affected by stimulus-response mechanisms in the immediate 
surroundings of the individual; for instance, urges and cravings for drugs can be 
perceived as responses to external stimuli cues (Sherman, Jorenby & Baker, 1988). 
Identifying external stimuli cues would enable the individual to avoid settings that 
work as triggers to drug taking (Carroll, 2008). Operant conditioning is based on 
associations within a context of events (such as an antecedent stimulus) between a 
given behaviour and its consequences (Skinner, 1988). Rewards (that is, responses 
perceived as pleasurable in some way) work as positive reinforcers of a particular 
behaviour. If the psychological effect of a drug is experienced as pleasurable, this 
will work as a positive reinforcement of drug-using behaviour (Waldron & Kaminer, 
2004). Likewise, if drug use relieves anxiety, for example, this will work as a 
negative reinforcement of drug-using behaviour, assuming that anxiety is aversive. 
In a treatment context, non-drug using behaviour is rewarded and thus reinforced. 
 
Cognitive therapy 
The hypothesis behind cognitive therapy is that thoughts shape feelings and thereby 
behaviour, so that by changing thought patterns, behaviour can be changed as well 
(Beck, Wright, Newman & Liese, 1993; Kendall, 2006; Nielsen & Thomsen, 2005). 
Cognitive therapy was first used in the 1960s to treat depression, and has since been 
extensively modified and adapted to deal with a wide range of clinical problems and 
populations, including people with issues relating to drug use (Beck, 2008; 
Holmbeck et al., 2006; Weisz & Hawley, 2002). 
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Cognitive and behavioural therapy  
The foundation and premise of CBT for drug use is that cognitive techniques and 
skills training can tackle drug-related beliefs and the automatic thoughts that lead to 
urges and cravings, while additional behavioural techniques can address actions that 
interact with the individual’s cognitive processes that trigger and maintain drug 
using behaviour (Beck et al., 1993). Irrational and erroneous assumptions can cause 
and/or maintain undesirable behaviour (Beck et al., 1993). CBT calls specific 
attention to the propensity among substance users to mistakenly believe that the 
perceived advantages of using drugs (such as pleasure and relief from anxiety) are 
greater than the disadvantages (e.g. financial, interpersonal), as such 
misconceptions help sustain the avoidance of a realistic assessment of the 
disadvantages (Beck et al., 1993; Carroll, 2008; Nielsen & Thomsen, 2005). Thus, it 
is believed that the users’ assessment of the potential for ceasing to use drugs might 
be based on cognitive distortions. In CBT, clients are helped to identify and 
challenge dysfunctional beliefs (such as, ‘I cannot be happy unless I am using,’ or, 
‘the withdrawal will be too painful,’) because thinking that one is incapable of 
controlling the urge to use drugs will create a self-fulfilling prophecy, as users who 
believe they are incapable of ending their drug use will not even try (Beck et al., 
1993). The common denominator in all CBT interventions is to make, create and 
support continuous positive change in the client’s feelings and behaviour by 
examining and reframing the basic maladaptive assumptions and thoughts 
underlying drug use (Beck, 2008; Carroll, 2008; Moos, 2007; McGuire, 2000). 
 
CBT outlines a pattern and series of phases of drug use, from the first stimulating 
cue to the actual act of drug using specific to the client. The activating stimulus can 
be external (such as a gathering of friends using cocaine) or internal (such as anxiety 
or boredom) (Beck et al., 1993; Beck, 2008; McGuire, 2000; Nielsen & Thomsen, 
2005; Carroll, 2008). These stimuli can trigger basic assumptions (e.g. ‘I am socially 
isolated,’) that trigger automatic thoughts (e.g. ‘a little cocaine will make me feel 
better,’) which in turn trigger cravings and permissive beliefs that make it easier for 
the person to engage in the behaviour (e.g. ‘it's okay as long as I don’t inject,’). The 
individual would then form a mental strategy for obtaining the drugs and the actual 
drug using act could then take place. CBT addresses this pattern of drug use by 
enlisting a number of techniques and strategies. The therapist can use training in 
problem solving, coping strategies, rehearsal, social skills and communication, as 
well as helping to respond to criticism and refuse drugs, to help the young person 
identify stimulating cues, discuss how to cope, and avoid drug taking behaviour. 
However, some stimulating cues (such as emotional states) may be unavoidable, and 
in such cases modifying the maladaptive beliefs and automatic thought patterns that 
maintain drug using behaviour would be equally important (Beck et al., 1993; Beck, 
2008; McGuire, 2000). 
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CBT components and therapy sessions 
CBT is a highly structured intervention and is organised closely around well-
specified and individualized treatment goals (Carroll, 2008). Each CBT session is 
structured by an articulated agenda and discussions remain focused around issues 
directly related to substance use. In some cases, the therapist may lead the therapy 
session with ‘motivational interviews’6 (Carroll, 2008; Nielsen & Thomsen, 2005). 
CBT interventions may include permutations of various components such as thought 
diaries, social skills training, problem solving strategies, coping strategies, self-
control and stress management techniques, and relapse prevention training. CBT 
has different modalities and can be implemented in an individual and/or group 
setting (Moos, 2007). 
 
 
Typical Therapy Sessions 
A therapy session typically (but not invariably) includes the following three parts: 
 
First, a client’s substance use and general functioning would be assessed (and would 
vary according to the degree of dependency and individual conditions). A specific 
cognitive technique that can help identify and modify drug-related beliefs is an 
‘advantages-disadvantages’ analysis (Beck et al., 1993). In this, the therapist guides 
the client through the process of listing and re-evaluating the advantages and 
disadvantages of drug use, and so helps the young person gain a more accurate, 
objective and balanced view of drug use. 
 
The second part of the therapy session is typically didactic in structure and devoted 
to skills training, coping and problem-solving strategies, and practice. One 
technique for examining beliefs and considering their validity in a more systematic 
way is ‘The Daily Thought Record’. Clients are asked to record their thoughts and 
feelings and then re-evaluate their validity, identify possible patterns of cognitive 
distortions, and develop strategies for change (Beck et al., 1993; Nielsen & Thomsen, 
2005; Carroll, 2008). The therapist may also encourage the client to try new 
behaviour patterns through role playing. This aims to teach the client new effective 
interpersonal skills, such as how to handle interpersonal conflicts without taking 
drugs and how to develop effective repertoires of social behaviour to reduce 
undesirable drug use and deal with relapse if it occurs (Beck et al., 1993; Kaminer & 
Waldron, 2006). 
 
The third part of the therapy session is usually dedicated to planning for the week 
ahead and discussing how new skills and strategies could be implemented (Carroll, 
2008). This kind of collaborative empiricism characterises CBT and is particularly 
important when dealing with young substance users in order to assist them in 
                                                          
6 Motivational interviewing (MI) is sometimes referred to as an independent treatment form but can also function as 
a component of other treatment forms including CBT. CBT interventions can use MI as a means to motivate clients 
for change. The aim of MI is to activate and capitalize on the client’s motivation and commitment to change and MI 
seeks to help clients resolve their ambivalence about change (Moos, 2007; Miller & Rollnick, 2002). 
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learning self-regulation and to exert self-control. However, this kind of collaboration 
may also be a point of concern for the intervention’s effectiveness, as participation in 
CBT demands a certain (above average) level of verbal articulation and self-
awareness (Nielsen & Thomsen, 2005). 
 
CBT interventions can range from 5 to 24 weeks in duration. Delivery can take place 
in the home or in community facilities, and can be delivered to individuals, groups 
or families, or a combination of these (Dennis et al., 2004; Carroll, 2008). 
Approaches that are purely behavioural (such as a stand-alone contingency 
intervention) will not be considered in this review. 
 
1.3  HOW THE INTERVENTION MIGHT WORK 
Existing research 
Along with a handful of other interventions, CBT is one of the most researched 
treatment forms in existence (Becker & Curry, 2008; Carroll, 2008). CBT has shown 
promising potential for young drug users in a number of primary studies (Kaminer 
et al., 1998a; Kaminer & Burleson, 1999; Waldron, Slesnick, Brody, Peterson & 
Turner, 2001; Kaminer, Burleson, & Goldberger 2002; Dennis et al., 2004; Liddle, 
Dakof, Turner, Henderson & Greenbaum, 2008; Latimer, Winters, D’Zurilla & 
Nichols, 2003). 
 
Several reviews (that for the most part lack pre-published protocols)7 on CBT 
interventions targeting young drug users already exist (Waldron & Kaminer, 2004; 
Vaughn & Howard, 2004; Becker & Curry 2008; Waldron & Turner 2008; Tanner-
Smith, Wilson & Lipsey, 2013). However, with only one exception (Waldron & 
Kaminer, 2004), all of the above focus broadly on psychosocial therapies in general, 
rather than CBT specifically. Generally, the most recent reviews conclude that CBT is 
associated with reduced drug use in young people (Waldron & Kaminer, 2004; 
Waldron & Turner, 2008; Tanner-Smith et al., 2013). 
 
The findings of the aforementioned studies and reviews indicate that CBT can 
reduce drug use in young people receiving treatment. However, closer interpretation 
of findings reveals a complex picture that is far from clear-cut: the reduction in 
young people’s drug use following CBT is relative to the comparison interventions 
used in the individual studies (Tanner-Smith et al., 2013) and dependent on the 
types of CBT interventions and modalities used in those studies. 
 
 
                                                          
7Although two Cochrane reviews have evaluated psychosocial/psychotherapeutic interventions for substance users, 
these reviews have focused on treatments for adult cannabis users (Denis, Lavie, Fatseas, & Auriacombe, 2006) and 
adult substance users with  severe mental illness (Cleary, Hunt, Matheson, Siegfried, & Walter, 2008) respectively. 
Moreover, the Cochrane reviews focus broadly on psychosocial/psychotherapeutic interventions for adults and not 
on CBT as a specific intervention for young people. In contrast, in our review we are only interested in CBT 
interventions that specifically target treating young people for non-opioid drug use. 
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CBT Mechanisms 
Lack of research on the mechanisms of change specifically underpinning CBT 
(Waldron & Kaminer, 2004) make any identification of key mechanisms speculative. 
Nevertheless, problem solving and coping strategy skills may be a key to change. 
Myers and Brown (1990) found that young drug abstainers and minor relapsers had 
higher levels of these skills than major relapsers and non-abstainers. The particular 
focus of CBT for substance abuse on problem solving, coping strategies, 
communication and social skills may support younger people positively in 
abstaining and dealing with possible relapse. 
 
Moderators 
Whether certain population characteristics moderate CBT outcomes for non-opiates 
remains largely unknown (Morgenstern & McKay, 2007). In a study including 13 to 
18 year olds, Kaminer et al. (2002) found that only older males in the CBT group 
experienced a significant reduction in drug use in comparison to the 
psychoeducational therapy group. This could indicate that CBT is more appropriate 
for the older males in the study (i.e. 16 to 18 year olds). Alternatively, the group 
delivery aspect may provide an additional explanation: study findings suggest that 
group CBT has a greater effect in reducing drug use than does individual CBT 
(Waldron et al., 2001; Liddle, Rowe, Dakof, Ungaro & Henderson, 2004). A group 
setting may be one that is more conducive and realistic for practicing new skills and 
strategies with peers in the same situation. The group environment may also 
contribute to the support and promotion of cognitive and behavioural change among 
participants (Waldron & Kaminer, 2004). 
 
Finally, the clients’ motivation also plays an important role, as increased motivation 
for change has been shown to lead to increased engagement, improved attendance 
and better outcomes from the therapy (Waldron & Turner, 2008), although this 
finding seems to apply to all drug treatment therapies. The duration of therapy may 
also moderate treatment outcomes, and several studies have found that shorter CBT 
interventions can be just as effective, if not more effective, than those of longer 
duration (Dennis et al., 2004; Kaminer, 2008). 
 
1.4  WHY IT IS IMPORTANT TO DO THIS REVIEW 
Drug use among young people is strongly associated with delinquency, poor 
scholastic attainment, mental and physical health problems, suicide and other 
individual or public calamities (Lynskey & Hall, 2000; Tims et al., 2002; Essau, 
2006; Rowe & Liddle, 2006; Knudsen, 2009). Yet research has documented a 
significant gap between young people in need of treatment and young people 
actually receiving treatment8.  McLellan (2006) linked this treatment gap to a 
                                                          
8For example, 8.4 percent of 18 to 25 year olds in the US are classified as needing drug use treatment (based on the 
criteria specified in the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorder, 
version DSM-IV), but less than one tenth of these young people actually receive treatment (NSDUH, 2009). 
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public concern regarding the effectiveness of the available treatments for young 
people and suggests that the public feeling is that nothing works for substance use 
among young people.  There is a need for identifying effective interventions for 
young drug users to inform treatment policy and practitioners’ decisions. Current 
evidence suggests that CBT for the treatment of young people’s drug use is a 
promising intervention. Research also points to the need for more solid and specific 
knowledge on what moderates CBT treatment effects, and for whom (Moos, 2007; 
Kaminer & Waldron 2006; Kaminer, 2008; Waldron & Turner, 2008). A protocol-
led systematic review on CBT for non-opioid drug use in young people has the 
potential to provide this knowledge and inform policy and practice. 
                                                          
Likewise, among youth aged 12 to 17, 4.5 per cent were estimated to be in need of treatment for a drug use problem, 
but only one tenth of this group actually received any (SAMSHA, 2008). 
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2 Objective of the review 
The objective of this review is to assess the effectiveness of CBT for young people 
(aged 13-21) in outpatient treatment for non-opioid drug use and to explore any 
factors that may moderate outcomes. 
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3 Methodology 
3.1  TITLE REGISTRATION AND REVIEW PROTOCOL 
The title for this systematic review was approved in The Campbell Collaboration on 
28 April, 2010. The review protocol was approved on 31 August 2012. Title and 
protocol are available at: http://campbellcollaboration.org/lib/project/170/. 
3.2  CRITERIA FOR CONSIDERING STUDIES FOR THIS 
REVIEW 
3.2.1 Types of studies 
The study designs included in the review were:  
 
 RCTs - randomised controlled trials. 
 QRCTs - quasi-randomised controlled trials (where participants are allocated 
by means such as alternate allocation, person’s birth date, the date of the 
week or month, case number or alphabetical order). 
 NRCTs - non-randomised controlled trials (where participants are allocated by 
other actions controlled by the researcher).  
 
3.2.2 Types of participants 
The population included in this review comprised young people aged 13-21 years 
who were enrolled in a CBT outpatient drug treatment for non-opioid drug use (e.g., 
cannabis, amphetamine, ecstasy, or cocaine). 
 
Definitions of young people and the age at which someone is considered a young 
person, and so may be entitled to special services such as drug treatment, varies 
internationally (United Nations, 2011). Age group distinctions for young people are 
unclear, as the boundaries are fluid and culturally specific (Weller, 2006). 
Furthermore, young people start experimenting with illegal drugs at different ages in 
different countries (Hibell et al., 2009). Similarly, patterns of independence from 
parents and of independent living vary internationally for young people. In order to 
encapsulate these international differences, we set the age range from 13 to 21 years 
(Hibell et al., 2009; United Nations, 2011; SAMSHA, 2010; Danish Youth Council, 
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2011). Any study involving age groups extending well beyond the 13 to 21 age 
threshold  (one of 13 to 65 year olds, for example) was only included if the trial 
investigators reported findings by age group for the intervention and control group.  
 
No universal international consensus exists on the categories that should be used 
when classifying drug users, and different assessment tools and ways of classifying 
the severity of drug use are applied in different research studies (American 
Psychiatric Association, 2000; World Health Organization, 2011; Nordegren, 2002). 
We chose to include participants regardless of formal drug use diagnosis: the main 
criterion for inclusion was that the young person had been enrolled in treatment for 
drug use (i.e. intervention or comparison intervention). Referral to and enrolment in 
treatment required a level of drug use to the extent that the young person, his/her 
parent or significant other, or a representative of a statutory authority, had found it 
necessary to solicit or require treatment. We therefore defined the population as 
young people referred to treatment, or in treatment, for using non-opioid drugs.  
 
As psychosocial interventions for the treatment of youth opioid use have already 
been evaluated in Cochrane reviews (Amato et al., 2011; Minozzi et al., 2010), the 
focus of this review is on non-opioid use. We included participants with poly-drug 
use as long as the majority of the study participants were users of non-opioid drugs. 
Study populations with severe mental illnesses (such as schizophrenia or psychotic 
illness) were excluded. We expected that some study populations might include 
young people with ‘common’ non-severe comorbid conditions (such as behavioural, 
emotional, mental health issues) (Hawkins, 2009). These studies were not excluded 
as long as the focus of the CBT intervention was on treating drug use. Studies where 
the primary focus of the intervention was to treat a comorbid condition (e.g. 
depression) in young people who also used drugs were excluded. 
 
3.2.3 Types of interventions 
The review focused on outpatient CBT interventions (as defined in section 1.2) of 
any duration delivered to young people individually or in groups (e.g. peers or 
families), and described by the authors as CBT. We only included studies with CBT 
interventions specifically directed at treating young people for non-opioid drug use. 
 
CBT interventions were included if they were delivered in outpatient settings and 
did not involve overnight stays in a hospital or other treatment facility.  To be 
eligible, the intervention should have taken place in the home, at a community 
centre, in a therapist’s office or at an outpatient facility, and should have been 
delivered to individuals, groups or families, or a combination of these. 
 
CBT interventions were considered ineligible if they were conducted by non-
professionals such as lay volunteers, were delivered in restrictive environments such 
as prisons or other locked institutions (such as detention centres or institutions for 
 20  The Campbell Collaboration | www.campbellcollaboration.org 
 
sentence-serving juvenile delinquents), or if focused exclusively on treating mental 
disorders.  
 
Studies where CBT was delivered in combination with add-on components (such as 
motivational interviewing) were eligible providing CBT was the primary 
intervention.  
 
Eligible comparison conditions were no intervention, wait list controls and 
alternative interventions. Due to ethical considerations and the nature of the 
problem (i.e. young peoples’ drug use) the likelihood of a no-treatment control 
group was anticipated to be small. We expected that the comparison would be an 
alternative intervention (Tanner-Smith et al., 2013).  
 
3.2.4 Types of outcomes 
We considered the following outcomes: 
Primary outcomes 
Abstinence or reduction of drug use as measured by:  
 Biochemical test (e.g. urine screen measures for drug use). 
 Self-reported estimates on abstinence or drug use (e.g., Time-Line Follow-Back 
interview; Fals-Stewart, O’Farrell, Freitas, McFarlin & Rutigliano, 2000). 
 Psychometric scales (e.g., Addiction Severity Index; McLellan, Luborsky, 
Woody & O’Brien, 1980). 
 
Secondary outcomes 
 Social functioning and family functioning (e.g. as measured by the Beavers 
Interactional Competence Scale; Beavers & Hampson, 2000). 
 Education or vocational involvement (e.g. as measured by grade point average, 
attendance, self-reported or reported by authorities, files, registers or 
employment record). 
 Retention (e.g. as measured by days in treatment, completion rates and/or 
attrition rates). 
 Risk behaviour such as crime rates (e.g. as measured by self-reports or 
reported by authorities, administrative files or registers). 
 Other adverse effects (e.g. as measured by rates of suicide and overdoses). 
 
Outcomes were considered in the following intervals: 
 
 Short term (beginning of treatment to less than 6 months after beginning of 
treatment). 
 Medium term (6 months to less than 12 months after beginning of treatment). 
 Long term (12 months or more after beginning of treatment). 
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3.3  SEARCH METHODS FOR IDENTIFICATION OF STUDIES 
3.3.1 Electronic searches 
Relevant studies were identified through electronic searches of the following 
bibliographic databases and government policy databanks. No language or date 
restrictions were applied to the searches. 
 
International bibliographic databases 
CINAHL searched until September, 2012 
Cochrane Controlled Trial Register (CENTRAL) searched until September, 2012 
Criminal Justice Abstracts searched until September, 2012 
EMBASE searched until September, 2012 
ERIC searched until September, 2012 
MEDLINE searched until September, 2012 
PsycINFO searched until September, 2012 
Social Care Online searched until September, 2012 
SocIndex searched until September, 2012 
Web of Science (SCI, SSCI) searched until September, 2012 
 
Nordic databases 
Bibliography of Nordic Criminology (up to summer 20089)  
Bibliotek.dk searched until September, 2012 
LIBRIS searched until September, 2012 
BIBSYS searched until September, 2012 
 
3.3.2  Search terms 
An example of the search strategy for MEDLINE on the OVID platform is listed in 
section 14. The strategy was modified for the different databases (see Appendices, 
section 14.1 for details).  
 
3.3.3  Searching other resources 
The review authors checked the reference lists of other relevant reviews and each of 
the included primary studies in an attempt to identify new leads. We also contacted 
international experts in an attempt to identify unpublished and ongoing studies.  
3.3.4  Grey literature 
We used Google and Google Scholar search engines and the advanced search options 
to search the web to identify potential unpublished and/or studies in progress. We 
checked the first 150 hits. OpenGrey (http://www.opengrey.eu/) was used to search 
                                                          
9This database has not been updated since summer 2008.  
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for European grey literature. Sites such as NCJRS (National Criminal Justice 
Reference Service) were searched. Copies of relevant documents were stored and we 
recorded the exact URL and date of access. 
 
We also searched the following websites:  
 
 National Institute on Drug Abuse (NIDA), http://www.drugabuse.gov/ 
 The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 
http://www.emcdda.europa.eu/index.cfm 
 Substance Abuse and Mental Health Services Administration (SAMHSA), 
http://www.samhsa.gov/ 
 
3.3.5  Hand searching journals 
The following journals that we considered most likely to include relevant primary 
studies were hand searched for the years 2011 and 2012: 
 
 Addiction  
 Journal of Consulting and Clinical Psychology 
 Journal of Substance Abuse Treatment  
 Journal of Clinical Child and Adolescent Psychology  
 Research on Social Work Practice 
 
3.4  DATA COLLECTION AND ANALYSIS 
3.4.1  Selection of studies 
Two members of the review team independently screened titles and abstracts to 
exclude studies that were clearly irrelevant, under the supervision of one of the 
review authors. Studies considered eligible by at least one of the reviewers were 
retrieved in full text. The full texts were then screened by two members of the review 
team to determine study eligibility based on the inclusion criteria. Any 
disagreements about eligibility were resolved by discussion. We checked for multiple 
publications of studies (i.e. whether several studies were based on the same data 
source). 
Reasons for exclusion were documented for each study that was retrieved in full text. 
The study inclusion coding sheet was piloted and adjusted when required by the 
review authors and used throughout the screening (see Appendices, section 14.2). 
The overall search and screening process is illustrated in a flowchart (see section 13). 
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3.4.2  Data extraction and management 
Two review authors independently coded and extracted data from the included 
studies. A data extraction sheet was piloted on several studies and revised when 
necessary (see Appendices, section 14.3). Extracted data was stored electronically. 
Any disagreements were resolved by discussion. Data and information were 
extracted on: characteristics of participants (e.g. age, gender, drug use severity, and 
history), intervention characteristics and control/comparison interventions, 
research design, sample size, outcomes and results. 
 
3.4.3  Assessment of risk of bias in included studies 
We assessed the risk of bias using a model developed by Prof. Barnaby Reeves in 
association with the Cochrane Non-Randomised Studies Methods Group (Reeves, 
Deeks, Higgins & Wells, 2011)10. This model, an unpublished extension of the 
existing Cochrane Collaboration’s risk of bias tool (Higgins & Green, 2008), covers 
risk of bias in RCTs, quasi-randomised trials and non-randomised studies that have 
a well-defined control group. The extended model is organized and follows the same 
steps as the existing Risk of Bias model according to chapter 8 of the Cochrane 
Handbook (Higgins and Green, 2008). The extension to the model is explained in 
Appendices, section 14.4. 
 
Risk of bias judgement items and assessment 
The risk of bias model used in this review is based on nine items (for guidelines and 
coding sheets, see Appendices, section 14.4). 
 
The nine items refer to:   
 sequence generation (judged on a low/high risk/unclear scale – NRCTs will 
automatically have high risk of bias ) 
 allocation concealment (judged on a low/high risk/unclear scale)  
 confounders (judged on a 5-point scale/unclear, only relevant for non-
randomised studies i.e. NRCTs)  
 blinding (judged on a 5-point scale/unclear)  
 incomplete outcome data (judged on a 5-point scale/unclear)  
 selective outcome reporting (judged on a 5-point scale/unclear)  
 other potential threats to validity (judged on a 5-point scale/unclear ) 
 a priori protocol (judged on a yes/no/unclear scale) 
 a priori analysis plan (judged on a yes/no/unclear scale). 
 
The assessment was based on pre-specified questions (see Appendices, section 14.4). 
“Yes” indicates a low risk, “No” indicates a high risk of bias, “and “Unclear” indicates 
an unclear or unknown risk of bias. In the 5-point scale, 1 corresponds to No/Low 
                                                          
10This risk of bias model was introduced to the review authors by Prof. Reeves at a workshop on risk of bias in non-
randomised studies at SFI Campbell, February 2011. This model is developed by the Cochrane Non-Randomised 
Studies Method Group (NRSMG). 
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risk of bias (e.g. 1 = a high quality RCT) and 5 corresponds to Yes/High risk of bias 
(e.g. 5= too risky, too much bias, i.e. a poor quality study). A score of five points on 
any of the items assessed translates to a risk of bias so high that the findings will not 
be considered in the data synthesis (because they are more likely to mislead than 
inform). In this systematic review, none of the included studies or parts thereof was 
judged as 5 on the risk of bias scale. 
 
Confounding 
Confounding was not relevant in this review since we did not find any non-
randomised studies meeting the inclusion criteria. 
 
Assessment 
Review authors independently assessed the risk of bias for each included study as 
described in the previous sections. Any disagreements were resolved by discussion. 
The risk of bias assessments were reported in risk of bias tables for each included 
study (see Appendices, section 14.5) and were used to inform the data synthesis. 
 
3.4.4  Measures of treatment effect  
For dichotomous outcomes, for example “recovery” and “retention”, we calculated 
odds ratios with 95 percent confidence intervals and p-values for the meta-analysis 
(Higgins & Green, 2008). Computations of effect sizes were carried out with the 
natural logarithm of the odds ratio.  
 
For continuous outcomes, effect sizes were calculated when means and standard 
deviations were available. When this information was not available, as was the case 
in two studies, the review authors requested means and standard deviations from 
the principal trial investigators. Hedges g was used for estimating SMDs. 
 
3.4.5  Unit of analysis issues 
We planned to take into account the unit of analysis of the studies to determine 
whether there were multiple intervention groups, whether outcomes were measured 
at multiple time points,  and whether individuals were randomised in groups (i.e. 
cluster randomised trials). 
 
Multiple intervention groups 
Multiple intervention groups (with different individuals) within a study with one 
control group were not pooled, nor were multiple controls. All possible comparisons 
from studies with multiple intervention/control groups were analysed. Data was 
rigorously checked to avoid overlapping samples in the meta-analyses. 
 
Multiple time points 
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When results were measured at multiple time points, they were pooled and analysed 
in the following groups: short-term (beginning of treatment to less than 6 months 
after the beginning of treatment), medium term (6 months to less than 12 months 
after the beginning of treatment), and long term (12 months or more after the 
beginning of treatment) (see section 4.2.1). When conducting analyses separately by 
time point, there were no remaining dependencies within each of those time points. 
 
Cluster randomised trials 
No cluster randomised trials were identified.  
3.4.6  Dealing with missing and incomplete data 
In cases where data was missing (e.g. valid Ns, means and standard deviations), we 
contacted the primary study authors to request this11. We recorded attrition rates 
and (when possible) reasons for attrition from included studies. 
 
Information on intention to treat analysis (ITT) was also recorded. We performed 
sensitivity analysis to examine influences on effects in studies using ITT analysis vs. 
studies not using ITT analysis (see section 4.4.4). 
 
3.4.7  Assessment of heterogeneity  
Statistically significant heterogeneity among primary outcome studies was assessed 
with Chi-squared (Q) test, tau-squared and I-squared statistics (Higgins & Green, 
2008). A significant Q or tau-squared (p < .05) and I-squared value of at least 50 
percent were considered as evidence of statistical heterogeneity. 
 
3.4.8  Assessment of publication bias 
Reporting bias refers to both publication bias and selective reporting of outcome 
data and results. Selective reporting was dealt with in the risk of bias assessment 
and any concerns were reported in section 4.3.5. As stated in the protocol (Kowalski 
et al., 2012), we used funnel plots to provide information about possible publication 
bias (Higgins & Green, 2008).  
 
3.5  DATA SYNTHESIS 
No studies were excluded for scoring 5 on a risk of bias item. 
 
Analysis of the absolute effects of CBT was not possible since no study compared 
CBT to no treatment or to untreated wait list controls. Examination of the relative 
effects of CBT (versus other interventions) was conducted on studies that compared 
CBT to alternative interventions and/or treatment as usual (TAU). Studies of CBT 
                                                          
11Authors were contacted for missing data in October 2011, January 2012 and May 2013. 
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interventions that included an add-on component such as motivational interviewing 
or a pharmacological treatment were analysed separately. All follow-up durations 
reported in the primary studies were recorded and we conducted separate analyses 
for short-term (beginning of treatment to less than 6 months after beginning of 
treatment), medium-term (6 months to less than 12 months after beginning of 
treatment), and long-term (12 months or more after beginning of treatment) 
outcomes. 
 
We pooled the results from primary studies based on outcomes and performed 
meta-analysis. All analyses were inverse variance weighted using random effects 
statistical models that incorporated both the sampling variance and between-study 
variance components into the study level weights. A random effects model was 
chosen to represent the overall effect, as we expected the studies to deal with diverse 
populations of participants. We reported the 95 percent confidence intervals and 
have provided graphical displays (forest plots) of effect sizes in section 4.4. 
 
3.5.1  Analysis of heterogeneity 
We planned, where possible, to investigate the following study-level covariates with 
the aim of explaining observed heterogeneity: intervention characteristics (e.g., 
treatment duration, treatment intensity), participants’ characteristics (e.g., gender, 
age, family composition, ethnicity, co-morbidity, and history of drug use) and 
comparison intervention characteristics. 
If the number of included studies had been sufficient (dependent on the spread of 
the study means of the covariates and study sizes, see Borenstein, Hedges, Higgins & 
Rothstein, 2009 and Simmonds & Higgins, 2007), we planned to perform 
moderator analyses (meta-regression) to explore how observed variables were 
related to heterogeneity using a mixed model. Otherwise, single factor subgroup 
analysis was planned to be performed. We did not, however, identify sufficient 
studies to allow any moderator analysis to be conducted.  
 
3.5.2  Sensitivity analysis 
Sensitivity analysis was used to evaluate whether the pooled effect sizes were robust 
across analysis method (intention-to-treat) and components of risk of bias. We 
conducted sensitivity analysis for two components of the risk of bias checklists 
(‘blinding’ and ‘incomplete outcome data’) by removing studies scoring 3 or 4 (see 
section 3.4.3 for a definition). 
 
Developer bias can occur in studies conducted by developers, who may 
unconsciously influence the success of an intervention (Petrosino & Soydan, 2005; 
Eisner, 2009; Sherman & Strang, 2009). Risk of developer bias was present in one 
of the included studies. To check for the possible influence of developer bias on 
effect sizes, we ran sensitivity analyses by removing that study.  
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We also ran sensitivity analysis to examine for effects of program fidelity (i.e. 
compliance with the program manual and requirements for therapist training).  
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4 Results 
4.1  RESULTS OF THE SEARCH 
The initial search was performed between December 2010 and January 2011. An 
updated search was executed in September 2012. 
 
The results of the searches are summarised in Figure 13.1. The total number of 
potential relevant records was 18,514 after excluding duplicates (database: 13,733, 
grey: 2,610, hand search, snowballing and other resources: 2,171). All 18,514 records 
were screened based on title and abstract and 394 records were ordered for retrieval 
and screening in full text. Of these, 360 did not fulfil the screening criteria and were 
excluded. Two records were unobtainable, and two unpublished manuscripts could 
not be located.   
 
A total of seven unique studies, reported in 17 papers, were included in the review. 
See section 4.2 for further details of the included and excluded studies.  
 
4.2  DESCRIPTION OF THE STUDIES 
4.2.1  Included studies 
Seven studies met our inclusion criteria, of which four were reported in a number of 
full text papers. No NRCTs were identified for inclusion. None of the studies simply 
named the intervention they assessed as CBT without providing further information 
to suggest that the intervention was CBT as defined in section 2.1. We did not find 
any studies comparing CBT to no treatment or to untreated wait list controls, and we 
were therefore unable to draw any conclusions about the absolute effects of CBT. 
 
Dennis et al. (2004) 
This study, named The Cannabis Youth Treatment (CYT) Study, is an RCT that 
includes two separate experiments (Dennis et al., 2004). The first experiment is a 
three-armed trial where CBT is a major component in all three groups and so cannot 
be included in this systematic review. The second experiment is a three-armed trial 
comparing Motivational Enhancement Treatment/Cognitive-Behavioural Therapy 
(MET/CBT5), The Adolescent Community Reinforcement Approach (ACRA), and 
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The CYT study
Study protocol
Dennis et al., 2002
Description of 
interventions
Diamond et al., 2002
Journal article with  
results
Dennis et al., 2004
Multidimensional Family Therapy (MDFT). This second experiment is included in 
this review. All possible combinations of comparisons from this study were analysed. 
The trial investigators also published a study protocol describing all major issues 
linked to realizing the experiment (Dennis et al., 2002), and all five interventions are 
described in a separate paper (Diamond et al., 2002). In the following paragraphs, 
this (CYT) study is cited as Dennis et al. (2004). Figure 4.1 gives an overview of the 
publications linked to the CYT study. 
 
 
 
 
 
 
 
 
 
 
 
Godley et al., (2010) 
This study is a four-armed RCT which compares Motivational Enhancement 
Therapy/Cognitive-Behavioural Treatment (MET/CBT7) and Chestnut Bloomington 
Outpatient (CBOP) as main interventions with and without Assertive Continuing 
Care (ACC) as an add-on. All possible combinations of comparisons from this study 
were analysed. The study authors registered the trial at ClinicalTrials.gov with the 
identifier number NCT01381133 and reported the results in a journal article by 
Godley et al. (2010). In the following paragraphs, this study is cited as Godley et al. 
(2010). 
 
Hendriks et al. (2011) 
This is a cross-country experiment, the International Cannabis Need of Treatment 
(INCANT), conducted in five European countries – Belgium, France, Germany, the 
Netherlands and Switzerland – that has been reported in a number of articles. The 
study compares Multidimensional Family Therapy (MDFT) and active treatment as 
usual (TAU) in a two-armed RCT. It is described in a protocol (Rigter et al., 2010) 
and reported upon in a report (Rigter et al., 2011) and a journal article (Rigter et al., 
2013). The active treatment as usual component differs between countries, and it is 
only in Belgium and the Netherlands that CBT is identified as the dominant 
ingredient in the control condition (Rigter et al., 2011). Due to missing information 
and unobtainable background literature, we were unable to determine whether CBT 
was given to all participants in Belgium as a main ingredient or whether only a part 
of the comparison group was given CBT. Therefore we have not included the 
Belgium trial in this systematic review. However, the study from the Netherlands is 
included, because the TAU condition in this country consisted of full CBT (Rigter et 
al., 2013). This study is reported upon in a separate article by Hendriks, van der 
Figure 4.1: The CYT study 
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The INCANT study
Study protocol
Rigter et al., 2010
Report by the INCANT 
study team
Rigter et al., 2011
Journal article with 
cross-country results
Rigter et al., 2013
Journal article with 
results from the 
Netherlands 
Hendriks et al., 2011
Journal article with 
moderator analysis for 
the Netherlands 
Hendriks et al., 2012
Schee, & Blanken (2011) and is cited in the following paragraphs as Hendriks et al. 
(2011). The same authors have also published a moderator study linked to the trial 
in the Netherlands (Hendriks, van der Schee, & Blanken, 2012). Figure 4.2 gives an 
overview of the publications linked to the INCANT study. 
 
 
 
 
 
 
 
 
 
 
 
Kaminer et al. (1998a, 1999) 
This is a two-armed RCT which compares Cognitive-Behavioural Therapy (CBT) and 
Interactional Therapy (IT). The study is reported in two articles: Kaminer, Burleson, 
Blitz, Sussman & Rounsaville (1998a) report on the pilot study with a 3-month 
follow-up period post-intervention, whereas Kaminer & Burleson (1999) report on a 
15-month follow-up. The trial investigators also report on the treatment process in a 
separate article (Kaminer, Blitz, Burleson, Kadden, & Rounsaville, 1998b). In the 
following paragraphs, this study is cited as Kaminer et al. (1998a, 1999).  
 
Kaminer et al. (2002) 
This study compared Cognitive-Behavioural Therapy (CBT) and Psychoeducational 
Therapy (PET) in a two-armed RCT. The results of the trial are reported in Kaminer, 
Burleson, & Goldberger (2002) and this study is cited in the following paragraphs as 
Kaminer et al. (2002). 
 
Latimer et al. (2003) 
This is a two-armed RCT comparing Integrated Family and Cognitive-Behavioural 
Therapy (IFCBT) and Drugs Harm Psychoeducational curriculum (DHPE). This 
combined CBT intervention is included because the main component in the youth 
treatment is CBT. The results are reported in Latimer, Winters, D’Zurilla & Nichols 
(2003) and this study is cited in the following paragraphs as Latimer et al. (2003).  
 
Waldron et al. (2001) 
This is a four-armed RCT in which participants were allocated to Cognitive-
Behavioural Therapy (CBT), Functional Family Therapy (FFT), joint intervention 
combining CBT and FFT, and a psychoeducational group intervention. The study is 
reported in an article by Waldron, Slesnick, Brody, Turner & Peterson (2001) and in 
a cost-effectiveness study by French et al. (2008). The cost-effectiveness study is 
included in this review as it provides results on outcomes different from those 
Figure 4.2: The INCANT study 
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reported in the main article. Only data from the CBT and FFT groups is included in 
this review because the joint intervention and the psychoeducational group 
intervention both used CBT as a main ingredient. In the following paragraphs, this 
study is referred to as Waldron et al. (2001). 
 
4.2.2 Setting  
Of the seven studies included, six were conducted in the US and one was conducted 
in the Netherlands (Hendriks et al., 2011).  
 
Dennis et al. (2004) stated that one of the two sites set up clinical facilities, whereas 
the other site used multiple facilities. In Hendriks et al., 201112 the authors stated 
that MDFT sessions could take place at the office of the therapist, the family’s home, 
or at any other location. For the TAU condition, it was mandatory that sessions were 
conducted in the treatment centre, such as the therapist’s office, and not in the home 
or other community setting, as was possible with MDFT.  
 
Most studies did not provide sufficient information to determine treatment setting 
(Godley et al., 2010; Kaminer et al., 1998a, 1999; Kaminer et al., 2002; Latimer et 
al., 2003; Waldron et al., 2001). 
 
4.2.3 Design 
All included studies were described by the trial investigators as RCTs. Five studies 
used the individual adolescent as the unit of allocation during the randomization 
procedure (Dennis et al., 2004; Godley et al., 2010; Hendriks et al., 2011; Kaminer et 
al., 1998a, 1999; Kaminer et al., 2002;), whereas two studies used the family as the 
unit of allocation (Latimer et al., 2003; Waldron et al., 2001). 
 
4.2.4 Sample size 
Table 4.1 shows the number of participants allocated in each included study as well 
as the valid sample sizes used in the meta-analysis.  
 
The Kaminer study (Kaminer et al., 1998a, 1999) reported different sample sizes in 
their separate publications. We have used the sample size from the publication 
which included the relevant outcome; N=23 for medium term outcomes and N=12 
for long term outcomes. 
 
 
Table 4.1: Sample sizes for included studies 
Study Randomly allocated Valid sample size used in data synthesis 
Dennis et al., 2004 300 300 (MET/CBT5: 100, MDFT: 100, ACRA: 100) 
Godley et al., 2010 320 
320 (MET/CBT7: 79, MET/CBT7+ACC: 81, CBOP: 
80, CBOP+ACC:  80) 
                                                          
12 Reported in Rigter et al. (2011) and Rigter et al. (2013) 
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Hendriks et al., 2011 109 109 (CBT: 54, MDFT: 55) 
Kaminer et al., 
1998a & 1999 
32 23 (CBT: 13, IT: 10) 
Kaminer et al., 2002 88 88 (CBT: 51, PET: 37) 
Latimer et al., 2003 43 42 (IFCBT: 21, DHPE: 21) 
Waldron et al., 
20011 
61 61 (MET/CBT: 31, FFT: 30) 
Total N 953 853 
Note: 1This number of randomly allocated participants is for CBT and FFT. The study is a four-armed RCT where 
only these two groups are included in this review. The full sample size for all four groups is 120 participants.   
 
 
4.2.5 Participants 
The majority of participants across all the studies were male. Dennis et al. (2004) 
had the lowest proportion of females across groups (15-21 percent). In contrast, 
Kaminer et al. (1998a, 1999) had the highest proportion of females across groups (-
40 percent). 
 
Three studies included youths between 12 and 18 years of age (Dennis et al., 2004; 
Godley et al., 2010; Latimer et al., 2003). However, in the study by Latimer et al. 
(2003) the final sample consisted of youths between 14 and 18 years of age, and in 
Dennis et al. (2004) and Godley et al. (2010) the final samples consisted of youths 
between 13 and 18 years of age. Three studies included youths between 13 and 18 
years of age (Kaminer et al., 1998a, 1999; Kaminer et al., 2002; Hendriks et al., 
2011). Waldron et al. (2001) included youths aged 13 to 17 years. 
 
With respect to ethnicity, the majority of participants were white in five studies 
(Godley et al., 2010; Hendriks et al., 2011; Kaminer et al., 1998a, 1999; Kaminer et 
al., 2002; Latimer et al., 2003). In one study, nearly half of the participants were 
Hispanic and nearly one half African American (Waldron et al., 2001). In Dennis et 
al. (2004), around half of the participants were white and around half were African 
Americans.  
  
Three studies reported the proportion of young people living in a single-parent 
household. In one of these studies, the proportion was well above 50 percent 
(Dennis et al., 2004). In Hendriks et al. (2011) it was 24-46 percent across groups, 
and in Waldron et al. (2001) it was 32-53 percent across groups. In two of the 
included studies, some of the youths were mandated to treatment. Hendriks et al., 
201113 stated that 83-95 percent of the participants in the Netherlands were 
externally coerced. Waldron et al. (2001) did not state the proportion of participants 
mandated to treatment.  
 
                                                          
13 Reported in Rigter et al. (2011, 2013) 
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Further information on the participants’ characteristics (such as severity of drug use, 
inclusion criteria, and exclusion criteria) is given in section 10.1: Characteristics of 
included studies. 
 
 
4.2.6 Experimental interventions 
Three studies allocated participants to CBT without any further add-on treatment 
(Hendriks et al., 2011; Kaminer et al., 1998a, 1999; Kaminer et al., 2002). In one of 
these three studies, CBT was delivered individually (Hendriks et al., 2011), whereas 
CBT was delivered as group therapy in Kaminer et al. (1998a, 1999) and Kaminer et 
al. (2002). 
 
Three studies delivered Motivational Enhancement Therapy (MET) as part of the 
treatment process (Dennis et al., 2004; Godley et al., 2010; Waldron et al., 2001). All 
three studies included two individual MET sessions at the beginning of the 
treatment process.  
 
Two studies included the family during the treatment process. Latimer et al. (2003) 
included individual family sessions and peer group cognitive-behavioural sessions, 
which took place simultaneously. Godley et al. (2010) supplemented the MET/CBT 
sessions with two family sessions, one at the beginning of the treatment process and 
one at the end.  
 
In the four-armed RCT reported by Godley et al. (2010), two of the arms included an 
additional add-on named Assertive Continuing Care (ACC), which is a home-based 
continuing care approach. 
 
More information on experimental conditions is given in section 10.1: 
Characteristics of included studies. 
 
4.2.7 Control conditions 
All the included studies compared CBT with another intervention. One study 
included three control conditions, namely FFT, psychoeducational group 
intervention, and joint FFT and CBT (Waldron et al., 2001). However, as described 
in section 4.2.1, only one of these control conditions can be included in the review. 
Two studies included two control conditions, ACRA and MDFT (Dennis et al., 2004) 
and CBOP and CBOP+ACC (Godley et al., 2010). Four studies included only one 
control condition: MDFT (Hendriks et al., 2011); IT (Kaminer et al., 1998a, 1999), 
PET (Kaminer et al., 2002) and DHPE (Latimer et al., 2003). 
 
4.2.8 Time points for measurements 
Table 4.2 shows the measurement time points for each included study. The table 
shows both the study's own measure of time points and the calculated time points 
measured from the beginning of treatment. 
 34  The Campbell Collaboration | www.campbellcollaboration.org 
 
 
 
 
 
Table 4.2: Time points for measurements 
Study Time points as 
described in study 
Treatment duration Calculated time points measured 
from beginning of treatment 
Dennis et al., 
2004 
3 months 
6 months 
9 months 
12 months 
6-7 weeks 
(MET/CBT5), 12-14 
weeks (MDFT and 
ACRA) 
3 months 
6 months 
9 months 
12 months 
Godley et al., 
2010 
3 months 
6 months 
9 months 
12 months 
12 weeks 
(MET/CBT7), 12-14 
weeks (ACC), NA 
(CBOP) 
3 months 
6 months 
9 months 
12 months 
Hendriks et 
al., 2011 
3 months 
6 months 
9 months  
12 months 
5-6 months1 
(CBT), 5-6 months 
(MDFT) 
3 months 
6 months 
9 months  
12 months 
Kaminer et 
al., 1998a, 
1999 
3 months 
15 months 
12 weeks (CBT), 12 
weeks (IT) 
6 months 
18 months 
Kaminer et 
al., 2002 
3 months 
9 months 
8 weeks (CBT), 8 
weeks (PET) 
5 months 
11 months 
Latimer et al., 
2003 
1 month 
3 months 
6 months 
16 weeks (IFCBT), 16 
weeks (DHPE) 
5 months 
7 months 
10 months 
Waldron et 
al., 2001 
4 months 
7 months 
12 weeks (MET/CBT), 
12 weeks (FFT) 
4 months 
7 months 
Notes: 1In the meta-regression we use the mean number of weeks (22 weeks). 2As this duration is clearly included in 
our short term category we do not make any further assumptions regarding this duration. However, in the meta-
regression we use the mean number of weeks (14 weeks).  3As this duration interval overlaps both our short and 
medium term category we make the assumption that the duration is 5 months and use this assumption in the meta-
regression. 
 
 
Short term 
As table 4.2 shows, six of the seven studies included measurements in the ‘short 
term’ follow-up category. Only the study by Kaminer et al. (1998a, 1999) did not 
include measurements in this category. 
 
Medium term 
All seven studies included measurements in the ‘medium term’ category. Four 
studies provided outcome measures for two time points which could be included in 
the medium term category (Dennis et al., 2004; Godley et al., 2010; Latimer et al., 
2003; Hendriks et al., 2011). We chose to pool the outcomes as close to 6 months 
from beginning of treatment as possible. 
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Long term 
Four of the seven studies included measurements in the ‘long term’ category 
(Hendriks et al., 2011; Kaminer et al., 1998a, 1999; Godley et al., 2010; Dennis et al., 
2004). 
 
4.2.9 Primary outcomes 
Primary outcomes are listed in table 11.1 (see section 11). The table indicates whether 
the outcome measurements used in the respective studies were discrete or 
continuous, whether a high score was positive or negative (the direction of the 
measurements), and at what time-points the different outcome measurements were 
made. 
 
Abstinence or reduction of drug use – biochemical test 
Several of the included studies reported conducting urine screening tests. However, 
none of the included studies reported detailed outcome measurements in terms of 
means and standard deviations derived from biochemical tests. 
 
Abstinence or reduction of drug use – self reported estimates 
Except for the studies by Kaminer et al. (1998a, 1999) and Kaminer et al. (2002), all 
of the included studies used self-reported estimates on drug use frequency as a 
measure of abstinence or reduction of drug use.  
 
Two of the included studies (Hendriks et al., 2011; Waldron et al., 2001) used the 
Time-Line Follow-Back (TLFB) to measure abstinence or reduction of drug use. The 
TLFB is a self-reported measure which obtains retrospective reports of cannabis use 
for the period prior to each assessment using a calendar and/or other memory 
prompts to stimulate recall. Similar self-reporting methods were used to estimate 
drug use frequency in the remaining studies. Godley et al. (2010) and Dennis et al. 
(2004) used The Global Appraisal of Individual Needs (GAIN), which measured the 
percentage or total number of days of abstinence out of e.g. the past 90 days or 12 
months. Latimer et al. (2003) and Hendriks et al., 201114 used the Adolescent 
Diagnostic Interview (ADI), which measures the average number of days per month 
that marijuana was used during the specified post-treatment period.  
 
The outcome measure “Recovery” was used in three of the included studies (Godley 
et al., 2010; Dennis et al., 2004, Hendriks et al., 201115). Recovery was defined as 
“living in the community (vs. incarceration, inpatient treatment or other controlled 
environment) and reporting no past month substance use, abuse or dependence 
problems at the 12 month interview” (Dennis et al., 2004).  
 
Abstinence or reduction of drug use – psychometric scales 
                                                          
14 Reported in Rigter et al., 2013 
15 Reported in Rigter et al., 2011 
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Five of the included studies (Dennis et al., 2004; Godley et al., 2010; Kaminer et al., 
1998a, 1999; Kaminer et al., 2002; Hendriks et al., 201116) used psychometric scales 
to measure abstinence or reduction of drug use.  
 
In Hendriks et al., 2011, the Personal Involvement with Chemicals Scale was used, 
which is a subscale from the Personal Experience Inventory (PEI). The Personal 
Involvement with Chemicals Scale is a 29-item measure that focuses on the 
psychological and behavioural depth of substance use and related consequences 
(Liddle et al., 2002). 
 
Two of the included studies, Kaminer et al. (1998a, 1999) and Kaminer et al. (2002), 
used the T-ASI Chemical Scale from The Teen Addiction Severity Index, which 
measures the severity of adolescents’ substance abuse problems. The T-ASI 
Chemical Scale was composed of the two subscales; alcohol and drugs17. 
 
In Dennis et al. (2004) and Godley et al. (2010), reduction of drug use was measured 
with the Substance Problems Scale (SPS), which is a subscale from The Global 
Appraisal of Individual Needs (GAIN), and based upon ratings of 16 symptoms 
related to drug use. In the study by Dennis et al. (2004), the Substance Frequency 
Scale (SFS) (also from GAIN) was used as an additional outcome measurement. This 
subscale is based upon the average percentage of days during a 90-day period that 
an adolescent reports on substance use.  
 
 
4.2.10 Secondary outcomes 
The different secondary outcomes are listed in table 11.2 (see section 11). The table 
indicates whether the outcome measurements used in the respective studies were 
discrete or continuous, whether a high score was positive or negative (the direction 
of the measurements), and at what time-points the different outcome measurements 
were made. 
 
Social functioning and family functioning 
Four of the included studies (Kaminer et al., 1998a, 1999; Kaminer et al., 2002; 
Latimer et al., 2003; Hendriks et al., 201118) reported on outcome measures that 
were categorized as measures of social functioning and family functioning.  
 
In the two included studies by Kaminer et al. (1998a, 1999) and Kaminer et al. 
(2002), social functioning and family functioning were measured by three different 
outcomes (Family Problems, Peer Problems  and Psychological Problems), which 
were all measured by subscales from the Teen Addiction Severity Index (T-ASI). 
 
                                                          
16 Reported in Rigter et al., 2011 
17In the follow-up study by Kaminer (1999), drug use was measured by the combined T-ASI Chemical 
Scale and the separate subscales, drugs and alcohol. 
18 Reported in Rigter et al., 2011 
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Measures more specifically related to social functioning were included in Hendriks 
et al., 2011, who used “Internalizing disorders/symptoms” and “Internalized 
distress”. These measures were derived from the Youth-Self-Report (YSR) and 
included the following subscales: “Withdrawn”, “Somatic complaints” and 
“Anxiety/depression”.  
Finally, the study by Latimer et al. (2003) included 14 different measurements of 
social functioning and family functioning. Two of these outcome measurements, 
“Rational beliefs” and “Irrational beliefs” were derived from The Rational Thinking 
Questionnaire, which assesses rational and irrational beliefs in relation to drug-
related and general life issues. An additional five measurements, “Positive problem 
orientation”, “Negative problem orientation”, “Rational problem solving”, 
“Impulsive problem solving” and “Problem avoidance” were derived from The Social 
Problem Solving Inventory (SPSI). The remaining seven measurements, “Task 
accomplishment”, “Role performance”, “Communication”, “Affective expression”, 
“Involvement”, “Control” and “Values and norms” were derived from The Family 
Assessment Measure (FAM), which is a self-report tool administered to both 
children and parents. 
 
Education or vocational involvement 
Measurements of education or vocational involvement were used in three of the 
included studies (Kaminer et al., 1998a, 1999; Kaminer et al., 2002; Latimer et al., 
2003). In the studies by Kaminer et al. (1998a, 1999) and Kaminer et al. (2002), 
education or vocational involvement was measured by the subscale “School 
problems”, which was derived from The Addiction Severity Index. Additional 
measurements of education were used in the study by Latimer et al. (2003), which 
included the outcomes “Motivation to learn” and “Learning strategies”. Both of these 
measurements were derived from The Motivated Strategies for Learning 
Questionnaire (MSLQ), which is used to assess an adolescent’s motivation to learn 
in school and his or her use of effective learning strategies.  
 
Retention 
According to the protocol, examples of measurements of “retention” to be 
considered in this review included number of days in treatment, completion rates 
and/or attrition rates. On the basis of this description, we identified six of the 
included studies (Dennis et al., 2004; Godley et al., 2010; Hendriks et al., 2011; 
Kaminer et al., 2002; Kaminer et al., 1998a, 1999, Latimer et al., 2003) that 
reported on outcomes related to retention. 
 
In four of the above mentioned studies (Dennis et al., 2004; Hendriks et al., 2011; 
Kaminer et al., 2002; Kaminer et al., 1998a, 1999), retention was measured in terms 
of the number and/or percentage of young people who completed the treatment. 
However, the definition of 'treatment completers' varied from study to study. In 
Hendriks et al. (2011), adolescents were considered as treatment completers if they 
attended a treatment session in at least 75 percent of the planned number of 
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treatment weeks. In the studies by Kaminer et al. (1998a, 1999) and Kaminer et al. 
(2002), treatment completion was defined as having completed a valid Baseline and 
End-of-Treatment assessment and being present at the final therapy session 
(Kaminer et al., 1999: 115). In the study by Dennis et al. (2004), completion was 
defined as having completed 75 percent of the planned course of a given treatment 
(i.e. at least 200 minutes of therapy for MET/CBT5, at least 400 minutes of therapy 
for MET/CBT12, ACRA and MDFT, and at least 800 minutes for FSN).  
 
Additional measurements of retention were reported in the Godley et al. (2010) 
Latimer et al. (2003) and Hendriks et al., 201119 respectively. Hendriks et al., 2011, 
used the outcome measure “At least 3 months in treatment”, which measured the 
ability of interventions to retain adolescents in treatment for at least 3 months. In 
Godley et al. (2010), retention was measured in terms of both “Retention days” 
measured as the mean number of days in treatment and “Attended sessions” 
measured as the number of patients that attended more than 4 sessions, 1-3 sessions 
or no sessions (p. 46) respectively. Finally, Latimer et al. (2003) reported on 
retention in terms of “Retention-weeks” (i.e. the number of treatment weeks 
attended20) and “Retention- sessions” (i.e. the number of sessions attended during 
treatment).  
 
Risk behaviour 
Measures of risk behaviour such as crime rates were used in four of the included 
studies (Waldron et al., 200121; Hendriks et al., 2011; Kaminer et al, 2002; Kaminer 
et al., 1998a, 1999).  
 
In the study by Hendriks et al. (2011), risk behaviour was measured by the “Number 
of property and violent crimes committed”, which was based on The Self-Report 
Delinquency Scale. An additional outcome measurement was “Externalizing 
disorder/symptoms”22. This measurement was derived from The National Youth Self 
Report’s delinquent acts and aggressive behaviour subscales. 
  
Measurements of risk behaviour were also included in the studies by Kaminer et al. 
(1998a, 1999) and Kaminer et al. (2002), who reported on the outcome variable 
“Legal problems”. This measurement was based on The Teen Addiction Severity 
Index and measured the severity of the adolescent’s legal problems (Kaminer et al., 
1991). 
 
Waldron et al., 2001, used the variables “Delinquency”/“Any delinquency”, which 
were based on The Youth Self-Report delinquency subscales. 
                                                          
19 Reported in Rigter et al. (2011) 
20Youths attending the IFCBT condition were considered present for a given treatment week if at least 
two out of three sessions were attended during that week. For youths attending the control condition, 
the values for treatment duration in weeks and number of treatment sessions were identical because 
sessions met once weekly.  (Latimer et al, 2003: 310). 
21 Reported in French et al., 2008 
22 Reported in Rigter et al., 2011 
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Other adverse effects 
None of the included studies reported on any measures of other adverse effects, such 
as rates of suicide and overdose. 
 
4.2.11 Excluded studies 
Several studies which initially appeared to be eligible did not ultimately meet our 
inclusion criteria. Primary reasons for exclusion of these studies are listed below. 
 
The study examined an intervention that is not CBT 
Two studies were excluded due to the analysis of irrelevant interventions. A study by 
Goti et al. (2010) evaluated the relative effectiveness of a brief motivational 
enhancement intervention compared to treatment as usual which comprised 
diagnostic evaluation according to the presenting problem, and an initial therapeutic 
approach, either pharmacological and/or cognitive-behavioural therapy. 
Furthermore, the participants’ age range was 12-17 years. A study by Azrin et al. 
(2001) compared Family Behaviour Therapy (FBT) and Individual Cognitive 
Problem-Solving (ICPS), which was described as a relatively “pure” cognitive version 
of problem-solving training where behavioural features were not utilized. 
Furthermore, the participants’ age range was 12-17 years. 
 
The study did not include participants aged 13 to 21 years 
Six studies were excluded due to the inappropriate age groups considered in the 
studies. The study by Carroll et al. (1994) had no age limit on included participants 
and mean age was 28.8 years. The study by Carroll et al. (2006) included 
participants between 18 and 25 years of age, with a mean age around 21 years of age. 
Another study by Carroll et al. (2012) included participants aged 18 years and above, 
with a mean age ranging from 24.3 to 27.6 across groups. None of the studies by 
Carroll and colleagues reported results divided between age groups. The study by 
Hunter et al. (2012a) did not focus on young people, with the mean age being 37.4 
years in the intervention group and 31.1 years in the control condition. Two trials 
reported in three papers (Liddle et al., 2004 and 2009; Liddle et al., 2008) included 
participants younger than 13 years of age and did not explicitly report results on the 
age range 13-21 years. 
 
The study design did not allow the effect of CBT to be quantified 
Three studies were excluded as they all included CBT in both the intervention and 
comparison intervention. A study by Ramchand, Griffin, Suttorp, Harris & Morral 
(2011) compared Motivational Enhancement Therapy/Cognitive-Behavioural 
Therapy 5 (MET/CBT5) and the Adolescent Treatment Model (ATM). The 
comparison interventions included in ATM were based on cognitive-behavioural 
theories and thus cannot be used to identify the effect of CBT. Another study, 
conducted by Hunter et al. (2012b), represented the same problem, in that it too 
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compared MET/CBT5 and ATM. The third study, by Godley, Jones, Funk, Ives & 
Passetti (2004), compared Chestnut Health System’s outpatient treatment (CHS) 
and the interventions included in the CYT study, which included CBT. However, this 
study did not separate the interventions in the CYT study and therefore, did not 
identify any effect of CBT. 
 
For a list of excluded studies, please see section 10.2: Characteristics of excluded 
studies. 
 
4.2.12 Studies awaiting classification 
No studies are awaiting classification 
 
4.2.13 Unobtainable studies  
Four potentially relevant studies were unobtainable: A reference by Bean, White, 
Gabbert & Lake (2005) was not identified in the journal article linked to this 
reference and it could not be identified anywhere else. In addition, three references 
were identified as possible relevant studies when we conducted a snowball search 
from previously published reviews. These three unpublished papers (Hops et al., 
2007; Stanton, Rempala & Conway, 2007; Waldron et al., 2007) could not be 
located. 
 
4.3  RISK OF BIAS IN INCLUDED STUDIES 
None of the included studies were coded with a very high risk of bias (5 on the risk of 
bias scale) on any item, and the results from all studies were included in the data 
synthesis where possible. The ratings of each study in relation to the nine domains 
in the risk of bias tool are described below (see also risk of bias tables in section 11 
and in Appendices, section 14.5). The risk of bias judgements are based on pre-
specified questions and a 5-point scale with ratings of 1=low risk and 5=high risk 
(see Appendices, section 14.4). 
 
In the ratings listed below, we report the risk of bias judgements for the primary 
outcomes of interest, abstinence or reduction of drug use. Further details on risk of 
bias, including judgements for secondary outcomes, are provided in section 11 and in 
Appendices, section 14.5.                                                                                                                                                                                                      
4.3.1  Sequence generation 
All seven included studies were described by trial investigators as randomised; 
however, the description of the randomisation procedure was insufficient for a 
judgement to be made in the studies by Kaminer et al. (1998a, 1999), Kaminer et al. 
(2002), and Latimer et al. (2003), and these studies were therefore judged as having 
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an unclear risk of bias for sequence generation. The remaining four studies (Dennis 
et al., 2004; Godley et al., 2010; Hendriks et al., 2011; Waldron et al., 2001) were all 
judged as having a low risk of bias for sequence generation, as the randomization 
procedure was adequate.  
 
4.3.2  Allocation  
Only three of the included studies (Dennis et al., 2004; Godley et al., 2010; Hendriks 
et al., 2011) reported on procedures for allocation concealment, and were judged as 
having a low risk of allocation concealment bias. The remaining five studies did not 
report on how allocation was handled, and were therefore judged as having an 
unclear risk of bias in this category. 
 
4.3.3  Blinding of outcome assessors 
Since blinding of participants and personnel was not possible in the trials examined 
in this review, we chose to make judgements of the risk of bias emerging from lack of 
blinding of outcome assessors only. 
 
Abstinence or reduction of drug use 
Three of the included studies (Dennis et al., 2004; Kaminer et al., 2002; Waldron et 
al., 2001) did not report on procedures of blinding outcome assessors and were 
therefore judged as having an unclear risk of bias. An additional two studies (Godley 
et al., 2010; Latimer et al., 2003) reported that follow-up data was collected by a 
separate group of staff that had no treatment delivery duties. However, this 
procedure was not judged to be sufficient blinding of the outcome assessors and the 
self-reported outcomes of drug use in these studies were therefore rated 3 on the 5-
point risk of bias scale. Kaminer et al. (1998a, 1999) was rated 2 on the 5–point 
scale, as this study reported that data was collected by a research assistant who was 
not informed of the matching hypothesis being studied, but who was not blinded in 
regard to group allocation. In the study by Hendriks et al. (2011), outcome assessors 
were reported to be blinded and the study was therefore rated 1 on the 5-point risk 
of bias scale. 
 
4.3.4  Incomplete outcome data 
Abstinence or reduction of drug use 
Three of the included studies (Godley et al., 2010; Latimer et al., 2003; Waldron et 
al., 2001) reported low or no missing data for their measurements of reduction of 
drug use and were therefore rated 1 for risk of bias caused by incomplete outcome 
data. Two studies (Dennis et al., 2004; Hendriks et al., 2011) were rated 2 on the risk 
of bias scale because these studies reported on low attrition, although some 
uncertainty existed as to whether these attrition rates applied to all measurements. 
One study (Kaminer et al, 1998a, 1999) was rated 3 for risk of attrition bias, since 
 42  The Campbell Collaboration | www.campbellcollaboration.org 
 
the study reported high rates of missing data. The study by Kaminer et al. (2002) 
was rated 4 on the 5-point scale, as this study not only reported high rates of missing 
data but also omitted to address the method used to fill in the missing data.     
 
4.3.5  Selective reporting 
Abstinence or reduction of drug use 
Six of the included studies (Dennis et al., 2004; Godley et al., 2010; Kaminer et al., 
2002 Latimer et al., 2003; Hendriks et al., 2011; Waldron et al., 2001) were rated 1 
for selective reporting, since all planned outcomes were reported. Kaminer et al. 
(1998a, 1999) was rated 2 for selective reporting bias, as the primary outcome in the 
follow-up study was reported differently from the outcome reported in the first 
study.  
   
4.3.6 Other potential sources of bias 
In Godley et al., 2010, some adolescents participated in other mental health 
treatment (e.g. counselling and/or medication management) and the study was 
rated 2. The remaining studies were all rated 1.  
  
4.3.7 A priori protocol 
Only three of the included studies (Dennis et al., 2004; Godley et al., 2010; Hendriks 
et al., 2011) stated whether an a priori protocol had been complied with. The 
remaining four studies (Kaminer et al., 1998a, 1999; Kaminer et al., 2002; Latimer 
et al., 2003; Waldron et al., 2001) either failed to report whether an a priori protocol 
had been produced or if they did, whether it had been followed, and the studies were 
therefore denoted as unclear on this topic. 
 
4.3.8  A priori analysis 
Only Dennis et al. (2004) and Hendriks et al. (2011) reported that an a priori 
analysis plan had been produced and followed. The additional five studies (Godley et 
al., 2010; Kaminer et al., 1998a, 1999; Kaminer et al., 2002; Latimer et al., 2003; 
Waldron et al., 2001) did not report whether an a priori analysis plan had been 
produced and followed, and these studies were therefore judged as having an 
unclear risk of bias on this topic. 
 
4.4  EFFECTS OF THE INTERVENTIONS 
In the protocol for this review the following comparisons were planned: 
 
- Absolute effects, comparing CBT to no treatment and untreated waitlist 
controls. 
 43  The Campbell Collaboration | www.campbellcollaboration.org 
 
- Relative effects, comparing CBT to other interventions and/or treatment as 
usual (TAU). 
 
We were unable to examine absolute effects of CBT, since the only available 
comparisons were against other interventions.  
 
Four studies evaluated CBT with an add-on component and three studies evaluated 
CBT without an add-on component. Those studies that evaluated CBT plus an add-
on component were analysed separately from those without an add-on component. 
 
In the following sections,  a number of forest plots are shown. In each case, the 
results have been presented in a way that favours CBT (below 0 for SMD or below 1 
for OR results). This has been chosen because the main primary outcome is drug use 
frequency, for which a reduction is favourable. 
 
Outcomes were considered in the following intervals: 
 
 Short term (beginning of treatment to less than 6 months after beginning of 
treatment). 
 Medium term (6 months to less than 12 months after beginning of treatment). 
 Long term (12 months or more after beginning of treatment). 
 
4.4.1 Primary outcomes results 
We identified two subgroups of primary outcomes, namely ‘drug use’ and ‘recovery’. 
 
Drug use 
Drug use was measured by drug use scales and drug use frequency. Meta-analyses 
were performed based on the following study outcomes: cannabis use measured with 
TLFB from Hendriks et al. (2011), substance use problems measured with T-ASI 
from Kaminer et al. (1998a, 1999), substance abuse problems measured with T-ASI 
from Kaminer et al. (2002), percentage of days abstinent from alcohol and other 
drugs measured with GAIN from Godley et al. (2010), marijuana use measured with 
ADI-R from Latimer et al. (2003), substance use frequency measured with SFS from 
Dennis et al. (2004) and percentage of days marijuana was used measured with 
TLFB from Waldron et al. (2001). 
 
As mentioned, the primary outcome in Godley et al. (2010) was measured as days 
abstinent from alcohol and other drugs. This outcome measure was reversed before 
entry into meta-analysis so that it represents days of use.  
 
The study by Dennis et al. (2004) included two comparison interventions (MDFT 
and ACRA) and the study by Godley et al. (2010) included two experimental 
conditions (MET/CBT7 and MET/CBT7+ACC) and two comparison interventions 
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(CBOP and CBOP+ACC). We performed analyses for all usable combinations (eight 
in all), repeating the analysis for each time interval. However, the forest plot below 
shows the results for just one of these combinations, namely MDFT as the control 
condition in Dennis et al. (2004) and MET/CBT7 as the experimental condition, and 
CBOP as the control condition in Godley et al. (2010). In only one case (recovery in 
the long term) did these repeated analyses change the overall conclusion. For this 
outcome, all repeated analyses are reported in this section. Otherwise, the repeated 
analyses for all other outcomes can be found in section 12.1. 
 
Short term 
Four studies with CBT plus an add-on component and two studies without an add-
on treatment provided data that enabled calculation of effect estimates on this 
outcome in the short term. Figures 4.3a and 4.3b show the forest plots. Pooled 
results did not reveal a statistically significant relative effect of CBT with an add-on 
component on drug use frequency in the short term. The pooled estimate SMD was -
0.14 (95% CI -0.64, 0.36) with statistically significant heterogeneity between studies 
(p=0.0004 and I2=84%). Nor was there a statistically significant relative effect of 
CBT without an add-on component on drug use frequency in the short term. The 
pooled estimate SMD was -0.13 (95% CI -0.68, 0.42) with statistically significant 
heterogeneity between studies (p=0.05 and I2=73%).  
 
 
 
Note: Dennis et al., 2004: MDFT used as comparison group. Godley et al., 2010: MET/CBT7 used as experimental 
condition and CBOP as comparison intervention. This analysis was also performed with the comparison 
intervention in Dennis et al., (2004) being ACRA, the experimental condition in Godley et al., (2010) being 
MET/CBT7+ACC and the comparison intervention in Godley et al. (2010) being CBOP+ACC. None of these seven 
additional analyses changed the overall conclusion (see  table 12.1). 
 
 
 
 
 
 
 
Figure 4.3a: Drug use, short term, CBT with add-on, forest plot 
Figure 4.3b: Drug use, short term, CBT without add-on, forest plot 
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Medium term 
Four studies with CBT plus an add-on component and three studies without an add-
on provided data that enabled calculation of effect estimates in the medium term. 
Three studies with CBT plus an add-on component provided outcome measures for 
two time points which could be included in the medium term category (Dennis et al., 
2004; Godley et al., 2010; Latimer et al., 2003). In the following analysis, we chose 
to pool the outcomes as close to 6 months from beginning of treatment as possible. 
 
Figures 4.4a and 4.4b show the forest plots. Pooled results revealed a statistically 
significant relative effect of CBT with an add-on component on drug use frequency 
in the medium term. The pooled estimate SMD was -0.06 (95% CI -0.44, 0.32) with 
statistically significant heterogeneity between studies (p=0.01 and I2=75%). For CBT 
without an add-on component there was no statistically significant relative effect of 
CBT on drug use frequency in the medium term. The pooled estimate SMD was -
0.08 (95% CI -0.48, 0.31). The estimated between studies variance component, τ2, 
was 0.06, but there is no statistically significant heterogeneity between studies 
(p=0.15 and I2=47%).  
 
 
 
 
Note: Dennis et al., 2004: MDFT used as comparison group. Godley et al., 2010: MET/CBT7 used as experimental 
condition and CBOP as comparison intervention. This analysis was also performed with the comparison 
intervention in Dennis et al., (2004) being ACRA, the experimental condition in Godley et al., (2010) being 
MET/CBT7+ACC and the comparison intervention in Godley et al. (2010) being CBOP+ACC. None of these seven 
additional analyses changed the overall conclusion (see  table 12.1). 
 
 
 
Figure 4.4a: Drug use, medium term, CBT with add-on, forest plot 
Figure 4.4b: Drug use, medium term, CBT without add-on, forest plot 
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Long term 
Two studies with CBT plus an add-on component and two studies without an add-on 
treatment provided data that enabled calculation of effect estimates in the long term. 
Figures 4.5a and 4.5b show the forest plots. Neither of the analyses revealed a 
statistically significant relative effect of CBT with or without an add-on component 
on drug use frequency in the long term. The weighted SMD for the analysis with an 
add-on was -0.15 (95% CI -0.36, 0.06) with no heterogeneity between studies 
(p=0.45 and I2=0%). The weighted SMD for the analysis without an add-on 
component was 0.02 (95% CI -0.48, 0.52). Although the between studies variance 
component, τ2, was 0.04, there was no statistically significant heterogeneity between 
studies (p=0.27 and I2=17%).  
 
 
 
Note: Dennis et al., 2004: MDFT used as comparison group. Godley et al., 2010: MET/CBT7 used as experimental 
condition and CBOP as comparison intervention. This analysis was also performed with the comparison 
intervention in Dennis et al., (2004) being ACRA, the experimental condition in Godley et al., (2010) being 
MET/CBT7+ACC and the comparison intervention in Godley et al. (2010) being CBOP+ACC. None of these seven 
additional analyses changed the overall conclusion (see  table 12.1). 
 
 
 
 
Recovery 
Three studies provided data that enabled calculation of effect estimates on recovery 
status. Hendriks et al. (2011), Godley et al. (2010), and Dennis et al. (2004) reported 
Figure 4.5a: Drug use, long term, CBT with add-on, forest plot 
Figure 4.5b: Drug use, long term, CBT without add-on, forest plot 
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on recovery status 12 months from the beginning of treatment. Two of the studies 
analysed CBT with an add-on component and one study analysed CBT without an 
add-on. 
 
Pooled results show a statistically significant relative effect of CBT with an add-on component on 
recovery status in the long term (OR = 0.63 (95% CI 0.39, 1.00) with no statistically significant 
heterogeneity between studies (p=0.37 and I2=0%; see Figure 4.6a). This result should be interpreted 
with considerable caution as the repeated analyses for all other combinations (the comparison 
intervention in Dennis et al., (2004) being ACRA, the experimental condition in Godley et al., (2010) 
being MET/CBT7+ACC and the comparison intervention in Godley et al. (2010) being CBOP+ACC.) 
show different results (see table 4.3). One of the repeated analyses showed a statistically significant 
result favouring the control group (Dennis et al., 2004: ACRA; Godley et al. 2010: MET/CBT7+ACC, 
CBOP+ACC); whereas the remaining six analyses did not show any statistically significant result. 
 
 
 
 Note: Dennis et al., 2004: MDFT used as comparison group. Godley et al., 2010: MET/CBT7 used as experimental 
condition and CBOP as comparison intervention.  
 
 
  
Figure 4.6a: Recovery, long term, CBT with add-on, forest plot 
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Table 4.3: Repeated analyses, Recovery, long term, CBT with add-on 
Comparison combination Recovery,  OR [95% CI]  Long term 
Dennis et al., 2004: ACRA 
Godley et al. 2010: MET/CBT7, CBOP 
0.94 [0.28, 3.12] 
Dennis et al., 2004: MDFT 
Godley et al. 2010: MET/CBT7, CBOP+ACC 
0.77 [0.48, 1.22] 
Dennis et al., 2004: ACRA 
Godley et al. 2010: MET/CBT7, CBOP+ACC 
1.14 [0.51, 2.57] 
Dennis et al., 2004: MDFT 
Godley et al. 2010: MET/CBT7+ACC, 
CBOP+ACC 
1.07 [0.59, 1.91] 
Dennis et al., 2004: ACRA 
Godley et al. 2010: MET/CBT7+ACC, 
CBOP+ACC 
1.58 [1.00, 2.48] 
Dennis et al., 2004: MDFT 
Godley et al. 2010: MET/CBT7+ACC, CBOP 
0.87 [0.54, 1.41] 
Dennis et al., 2004: ACRA 
Godley et al. 2010: MET/CBT7+ACC, CBOP 
1.31 [0.74, 2.32]  
 
The effect estimate for the study analysing CBT without an add-on component is not 
statistically significant (OR = 2.89 [95% CI 0.72, 11.56]; see figure 4.6b). 
 
 
 
 
 
Summary of primary outcome results 
The primary outcome of drug use was analysed separately in the short term, medium 
term and long term. The analyses were divided between studies analysing CBT with 
and without an add-on component. The meta-analyses showed no statistically 
significant relative effect of CBT with an add-on component for drug use frequency 
compared to a group of different treatment interventions for youth drug use (see 
section 10.2).  
 
Statistically significant heterogeneity was present in the short term. In the medium 
term statistically significant heterogeneity was present between studies analysing 
CBT with an add-on. In the analysis of studies without an add-on there was no 
statistically significant heterogeneity in the medium term. Due to the low power of 
detecting heterogeneity with only two studies included in the analysis this result 
should be interpreted with caution. The estimated between studies variance 
Figure 4.6b: Recovery, long term, CBT without add-on, forest plot 
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component, τ2, was 0.06. There was no heterogeneity between studies in the long 
term although the estimated between studies variance component, τ2, was 0.04 in 
the analysis of CBT without an add-on. With only two studies included in the 
analysis the power to detect heterogeneity was low. 
 
The primary outcome of recovery could only be analysed in the long term.  
The meta-analysis of CBT with an add-on component is inconclusive, as the eight 
different comparison combinations analysed show different results. Only one study 
analysing CBT without an add-on component provided data on recovery status, and 
here, the reported effect was not statistically significant. 
 
4.4.2  Secondary outcomes 
The protocol for this systematic review arranged the secondary outcomes into five 
groups. All studies that reported on secondary outcomes corresponded to at least 
one of these five groups. 
 
Social functioning and family functioning 
For this group of secondary outcomes, it was possible to identify two meaningful 
areas of analysis based upon the included studies, namely psychological problems 
and family problems. 
 
With respect to psychological problems, three studies analysing CBT without an 
add-on component provided data that enabled calculation of effect estimates on this 
outcome. Hendriks et al. (2011) reported on internalizing disorder/symptoms and 
Kaminer et al. (2002) and Kaminer et al. (1998a, 1999) both reported on 
psychological problems. Three studies reported outcomes measured at the medium 
term and two studies at the long term follow-up. 
 
Pooled results did not reveal a statistically significant relative effect of CBT without 
an add-on component on psychological problems in the medium term. The pooled 
estimate SMD was -0.08 (95% CI -0.35, 0.18) with no heterogeneity between studies 
(p=0.66 and I2=0%).  
 
  
Pooled results did not reveal a statistically significant relative effect of CBT without 
an add-on component on psychological problems in the long term. The pooled 
Figure 4.7: Psychological problems, medium term, CBT without an add-on, forest plot 
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estimate SMD was -0.32 (95% CI -0.68, 0.04) with no heterogeneity between studies 
(p=0.75 and I2=0%).  
 
 
 
  
With respect to family problems, two studies analysing CBT without an add-on 
component provided data that enabled calculation of effect estimates on this 
outcome. Kaminer et al. (2002) and Kaminer et al. (1998a, 1999) both reported 
numeric outcome on family problems. The outcomes for family problems were not 
pooled to reflect the short, medium or long term categories. In order to exploit the 
available data, the outcomes were pooled as close to 6 months from the beginning of 
treatment as possible. This also made them more comparable with respect to time 
point measurement. In Kaminer et al. (1998a, 1999) the outcome was measured 5 
months from the beginning of treatment and in Kaminer et al. (2002) the outcome 
was measured 6 months from the beginning of treatment. 
 
Pooled results did not reveal a statistically significant relative effect of CBT without 
an add-on component on family problems. The pooled estimate SMD was -0.48 
(95% CI -1.17, 0.22) with no statistically significant heterogeneity between studies 
(p=0. 14 and I2=55%). Note that this result concerning heterogeneity should be 
interpreted with caution, due to the low power of detecting statistically significant 
heterogeneity with only two studies. The estimated between-study variance 
component, τ2, was 0.15. 
 
 
 
 
Education or vocational involvement 
For this group of secondary outcomes, it was possible to identify one meaningful 
area of analysis based upon the included studies, namely school problems. Two 
studies analysing CBT without an add-on component included outcome measures in 
Figure 4.9: Family problems, CBT without an add-on, forest plot 
Figure 4.8: Psychological problems, long term, CBT without an add-on, forest plot 
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this area. Kaminer et al. (2002) and Kaminer et al. (1998a, 1999) both included 
school problems measured using the T-ASI scale. 
 
The outcomes for school problems were not pooled to reflect the short, medium or 
long term categories. Instead, the outcomes were pooled as close to 6 months from 
the beginning of treatment as possible so as to make them comparable. In Kaminer 
et al. (1998a, 1999), the outcome was measured 5 months from the beginning of 
treatment, while in Kaminer et al. (2002) the outcome was measured 6 months from 
the beginning of treatment. 
  
Pooled results did not reveal a statistically significant relative effect of CBT on school 
problems. The pooled estimate SMD was -0.24 (95% CI -0.63, 0.14) with no 
heterogeneity between studies (p=0.74 and I2=0%).  
 
 
 
Retention 
Four studies reported data that enabled calculation of effect estimates on treatment 
retention. One of the studies analysed CBT with an add-on component (Dennis et al. 
(2004) and three studies analysed CBT without an add-on component (Hendriks et 
al. (2011); Kaminer et al. (2002) and Kaminer et al. (1998a, 1999). All four studies 
reported numeric outcomes for treatment completers. Despite the fact that these 
studies used different ways to define when an individual had completed treatment, 
in the following analysis we used the outcome as denoted by the investigators to 
refer to completion of treatment. 
 
The effect estimate for the study analysing CBT with an add-on component was not 
statistically significant (OR = 1.56; 95% CI 0.87, 2.79). 
For CBT without an add-on component, the weighted OR was not statistically 
significant (OR = 2.67; 95% CI 0.24, 29.35) with statistically significant 
heterogeneity between studies (p<0.00001 and I2=91%). Note that the result 
reported in Hendriks et al. (2011) differed considerably from the results reported in 
the two other studies and has a very wide confidence interval. When Hendriks et al. 
(2011) is excluded, no heterogeneity is detected (p=0.69 and I2=0%) and this result 
does not support any change in the overall conclusion; the weighted OR is not 
statistically significant (OR = 0.81; 95% CI 0.32, 2.03). 
 
Figure 4.10: School problems, CBT without an add-on, forest plot 
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Note: Dennis et al., 2004: MDFT used as comparison group. With the control condition in Dennis et al., (2004) 
being ACRA , this did not support any change in the overall conclusion. 
 
 
 
 
 
Risk behaviour 
Four studies included an outcome that could be categorized as risk behaviour. One 
of the studies analysed CBT with an add-on component (Waldron et al. (2001) and 
three studies analysed CBT without an add-on component (Hendriks et al., 2011; 
Kaminer et al., 2002; Kaminer et al., 1998a, 1999). Waldron et al. (2001) included 
delinquency, Hendriks et al. (2011) included the number of property and violent 
crimes committed and Kaminer et al. (2002) as well as Kaminer et al. (1998, 1999) 
reported on legal problems.  
 
Three of these studies reported outcomes in the short term interval, all four in the 
medium term interval, and two in the long term interval. 
 
The study analysing CBT with an add-on component reported a statistically 
significant SMD in the short term favouring the control group (SMD = 0.55; 95% CI 
0.04, 1.06). 
 
For CBT without an add-on, the weighted SMD was not statistically significant in the 
short term. The pooled estimate SMD is 0.11 (95% CI -0.17, 0.39) with no 
statistically significant heterogeneity between studies (p=0.95 and I2=0%).  
 
 
 
 
 
Figure 4.11a: Retention, CBT with an add-on, forest plot 
Figure 4.11b: Retention, CBT without an add-on, forest plot 
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The effect estimate for the study analysing CBT with an add-on component was not 
statistically significant in the medium term (SMD=0.28; 95% CI -0.23, 0.79). 
 
Nor was the weighted SMD for CBT without an add-on component statistically 
significant. The pooled estimate SMD was -0.02 (95% CI -0.28, 0.25) with no 
statistically significant heterogeneity between studies (p=0.56 and I2=0%).  
 
 
 
 
 
 
Pooled results did not reveal a statistically significant relative effect of CBT without 
an add-on component on risk behaviour in term of crime in the long term. The 
pooled estimate SMD was 0.11 (95% CI -0. 25, 0.46) with no heterogeneity between 
studies (p=0.96 and I2=0%).  
  
Figure 4.12a: Crime, short term, CBT with an add-on, forest plot 
Figure 4.13a: Crime, medium term, CBT with an add-on, forest plot 
Figure 4.12b: Crime, short term, CBT without an add-on, forest plot 
Figure 4.13b: Crime, medium term, CBT without an add-on, forest plot 
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Other adverse effects 
No study reported adverse effects.  
 
Summary of secondary outcome results 
The secondary outcomes, psychological problems and crime, were analysed 
separately in the short term, medium term and long term. The secondary outcomes 
of family problems and school problems could not be divided to reflect the short, 
medium or long term categories. In order to exploit the available data, those 
outcomes reported as closest to 6 months from the beginning of treatment were 
used. Retention was measured as completion of treatment as denoted by the 
investigators of the primary studies. 
 
All analyses were divided between studies analysing CBT with and without an add-
on component. In conclusion, none of the meta-analyses showed a statistically 
significant relative effect of CBT either with an add-on or without an add-on 
component for any of the secondary outcomes compared to a group of different 
treatment interventions for youth drug use (see section 10.2). There was one 
exception, however; the one study that reported crime outcomes for the relative 
effect of CBT with an add-on component compared to Functional Family Therapy 
(FFT) reported a statistically significant outcome in the short term, favouring FFT. 
4.4.3  Sensitivity analysis  
The sensitivity analyses were only performed for the short and medium term follow-
up as too few studies provided data for the long term. We examined the robustness 
of our conclusions by removing from the analyses studies with certain characteristics 
as displayed in table 4.4. The results of these sensitivity analyses did not support any 
change in the overall conclusions. Forest plots can be found in section 12.3. 
 
 
Table 4.4: Sensitivity analyses 
SMD [CI 95%]  
(Number of studies included) 
Short term 
With add-on 
Medium term 
With add-on 
Medium term 
Without add-on 
All studies -0.14 [-0.64, 0.36] (4) -0.06 [-0.44, 0.32] (4) -0.08 [-0.48, 0.31] (3) 
Figure 4.14: Crime, long term, CBT without an add-on, forest plot 
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Characteristics of studies removed from the analysis 
Did not present results from a 
true intention-to-treat 
analysis1 
* * 0.11[-0.26, 0.48] (1) 
Blinding: score 3 or 41 0.29 [-0.62, 1.20] (2) 0.06 [-0.18, 0.30] (2) * 
Did not report on treatment 
fidelity 
0.78[0.25, 1.31] (1) 0.28[-0.23, 0.79] (1) -0.82[-1.68, 0.04] (1) 
Incomplete outcome data: 
score 3 or 41 
* * 0.11[-0.26, 0.48] (1) 
Risk of developer bias 
present1 
-0.14 [-0.99, 0.71] (3) -0.13 [-0.76, 0.51] (3) * 
Note 1: * No studies removed  
4.4.4  Publication bias  
For the analyses of CBT with an add-on component, we assessed the possibility of 
publication bias for the short term and medium term follow-up time intervals. As 
only two studies provided data for the long term interval, we did not assess 
publication bias for the long term. For the analyses of CBT without an add-on 
component, we assessed the possibility of publication bias for the medium term 
interval. Because only two studies analysed CBT without an add-on component in 
the short term and the long term, we did not assess publication bias for those 
intervals. 
 
As stated in the protocol (Kowalski et al., 2012), we assessed the possibility of 
publication bias visually by examining funnel plots. The three funnel plots are 
displayed in section 12.4.  
The figures reveal approximately symmetrical, inverted funnels giving no indication 
of bias. We cannot, however, draw any firm conclusions on publication bias based on 
such a small number of included studies. 
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5 Discussion 
5.1  SUMMARY OF THE MAIN RESULTS 
Our main objective was to evaluate the current evidence on the effect of CBT on 
abstinence and drug use reduction for young people in outpatient treatment for non-
opioid drug use.  
Seven randomised trials involving 953 participants were included in this review. All 
included studies compared CBT, either with or without an add-on component, to an 
active intervention. In summary, we found the following: 
Abstinence or reduction of drug use 
Meta-analysis of data from the four included studies analysing CBT with an add-on 
component did not show a statistically significant relative effect of CBT for the 
reduction of youth drug use frequency either in the short term, medium term or long 
term. Nor did meta-analysis of data from the three included studies analysing CBT 
without an add-on component show a statistically significant relative effect of CBT 
for the reduction of youth drug use frequency, either in the short term, medium term 
or long term.  
 
The primary outcome measured as recovery could only be analysed in the long term.  
The meta-analysis of CBT with an add-on component was inconclusive, as the eight 
different comparison combinations analysed showed different results. Only one 
study analysing CBT without an add-on component provided data on recovery 
status. The reported effect was not statistically significant. 
 
Thus, the available data did not support the hypothesis that there is a relative 
reduction in drug use from using CBT (with or without an add-on component) with 
young drug users compared to other types of treatment (ACRA, CBOP (+ACC), 
DHPE, FFT, IT, MDFT and PET). 
 
Social functioning and family functioning 
Meta-analysis of included studies did not show a statistically significant relative 
effect for CBT without an add-on component on psychological problems in the 
medium and long term compared to other interventions (IT, MDFT and PET). 
Furthermore, a meta-analysis including two studies similarly failed to reveal a 
statistically significant relative effect for CBT without an add-on component on 
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family problems approximately six months from the beginning of treatment 
compared to other interventions (IT, MDFT and PET). 
 
Education or vocational involvement 
Meta-analysis of two included studies did not show a statistically significant relative 
effect for CBT without an add-on on component on school problems approximately 
six months from the beginning of treatment compared to other interventions (IT and 
PET). 
 
Retention 
One study analysing CBT with an add-on component and all three studies analysing 
CBT without an add-on component reported on treatment retention. The effect 
estimate for the study analysing CBT with an add-on component was not statistically 
significant. The meta-analysis of the three studies analysing CBT without an add-on 
component did not show any statistically significant relative effect of CBT compared 
to other interventions (IT, MDFT and PET ). 
 
Risk behaviour 
One study analysing CBT with an add-on component and all three studies analysing 
CBT without an add-on component reported an outcome which could be categorized 
as risk behaviour, namely problems related to crime. The effect estimate for the 
study analysing CBT with an add-on component was not statistically significant (and 
provided reports for the short term and medium term only). The meta-analysis of 
the three studies analysing CBT without an add-on component did not show any 
statistically significant relative effect of CBT on treatment retention compared to 
other interventions (IT, MDFT and PET ). 
 
No studies reported on other adverse effects, such as suicide or overdoses. 
Sensitivity analyses were only performed for the short and medium term, as too few 
studies provided data for the long term follow-up period. Sensitivity analyses were 
performed with respect to analysis method, risk of bias and intervention 
characteristics. Results of these sensitivity analyses did not support any change in 
the overall conclusions. 
 
5.2  OVERALL COMPLETENESS AND APPLICABILITY OF 
EVIDENCE 
Several findings across studies are worth mentioning.  
 
A number of studies used urine testing to determine drug use; however, several 
studies used the urine samples to confirm the quality of self-reported measures and 
did not explicitly report results from these urine tests. Had such results been 
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reported, we might have been able to use this outcome in a pooled analysis along 
with the self-reported measures.  
 
The majority of the included studies used a self-reported outcome assessment to 
measure the primary outcomes of abstinence and frequency of drug use. In 
particular, the Time-Line Follow-Back (TLFB) method was widely used across the 
studies. For the secondary outcomes (such as family life, education and mental 
health) a wider variety of assessment instruments were used across studies, which 
meant that we were unable to utilise all the available secondary outcomes in a meta-
analysis.  
 
All but one of the studies reported a follow-up measurement approximately one year 
from the beginning of treatment. This had the advantage of making it possible to 
document any longer-term effects. 
 
The number of included studies in this systematic review is small; only seven studies 
met the inclusion criteria. With one exception, all studies originated from the USA. 
This may limit the applicability of the evidence to a specific social and cultural 
setting, which in turn may be difficult to translate to other settings. This indicates a 
need for more well-conducted studies of CBT interventions in countries other than 
the USA.  
 
5.3  QUALITY OF THE EVIDENCE 
All seven included studies were randomised controlled trials. The included studies 
varied in terms of the risk of bias judgements; no single study can be characterised 
as a robust RCT with low risk of bias on all assessed risk of bias items.  
 
Four of the included studies provided insufficient information on core issues (such 
as the method of sequence generation and of allocation concealment) to allow us to 
assess fully the risk of bias and two of these studies had a significant level of missing 
data. These methodological weaknesses led us to question the validity of these 
studies.  
 
Meta-analyses were carried out separately for CBT with an add-on component (such 
as, for example, motivational interviewing) and CBT without an add-on component, 
which resulted in there being few studies (four and three, respectively) included in a 
single analysis. There was no overall consistency in the direction of treatment effect 
regarding the primary outcome (drug use). Very few studies reported on the 
secondary outcomes, and there was no overall consistency between studies in the 
direction of treatment effect regarding secondary outcomes.. 
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5.4  POTENTIAL BIASES IN THE REVIEW PROCESS 
The composition of the review team changed during the process of undertaking this 
review. This change of composition should not cause any bias in the review process 
because each procedure is documented and stored electronically, and considerable 
care was taken to ensure the review team members were consistent throughout in 
their approach.  
 
5.5  AGREEMENTS AND DISAGREEMENTS WITH OTHER 
REVIEWS 
Several reviews have reported on CBT and other outpatient treatment interventions 
for adolescent substance abuse (Becker & Curry, 2008; Tanner-Smith et al., 2013; 
Vaughn & Howard, 2004; Waldron & Kaminer, 2004; Waldron & Turner, 2008). 
Common to all these reviews is the finding that CBT is a promising intervention for 
reducing adolescent substance use. However, it has been shown that CBT is not 
necessarily better than other interventions where programs focusing on family 
therapy in particular perform well (Tanner-Smith et al., 2013; Vaughn & Howard, 
2004; Waldron & Kaminer, 2004). 
 
Several of these reviews focus on the quality of the studies in the field of adolescent 
substance use treatment. In that respect, the CBT studies do perform very well 
compared to studies investigating other treatment interventions (Becker & Curry, 
2008; Vaughn & Howard, 2004). A number of these reviews also make the point 
that it is necessary to investigate the heterogeneity in treatment effects in order to 
understand who benefits most from CBT (Vaughn & Howard, 2004; Waldron & 
Kaminer, 2004; Waldron & Turner, 2008).  
 
The results presented in this systematic review are in line with these earlier reviews 
in that we did not find any statistically significant effect of CBT compared to other 
interventions. Moreover, we identified several well-conducted and well-reported 
RCTs which could contribute to the analysis. However, we did not identify sufficient 
studies to allow moderator analysis to be performed.  
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6 Authors’ Conclusion 
6.1  IMPLICATIONS FOR PRACTICE 
Based on the small number of included studies, we are unable to conclude whether 
CBT interventions perform better or worse than the following alternative 
interventions: Adolescent Community Reinforcement Approach (ACRA), Chestnut 
Bloomington Outpatient (CBOP) (+Assertive Continuing Care (ACC)), Drugs Harm 
Psychoeducational curriculum  (DHPE), Functional Family Therapy (FFT), 
Interactional Therapy (IT), Multidimensional Family Therapy  (MDFT) and 
Psychoeducational Therapy (PET) ) with respect to young people’s drug use 
reduction.  
 
This systematic review is based on seven included studies. Data was examined in two 
separate analyses, depending on whether the intervention was CBT with an add-on 
component such as motivational interviewing (four studies) or CBT without an add-
on component (three studies). The seven studies varied in terms of their findings 
regarding the effects of CBT interventions compared to other interventions (ACRA, 
CBOP (+ACC), DHPE, FFT, IT, MDFT and PET ) on young people’s drug use. Our 
graphical examination in the forest plots shows that the studies’ individual effect 
estimates are distributed almost equally between effect sizes favouring CBT 
interventions and effect sizes favouring the comparison interventions. The overall 
conclusion regarding the effect of CBT interventions on drug use reduction for 
young people aged 13 to 21 years should therefore be interpreted with caution. 
 
In addition to knowledge of overall positive effects of interventions, practitioners 
also need to know about any potential differential effects on treatment of highly 
relevant participant characteristics such as age, gender, minority background, family 
composition and co-occurring conditions. These characteristics are potential 
predictors of treatment outcome, and practitioners need to be able to assess and 
tailor the program to particular types of young drug users. Unfortunately, it is not 
possible to identify which particular subgroups of youth may be more likely to 
respond to specific interventions, and subsequently how treatments could be 
adapted or tailored to the individual needs of a young person until the results of 
additional CBT outcome studies are available. 
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6.2  IMPLICATIONS FOR RESEARCH 
There is a need for more well-designed, randomised controlled trials of CBT 
interventions for adolescent substance use treatment. To improve generalisability, 
the populations studied should not be confined to Northern America. The results of 
such trials should be reported clearly in accordance with the principles of the 
CONSORT 2010 statement (Moher et al., 2010). All outcomes should be reported 
including, for example, the results of any urine testing. There is also a need for 
studies investigating heterogeneity in treatment effects so as to determine which 
adolescents are likely to benefit most from this intervention. 
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7 Deviations from the protocol   
In the protocol guiding this systematic review it was stated, that the review “…will 
include outpatient CBT interventions described by the authors as CBT or judged by 
the review authors to represent CBT,” (Kowalski et al., 2012). To judge whether or 
not an intervention is CBT can be very subjective and therefore the review authors, 
in agreement with the Social Welfare Group, changed the inclusion criteria to “…will 
include outpatient CBT interventions, described by the trial investigators as CBT”.  
 
In conducting the review, we became aware that the measure of time points as 
calculated from end of treatment would cause unequal comparisons23. We decided to 
change the measure of time points as calculated from the beginning of treatment24. 
Furthermore, the grouping of time intervals as described in the protocol would 
result in very few studies included in the long term interval. Therefore, the intervals 
used are the following: 
 Short term (beginning of treatment to less than 6 months after the beginning of 
treatment). 
 Medium term (6 to less than 12 months after the beginning of treatment). 
 Long term (12 months or more after the beginning of treatment). 
 
                                                          
23For example, in Dennis et al. (2004) the duration of the CBT intervention and the control condition was not the 
same. This would imply that “end of treatment” was measured unequally between groups. 
24From studies which measure the time points from end of treatment we used the duration of the treatment to 
measure the ”beginning of treatment” time point. In studies which measure the time points from baseline, we 
assume that this baseline is close to the beginning of treatment. Based on this assumption, we can use the baseline 
as an indicator for beginning of treatment. 
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10 Characteristics of studies 
10.1  CHARACTERISTICS OF INCLUDED STUDIES 
Table 10.1: Dennis et al., 2004 
Methods Design: RCT 
Unit of allocation: Individually 
Participants Sample size: n=300 
Age:  
MET/CBT5:  Aged 13-14: 11%, Aged 15-16: 57%, Aged 17-18: 32% 
        ACRA:          Aged 13-14: 14%, Aged 15-16: 56%, Aged 17-18: 30% 
        MDFT:          Aged 13-14: 13%, Aged 15-16: 48%, Aged 17-18: 39% 
Gender:  
MET/CBT5:  21% female  
ACRA: 20% female  
MDFT: 15% female 
Ethnicity:  
MET/CBT5:  Caucasian/white: 47%, African American/black: 50%, 
Hispanic/Latino: 2%, Other/mixed: 1% 
ACRA: Caucasian/white: 53%, African American/black: 44%, 
Hispanic/Latino: 1%, Other/mixed: 2% 
MDFT: Caucasian/white: 47%, African American/black: 47%, 
Hispanic/Latino: 1%, Other/mixed: 5% 
Family status:  
MET/CBT5: Single parent family: 53% 
ACRA: Single parent family: 59%                        
MDFT: Single parent family: 52% 
Main drug of use: Cannabis 
Severity:  
Marijuana dependence - MET/CBT5: 47%, ACRA: 47%, MDFT: 52% 
Marijuana abuse - MET/CBT5: 34%, ACRA: 33%, MDFT: 33% 
Comorbidity:  
Alcohol dependence - MET/CBT5: 7%, ACRA: 13%, MDFT: 12% 
Alcohol abuse - MET/CBT5: 34%, ACRA: 28%, MDFT: 30% 
Other substance dependence - MET/CBT5: 1%, ACRA: 1%, MDFT: 1% 
Other substance abuse - MET/CBT5: 12%, ACRA: 8%, MDFT: 12% 
Major depression - MET/CBT5: 27%, ACRA: 16%, MDFT: 11% 
Generalized anxiety disorder - MET/CBT5: 34%, ACRA: 21%, MDFT: 25% 
Suicidal thought or actions - MET/CBT5: 10%, ACRA: 7%, MDFT: 7% 
Any traumatic distress disorder - MET/CBT5: 17%, ACRA: 14%, MDFT: 
12% 
Conduct disorder - MET/CBT5: 56%, ACRA: 54%, MDFT: 58% 
Attention deficit-hyperactivity disorder - MET/CBT5: 34%, ACRA: 38%, 
MDFT: 38% 
Inclusion criteria:  
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The target population of this study was adolescents with cannabis related 
disorders who would be appropriate for and typically present to publicly 
funded outpatient treatment. Participants were eligible for CYT if they were 
aged 12 to 18, self-reported one or more DSM-IV criteria for cannabis 
abuse or dependence, had used cannabis in the past 90 days or 90 days 
prior to being sent to a controlled environment, and were appropriate for 
outpatient treatment. We included adolescents with alcohol and other drug 
diagnoses and co-occurring psychiatric disorders (as long as they could be 
managed at the outpatient level), as well as those with only cannabis abuse 
diagnoses, and/or less than weekly substance use. 
Exclusion criteria:  
Adolescents were excluded if they were inappropriate for short-term 
outpatient treatment or would be unable to participate in the study. The 
exclusion criteria were: a) reported use of alcohol 45 or more of the 90 days 
prior to intake; b) reported use of other drugs 13 or more of the 90 days 
prior to intake; c) reported an acute medical or psychological problem that 
was likely to prohibit full participation in treatment; d) had insufficient mental 
capacity to understand and provide informed consent or participate in 
treatment; e) lived outside of the program's catchment area; f) had a history 
of repeated, violent behavior or severe conduct disorder that might put 
other participants at risk; or g) lacked sufficient ability to use English to 
participate in the consent process, treatment, or research interviews. (p. 
200) + more exclusion criteria in the protocol: d) had an acute psychological 
condition that required immediate treatment and/or was likely to prohibit full 
participation in treatment and could not be managed in this level of care; i) 
lacked a parent or significant other who had sufficient ability in English to 
understand the collateral consent form and participate in research 
assessments and potentially in treatment; j) had participated previously in 
the study. 
Interventions Intervention: MET/CBT5 
Duration: 6-7 weeks  
Total of any service hours: 4.8 
Total therapy sessions: 3.8 
Length of stay (mean days): 41.1 
Days of 1+ therapy sessions: 3.4 
Days of any contact: 7.8 
Location: Clinic, USA 
Comparisons:  
1) ACRA (Adoleescent Community Reinforcement Approach) 
2) MDFT (Multidimensional Family Therapy) 
Relevant Outcomes 
 
 
Primary outcomes: Days abstinent, substance problems, substance 
frequency, recovery 
Measures: GAIN 
 
Secondary outcomes: Retention 
Notes Quality assurance procedures (implementation): "The quality assurance 
reviews led to the remedial training and, in an extreme case, the removal of 
one therapist from the trial. The site visits involved seven or more project 
staff reviewing all aspects implementation and concluded with group 
problem-solving about how to quickly address any problems. In one case, 
the site visit resulted in the complete shut-down, redesign and restarting of 
a site." (Protocol, p. 26) 
 
(Note: we cannot conclude on this, as we don't know which site this relates 
to) 
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"After training for the intervention they were to deliver, clinical staff taped 
their sessions for review. Each treatment clinical coordinator reviewed 
audio or videotapes of all sessions provided by each therapist until he or 
she was certified as proficient in that intervention. Weekly supervision 
continued throughout the study and included review of at least two therapy 
tapes per month to prevent therapist drift. During tape reviews, the clinical 
coordinators completed treatment-specific rating forms to monitor 
adherence and provide feedback to therapists (...)" (p. 204) 
 
H. Liddle, the developer of MDFT, was involved in this study and therefore 
there is a potential risk of developer bias. 
 
This study address treatment fidelity and it is reported that the quality 
assurance led to remedial training and removal of one therapist. However 
the study does not explicitly report on results related to treatment fidelity. 
 
 
Table 10.2: Godley et al., 2010 
Methods Design: RCT 
Unit of allocation: Individually 
Participants  Sample size: n=320 
Age: Average participant age was 15,9 years old (SD = 1,2) 
Aged 13-14: 13%, Aged 15-16: 56%, Aged 17-18: 31% 
MET/CBT7 without ACC: Aged 13-14: 11%, Aged 15-16: 58%, Aged 
17-18: 30%  
MET/CBT7 with ACC: Aged 13-14: 20%, Aged 15-16: 63%, Aged 
17-18: 17%  
CBOP without ACC: Aged 13-14: 13%, Aged 15-16: 49%, Aged 17-
18: 39% 
CBOP with ACC: Aged 13-14: 9%, Aged 15-16: 53%, Aged 17-18: 
39% 
Gender: 76 % male. 
MET/CBT7 without ACC: 73% male. 
MET/CBT7 with ACC: 70% male.   
CBOP without ACC: 76% male.   
CBOP with ACC: 82% male. 
Ethnicity: 73% Caucasian, 13% African American, 14% 
Hispanic/Latino/other/mixed. 
MET/CBT7 without ACC: 73%Caucasian/white, 17% 
African/American/Black, 10% Hispanic/Latino/other/mixed.  
MET/CBT7 with ACC: 70% Caucasian/white, 10% 
African/American/Black, 20% Hispanic/Latino/other/mixed. 
CBOP without ACC: 75% Caucasian/white, 13% 
African/American/Black, 12% Hispanic/Latino/other/mixed. 
CBOP with ACC: 74% Caucasian/white, 11% 
African/American/Black, 5% Hispanic/Latino/other/mixed.  
Family status: Not reported. 
Main drug of use: Cannabis. 
Severity: Weekly alcohol and other drug use: 49%. 
Comorbidity:  
Any co-occurring problems: 56%, Major depressive disorder: 28%, 
Generalized anxiety: 8%, Traumatic distress: 19%, ADHD: 34%, Conduct 
 76  The Campbell Collaboration | www.campbellcollaboration.org 
 
disorder: 42%, Any prior mental health treatment: 52%, Alcohol abuse: 
38%, Other substance abuse: 3% 
Inclusion criteria:  
Adolescents met inclusion criteria if they were 12-18 years old, met ASAM's 
(2001) Patient Placement criteria for Level 1 outpatient treatment based on 
a substance abuse or dependence diagnosis and six dimensional 
admission criteria (i.e., severity of intoxication/withdrawal, physical health, 
emotional/behavioral health, treatment readiness, relapse potential, and 
recovery environment), and attended an admission appointment. 
Exclusion criteria:  
Adolescents were excluded from the study for one or more of the following 
reasons, they: a)were "stepped-down" from residential treatment and were 
therefore more severe than adolescents who entered outpatient treatment 
from the community (n=102); b) were recommended only for individual 
counseling, as both outpatient treatment conditions had group component 
(n=21); c) were a ward of the state (n=27); d) did not have a 
parent/guardian present during admission to outpatient treatment (n=4); e) 
appeared to have insufficient mental capacity to provide informed consent 
(n=2); or f) did not speak English with sufficient ability to understand study 
procedures and instruments 8n=1). 
Interventions Interventions:  
1) MET/CBT7 (Motivational Enhancement Therapy/Cognitive 
Behavior Treatment) without ACC. 
2)  MET/CBT7 (Motivational Enhancement Therapy/Cognitive 
Behavior Treatment) with ACC. 
Duration:   
MET/CBT7 without ACC: 12 weeks. 
MET/CBT7 with ACC: MET/CBT: 12 weeks, ACC: 12-14 weeks. 
Location: Adolescents from rural and urban parts of Central Illinois were 
enrolled. 
Comparisons:  
1) CBOP without ACC (Chestnut's Bloomington Outpatient 
Program).   
2)  CBOP with ACC (Chestnut Bloomigton Outpatient with Assertive 
Continuing Care).  
Relevant Outcomes Primary outcomes: Days abstinent, substance problems, recover 
Measures: GAIN 
 
Secondary outcome: Retention 
Notes "In general, clinicians provided only one type of treatment; however, due to 
insurance requirements for specific credentials, one clinician treated three 
adolescents in each of the outpatient conditions." (p. 48)  
 
"Fidelity checks for MET/CBT7 and ACC were conducted based on reviews 
of taped therapy sessions, while the fidelity of CBOP was conducted using 
the program's existing methods to avoid changing the intervention." (p. 52) 
 
"Outpatient treatment cost for participants were covered either by 
insurance, grants, public aid or by self-pay. There were no significant 
differences by funder." (p. 48) 
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Although the study addresses treatment fidelity it does not report results 
that show whether or not CBT was given with high/low fidelity. 
 
 
Table 10.3: Hendriks et al., 2011 
Methods Design: RCT 
Unit of allocation: Individually 
Participants Sample size: n= 109 
Age:  
Mean age=16.8 years, aged 13-14: 10.1% 
CBT: Mean age=16.9, aged 13-14: 9.3% 
MDFT: Range 13-18: 16.6%, aged 13-14: 10.9% 
Gender: 79.8% male 
CBT: 79.6% male 
MDFT: 80% mal. 
Ethnicity:   
Ethnicity Dutch/western: 71.6% 
CBT:  Ethnicity Dutch/western: 70.4% 
MDFT: Ethnicity Dutch/western: 72.7% 
Family status:  
Single parent family: 40.4% 
CBT: 46.3%  
MDFT: Single parent family: 23.5% 
Main drug of use: Cannabis.  
Severity:  
Cannabis abuse: 23.9%, cannabis dependence: 76.1%, severity of 
cannabis use disorder (range 0-11): 6.9 (mean)  
Comorbidity:  
Conduct disorder (CD): 28.7%, oppositional defiant disorder (ODD): 17.2% 
(CD and/or ODD: 37.6%) 
Inclusion criteria:  
Eligible participants were boys and girls from 13 through 18 
years of age, with a cannabis use disorder (dependence or abuse) 
established for the past year at baseline, and with at least one parent willing 
to take part in the treatment. Cannabis use disorder was determined 
following DSM-IV guidelines, with dependence being diagnosed if at least 3 
of 7 dependence criteria had been met, and abuse if at least 1 of 4 abuse 
criteria had been met. 
Exclusion criteria:  
Adolescents were ineligible if they suffered from a current mental disorder 
or condition (psychosis, advanced eating disorder, suicide ideation) 
requiring inpatient treatment or had a substance use disorder requiring 
maintenance treatment with methadone or buprenorphine. Cases were 
excluded if the adolescent and/or parent were unable to speak and read the 
local language. 
Baseline assessment was scheduled in two meetings. In the first, the focus 
was on need for treatment. When the assessor thought the case might 
meet INCANT inclusion criteria, she explained the study and allowed the 
family time to consider giving informed consent. Cases (adolescent plus 
parent) were excluded if one or both did not show up for the second 
meeting, not even after prompting. 
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Interventions Intervention: CBT (Cognitive-Behavioural Therapy) 
Duration:  
Weekly 60 minutes (plus one monthly treatment session for the 
adolescent’s parents) sessions for 5-6 months 
Location:  
MDFT: Sessions could take place at the office of the therapist, the 
family's home, or any other location. 
Comparison: MDFT (Multidimensional Family Therapy) 
Relevant Outcomes Primary outcomes: Days of use, recent cannabis dependence, treatment 
responders, recovered adolescents, preoccupation with and motivation for 
substance use 
Measures: TLFB, ADI, PEI 
 
Secondary outcomes: Internalizing disorders/symptoms, property and 
violent crimes, externalizing disorder/symptoms, retention 
Measure: YSR 
Notes The study from The Netherlands is a part of a cross-country study called 
INCANT. 
The primary outcomes regarding recent cannabis dependence and 
preoccupation with and motivation for substance use are reported in Rigter 
et al. (2011). The secondary outcomes regarding internalizing and 
externalizing disorder/symptoms are reported in Rigter et al. (2011). 
Treatment adherence: "Overall, therapists providing MDFT delivered it 
according to MDFT parameters (…)" (p. 54) 
 
(note: adherence evaluation is not made/reported on the CBT-condition) 
 
 
Table 10.4: Kaminer et al., 1998a, 1999 
Methods  Design: RCT 
Unit of allocation: Individually 
Participants Sample size: n=32 
Age:  
CBT: Mean age: 15.4 (SD: 1.5) 
IT: mean age 16.3 (SD 1.1)  
Gender:  
CBT: 60% males 
IT:63% males 
Ethnicity: 
CBT: 80% white 
IT: 100% white 
Family status: Not reported 
Main drug of use: Not reported 
Severity:  
CBT: 10.0 (4.3) on T-ASI scale 
IT: 12.4 (3.0) on T-ASI scale 
Comorbidity: The referred youths were dually-diagnosed (psychoactive 
substance use disorder). 
Inclusion criteria:  
Inclusion criteria were subjects aged 13 to 18 years, and meeting DSM-III-R 
criteria for psychoactive substance use disorders. 
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Exclusion criteria:  
Patients with any of the following were excluded: required a more intensive 
treatment setting or treatment menu; current acute psychosis; reading level 
and comprehension below sixth grade; refusal to consent for either 
randomization to treatment conditions or for session videotaping; no 
permanent address; or transportation difficulties for treatment program. 
Interventions Intervention: CBT (Cognitive-Behavioral Therapy) 
Duration: 12 weeks, weekly, 30 minutes per session 
Location: Not reported 
Comparison: IT (Interactional treatment) 
Relevant Outcomes Primary outcomes: Substance use, drug use 
Measure: T-ASI 
 
Secondary outcomes: Family problems, peer problems, psychological 
problems, school problems, retention 
Measure: T-ASI 
Notes All therapy sessions were videotaped to assure that the therapists 
administered the specific treatment within the guidelines (Kaminer, ID. 
1101, p. 2). 
The GSRS (Group Sessions rating Scale) were used to detect the 
differences between cognitive behavioural therapy and interactional group 
therapy. (Kaminer, ID. 1101, p. 1) 
One of the findings from these analyses were: "CBT groups were confirmed 
to have engaged in didactic skill training, problem solving, and role playing 
of social skills. It groups devoted more time focusing on interpersonal 
issues, expressing  feelings, and on here-and-now group processes 
(Kaminer ID 1101, p. 4)  
 
Treatment fidelity is adressed and results from the analyses are reported 
and shows fidelity. 
 
 
Table 10.5: Kaminer et al., 2002 
Methods  Design: RCT 
Unit of allocation: Individually 
 
Participants 
Sample size: n=88 
Age: 13 to 18 years, Mean: 15.4, SD: 1.3 years 
Gender: Male: 70%, Female: 30% 
CBT: 71% males 
PET: 70% males 
Ethnicity: White: 90%, Non-white: 10% 
CBT: White: 90%, Non-white: 10% 
PET: White: 89%, Non-white: 11% 
Family status: Not reported 
Main drug of use: Not reported 
Severity:  
88% having marijuana disorder, 39% met diagnosis of abuse, 61% met 
diagnosis of dependence  
Comorbidity:  
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Disorders - Externalizing: 55%, Conduct: 39%, ADHD: 18%, Oppositional: 
9%, Internalizing: 36%, Depression: 22%, Anxiety: 26% 
Inclusion criteria: Not reported 
Exclusion criteria:  
Exclusion criteria included requirement for a more intensive treatment than 
offered in this study; current acute psychosis or any other psychiatric or 
medical condition that could interfere with treatment (e.g., poor compliance 
with medications for attention deficit hyperactivity disorder (ADHD), suicidal 
or aggressive behavior in the past 30 days); reading and comprehension 
level below fifth grade; refusal to consent for either randomization to 
treatment conditions or for session videotaping; no permanent address; or 
transportation difficulties for treatment program.  
Interventions Intervention: CBT (Cognitive-Behavioral Therapy) 
Duration: 8 weeks, weekly, 75- to 90 minutes.  
Location: Not reported. 
Comparison: PET (Psychoeducational substance abuse treatment) 
Relevant Outcomes Primary outcome: Substance abuse  
Measure: T-ASI 
 
Secondary outcome: Family problems, Peer problems, Psychological 
problems, School problems, legal problems, retention 
Measure: T-ASI 
Notes The first author is a part of the therapist supervision and training. 
Therapists were trained to adhere to each treatment condition by studying 
the CBT treatment manual and the guidelines for PET. Supervision was 
provided throughout the study by the first author. All therapy sessions were 
videotaped, and weekly feedback was given to the therapists regarding 
their adherence to their respective treatment protocol. (p. 738) 
 
(...) each pair of therapists provided treatment in CBT and PET cycles, 
minimizing therapist variability (p. 738) 
 
Treatment fidelity is addressed, however the study does not report results. 
 
 
Table 10.6: Latimer et al., 2003 
Methods Design: RCT 
Unit of allocation: Family 
Participants Sample size: n= 43 
Age:  
14: 9.3%, 15: 23.3%, 16: 25.6%, 17: 34.9%, 18: 7.0%,  
Mean: 16.07, SD: 1.12 
IFCBT: 14: 14.3%, 15: 23.8%, 16: 14.3%, 17: 38.1%, 18: 9.5% 
Mean: 16.05, SD: 1.28 
DHPE: 14: 4.5%, 15: 22.7%, 16: 36.4%, 17: 31.8%, 18: 4.5% 
Mean: 16.09, SD: 0.97 
Gender:  
Male: 76.7% 
IFCBT: Male: 76.2% 
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DHPE: Male: 77.3% 
Ethnicity:  
White: 86.0%, Native American: 7.0%, Hispanic: 4.6%, Asian: 2.3%, African 
american: 0.0% 
IFCBT:  White: 81.0%, Native american: 9.5%, Hispanic: 9.5%, 
Asian: 0.0%, African american: 0.0% 
DHPE: White: 90.9%, Native american: 4.5%, Hispanic: 0.0% , 
Asian: 4.5%, African american: 0.0% 
Family status: Not reported. 
Main drug of use:  
Alcohol abuse/dependence: 86.0%, Marijuana abuse/dependence: 97.7%, 
Other drug abuse/dependence: 20.9% 
Severity:  
Pretreatment substance use frequency (days during a month) -  
Alcohol: Mean: 6.33 (SD: 6.63), Marijuana: Mean: 16.21 (SD: 10.83), Other 
drugs: Mean: 4.46 (SD: 13.04) 
Comorbidity: Not reported. 
Inclusion criteria: 
Youth met inclusion criteria for the randomised treatment study by being 
between 12 and 18 years of age, meeting DSM-IV criteria for at least one 
psychoactive substance use disorder, being recommended for outpatient 
drug abuse treatment following the initial baseline assessment, and 
providing parental consent and adolescent assent. 
Exclusion criteria:  
Excluded from the randomised treatment study were youth who required 
less or more intensive treatment than the interventions provided (i.e. IFCBT 
and DHPE), exhibited acute psychosis, exhibited acute suicidal or 
homicidal behavior, or refused medication despite bipolar mental illness. 
Interventions Intervention:  
IFCBT (Integrated Family and Cognitive-Behavioral Therapy) 
Duration: 16 weeks, Family therapy sessions: 16 weekly 60 minutes 
sessions, CBT sessions: twice-weekly, 32 90 minutes sessions. IFCBT 
youth attending treatment for 10.14 weeks (SD: 4.87) and 26.67 sessions 
(SD: 13.31). 
Location: Youth were referred mainly by agencies throughout the 
Minneapolis/St. Paul metropolitan region. 
Comparison:  
DHPE (Drug Harm Psychoeducation Curriculum) 
Relevant Outcomes Primary outcome: Days of use 
Measure: ADI-R 
 
Secondary outcomes: Rational beliefs, irrational beliefs, positive problem 
orientation, negative problem orientation, rational problem solving, 
impulsive problem solving, problem avoidance, task accomplishments, role 
performance, communication, affective expression, involvement, control, 
values and norms, motivation to learn, learning strategies, retention 
Measure: FAM, Rational Thinking Questionnaire, SPSI, MSLQ 
Notes "The IFCBT individual family therapy sessions were delivered by the project 
PI (WL) with supervision provided by dr. Winters. The IFCBT and DHPE 
group sessions were delivered by two bachelor-level clinicians with 
chemical dependency treatment experience. Treatment therapists received 
an extensive therapist training protocol (...)" (p. 308) 
 
"All IFCBT and DHPE sessions were videotaped" (p. 308) 
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They use supervision and a training protocol to  control the treatment given. 
The study does however not report results related to treatment fidelity. 
 
 
Table 10.7: Waldron et al., 2001 
Methods Design: RCT 
Unit of allocation: Family 
Participants Sample size: n=114 
Age:  
CBT: Mean 15.71, SD: 1.16 
FFT: Mean 15.34, SD: 1.01 
Gender:  
CBT: Male 25 (N= 31) 
FFT: Male 24 (n=30) 
Ethnicity:  
CBT: Hispanic: 17, Anglo American: 9, Native American: 3, 
Mixed/other: 2 
FFT: Hispanic: 14, Anglo American: 14, Native American: 2. 
Mixed/other: 0 
Family status:  
CBT: Adolescent education (years): 9.26, Primary caregiver 
education: 13.67 (SD: 3.01) Other caregiver education: 13.47 (SD: 
2.53), Annual income (per $100): 45.30 (SD: 36.46), Family 
constitution-single parent: 16, Family constitution - two parent: 15  
FFT: Adolescent education (years): 9.37, Primary caregiver 
education: 14.07 (SD: 2.84), Other caregiver education: 13.61 (SD: 
2.31), Annual income (per $100): 40.40 (SD: 25.36), Family 
constitution-single parent: 10, Family constitution - two parent: 20 
Main drug of use: Cannabis.  
Severity: Not reported 
Comorbidity: Not reported 
Inclusion criteria:  
Youths between the age of 13 and 17 years were eligible for the study if 
they were living at home with a primary caretaker who was also willing to 
participate and if they met Diagnostic and Statistical manual of Mental 
Disorders (4th ed,: DSM-IV; American Psychiatric Association, 1994) 
diagnostic criteria for a primary substance abuse disorder. 
Exclusion criteria:  
The focus of the study was illicit drug use, with youths primarily abusing 
only alcohol and/or tobacco excluded from participation. As a result, in the 
final sample, marijuana typified the vast majority of substance abuse. 
Youths and families were also excluded if the adolescent needed services 
other than outpatient treatment (e.g., was dangerous to self or others, 
needed monitored detoxification), if there was evidence of a psychotic or 
organic state, or if a sibling was participating in the study.  
Interventions Intervention: CBT (Cognitive-Behavioural Therapy) + MET (Motivational 
Enhancement intervention) 
Duration: 1 hour per session. 12 weeks. 
Location: Participants were referred to the University of New Mexico Center 
for Family and Adolescent Research for drug-abuse treatment 
 83  The Campbell Collaboration | www.campbellcollaboration.org 
 
Comparisons:  
FFT (Functional Family Therapy),  
Relevant Outcomes Primary outcome: Days of use,  
Measure: TLFB 
 
Secondary outcome: Delinquency 
Measure: YSR  
Notes The secondary outcome is reported in French et al. (2008) 
To examine therapist effects, a repeated measures analysis was conducted 
with the percentage of days substance was used as the dependent 
measure and therapists as the independent variable with no significant 
interaction, F(2,28) = 0.96. 
 
To evaluate treatment adherence, we rated one therapy session for half of 
the total sample (n=60), selected random, on a 10 point scale for 
adherence (1= least adherence, 10 = greatest adherence) to the clinical 
manuals for the FFT condition (n=11, M=9.09, SD= 1.04), the CBT 
condition (N=11, M=08.91, SD=1.04), the family therapy sessions in the 
joint condition (n=9, M=9.33, SD=0.71), the CBT sessions in the joint 
condition (n=11, M09.09, SD=0.83), and the group condition (n=18, 
M09.50, SD=0.52). Ratings were based on standardized session checklists. 
The range of ratings was on a 7-10-point scale. A one-way analysis of 
variance (ANOVA) was calculated with the five tape sources operating as 
the independent variable and adherence rating treated as the independent 
variable. The results indicated that the five sources of tapes were not 
significantly different in adherence rating, F(4,55) = 1.09, p< 0.37. 
 
This study addresses treatment fidelity and reports that high adherence 
was achieved. 
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10.2  CHARACTERISTICS OF INTERVENTION AND 
COMPARISON INTERVENTIONS 
Table 10.7: Charactetistics of intervention and comparison interventions in 
included studies 
Study CBT-intervention Comparison 
Dennis et al., 
2004 
Intervention: Motivational Enhancement + 
Cognitive Behavior Therapy (MET/CBT5) 
Duration: 6-7 weeks 
Total of any service hours: 4.8 
Total therapy sessions: 3.8 
Length of stay (mean days): 41.1 
Days of 1+ therapy sessions: 3.4 
Days of any contact: 7.8 
Delivery: Individual MET session and 
group CBT session 
Location: Clinic, USA 
 
Intervention: The Adolescent Community 
Reinforcement Approach (ACRA) 
Duration: 12-14 weeks 
Total of any service hours: 10.7 
Total of therapy sessions: 7,9 
Length of stay (mean days): 73.4 
Days of 1+ therapy sessions: 7.9 
Days of any contact: 13.6 
Delivery: ACRA is composed of 10 
individual sessions with the adolescent 
and four sessions with caregivers. 
Location: Clinic, USA 
Intervention: Multidimensional Family 
Therapy (MDFT) 
Duration: 12-14 weeks 
Total of any service hours: 14.2 
Total of therapy sessions: 9.5 
Length of stay (mean days): 77.5 
Days of 1+ therapy sessions: 9.7 
Days of any contact: 24.2 
Delivery: Typically six sessions with the 
adolescent, three with the parents, and 
six with the whole family. 
Location: Clinic, USA 
Godley et al., 
2010 
Intervention: Motivational Enhancement 
Therapy/Cognitive behavior Therapy 
(MET/CBT5) without  Assertive 
Continuing Care (ACC) 
Duration: 12 weeks 
Delivery: Two family sessions, two 
individual sessions, three group sessions 
Location: (Adolescents from rural and 
urban parts of Central Illinois were 
enrolled) 
Intervention: Chestnut’s Bloomington 
Outpatient Program (CBOP) without 
Assertive Continuing Care (ACC) 
Duration: Not reported 
Delivery: The intervention is primarily 
delivered through skill and therapy 
groups, combined with a limited number 
of family and individual sessions for 
treatment planning and progress reviews. 
Location: (Adolescents from rural and 
urban parts of Central Illinois were 
enrolled) 
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Study CBT-intervention Comparison 
Intervention: Motivational Enhancement 
Therapy/Cognitive behavior Therapy 
(MET/CBT5) with  Assertive Continuing 
Care (ACC) 
Duration: 12-14 weeks 
Delivery: MET/CBT: Two family sessions, 
two indivdual sessions, and three group 
sessions. 
ACC: Not explicitly reported. However it is 
stated that the intervention cease "to help 
adolescents and their caregivers (...) 
during weekly home visits" (p. 47) 
Location: (Adolescents from rural and 
urban parts of Central Illinois were 
enrolled) 
Intervention: Chestnut’s Bloomington 
Outpatient Program (CBOP) with 
Assertive Continuing (ACC) 
Duration: CBOP: Not reported; ACC: 12-
14 weeks 
Delivery: CBOP: The intervention is 
primarily delivered through skill and 
therapy groups, combined with a limited 
number of family and individual sessions 
for treatment planning and progress 
reviews.  
ACC: Not explicitly reported. However it is 
stated that the intervention cease "to help 
adolescents and their caregivers (...) 
during weekly home visits” (p. 47) 
Location: (Adolescents from rural and 
urban parts of Central Illinois were 
enrolled) 
Hendriks et 
al., 2011 
Intervention: Cognitive-Behavioral 
Therapy 
Duration: Weekly, 60 minutes per session 
(plus one monthly treatment session for 
the adolescent’s parents) for 5-6 months 
Delivery: Individual 
Location: TAU sessions were conducted 
in the treatment centre, such as the 
therapist’s office (i.e., not in the home or 
other community setting as might be done 
in MDFT). 
Intervention: Multidimensional Family 
Therapy (MDFT) 
Duration: Twice a week, 60 minutes per 
session for 5-6 months 
Delivery: MDFT-therapists had twice-
weekly sessions (2 h total pr. week) with 
the individual adolescent, parent(s) and/or 
family, in addition to sessions or contacts 
with school, courts, and other persons. 
Location: Sessions could take place at 
the office of the therapist, the family’s 
home or any other location 
Kaminer et 
al., 1998a, 
1999 
Intervention: Cognitive-Behavioral-
Therapy 
Duration: Weekly, 30 minutes per session 
for 12 weeks 
Delivery: Group 
Location: Not reported 
Intervention: Interactional Treatment (IT) 
Duration: Weekly, 90 minutes per session 
for 
12 weeks 
Delivery: Group 
Location: Not reported 
Kaminer et 
al., 2002 
Intervention: Cognitive-Behavioral 
Therapy 
Duration: Weekly, 75- to 90 minutes for 8 
weeks 
Delivery: Group 
Location: Not reported 
 
Intervention: Psychoeducational 
substance abuse treatment (PET) 
Delivery: Group 
Duration: Weekly, 75- to 90 minutes for 8 
weeks 
Location: Not reported 
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Study CBT-intervention Comparison 
Latimer et al., 
2003 
Intervention: Integrated Family and 
Cognitive-Behavioral Therapy (IFCBT) 
Duration: 16 weeks 
(Family therapy: weekly, 16 sessions of 
60 minutes; CBT: twice a week, 32 
sessions of 90 minutes) 
Delivery: Individual family therapy 
sessions and group cognitive-behavioral 
therapy sessions.  
Location: (Youth were referred mainly by 
agencies throughout the Minneapolis/St. 
Paul metropolitan region) 
Intervention: Drug Harm Psychoeducation 
Curriculum (DHPE) 
Duration: 16 weeks, weekly 90 minutes 
sessions 
Delivery: Group 
Location: (Youth were referred mainly by 
agencies throughout the Minneapolis/St. 
Paul metropolitan region) 
 
Waldron et 
al., 2001 
Intervention: Cognitive-Behavioural 
Therapy (CBT) + Motivational 
Enhancement intervention (MET) 
Duration: 1 hour per session (duration not 
reported) 
Delivery: Individual 
Location: (Participants were referred to 
the University of New Mexico Center for 
Family and Adolescent Research for 
drug-abuse treatment) 
Intervention: Functional family Therapy 
(FFT) 
Duration: 1 hour per session (duration not 
reported - 12 weeks?) 
Delivery: Group (family) 
Location: (Participants were referred to 
the University of New Mexico Center for 
Family and Adolescent Research for 
drug-abuse treatment) 
 
 
10.3  CHARACTERISTICS OF EXCLUDED STUDIES AND 
TRIALS 
Table 10.8: List of excluded studies 
Study Reason 
Azrin et al., 2001 The intervention was judged not to be CBT as defined by our 
inclusion criteria; it evaluates the relative effectiveness of a 
relatively “pure” cognitive version of problem-solving training 
where behavioural features were not utilized compared to Family 
Behaviour Therapy. Participants’ age range is 12-17. 
Carroll et al., 1994 The study focus on the wrong age (has no age limit) - does not 
explicitly report on the age range 13-21 
Carroll et al., 2006 The study focus on the wrong age (18 years or above) - does not 
explicitly report on the age range 13-21 
Carrol et al., 2012 The study focus on the wrong age (18 years or above) - does not 
explicitly report on the age range 13-21 
Godley et al., 2004 The study is not about CBT-effects (the program evaluated 
included other interventions as well - cannot separate them) 
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Study Reason 
Goti et al., 2010 The intervention was judged not to be CBT as defined by our 
inclusion criteria, it evaluates the relative effectiveness of a brief 
motivational enhancement intervention compared to treatment as 
usual which comprised diagnostic evaluation according to the 
presenting problem, and an initial therapeutic approach, either 
pharmacological and/or cognitive-behavioural therapy. 
Participants’ age range is 12-17. 
Hunter et al., 2012a The study focus on the wrong age (18 years or above) - does not 
explicitly report on the age range 13-21 
Hunter et al., 2012b The study can not identify CBT-effects as the comparison 
intervention also includes CBT as a main ingredient. 
Liddle et al., 2004 The study focus on the wrong age (11-15 years) - does not 
explicitly report on the age range 13-21 
Liddle et al., 2008 The study focus on the wrong age (12-17.5 years) - does not 
explicitly report on the age range 13-21 
Liddle et al., 2009 The study focus on the wrong age (11-15 years) - does not 
explicitly report on the age range 13-21 
Ramchand et al., 
2011 
The study can not identify CBT-effects as the comparison 
intervention also includes CBT as a main ingredient. 
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11 Additional tables 
11.1  PRIMARY OUTCOMES  
Table 11.1: Primary outcomes - overview 
Study Measurement Dichotomous Continuous Direction Short term Medium term Long term 
Dennis et al., 2004 Days abstinent 
(GAIN) 
 X 
High score is 
positive 
X X X 
Recovery 
(GAIN) 
X  
High score is 
positive 
  X 
Godley et al., 2010 Days abstinent 
(GAIN) 
 X 
High score is 
positive 
X X X 
Recovery status X  
High score is 
positive 
  X 
Hendriks et al., 
2011 
 
 
 
 
 
Days of use 
(TLFB) 
 
 
X 
High score is 
negative 
X X X 
Treatment 
responders 
X  
High score is 
positive 
X X X 
Recovered 
adolescents 
X  
High score is 
positive 
X X X 
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Study Measurement Dichotomous Continuous Direction Short term Medium term Long term 
 
 
Recent 
cannabis 
dependence1 
(ADI) 
X  
High score is 
negative 
  X 
Latimer et al., 2003 Days of use 
(ADI-R) 
 X 
High score is 
negative 
X X  
Waldron et al., 
2001 
Days of use 
(TLFB) 
 X 
High score is 
negative 
X X  
Note: 1 Reported in Rigter et al., 2013 
 
 
11.2  SECONDARY OUTCOMES 
Table 11.2: Secondary outcomes - social functioning and family functioning 
Study Measurement Dichotomous Continuous Direction Short term Medium term Long term 
Kaminer et al., 
1998a, 1999 
 
 
Family problems 
(T-ASI) 
 X 
High score is 
negative 
 X X 
Peer Problems 
(T-ASI) 
 X 
High score is 
negative 
 X X 
Psychological problems 
(T-ASI) 
 X 
High score is 
negative 
 X X 
Kaminer et al., 
2002 
Family problems 
(T-ASI) 
 X 
Highs score is 
negative 
 X X 
Peer problems 
(T-ASI) 
 X 
High score is 
negative 
 X X 
Psychological problems 
(T-ASI) 
 X 
High score is 
negative 
 X X 
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Study Measurement Dichotomous Continuous Direction Short term Medium term Long term 
Latimer et al., 
2003 
Rational beliefs  X Unclear X X  
Irrational beliefs  X Unclear X X  
Positive problem 
orientation 
 X Unclear X X  
Negative problem 
orientation 
 X Unclear X X  
Rational problem 
solving 
 X Unclear X X  
Impulsive problem 
solving 
 X Unclear X X  
Problem avoidance  X Unclear X X  
Task accomplishments  X Unclear X X  
Role performance  X Unclear X X  
Communication  X Unclear X X  
Affective expression  X Unclear X X  
Involvement  X Unclear X X  
Control  X Unclear X X  
Values and norms  X Unclear X X  
Hendriks et 
al., 2011 
Internalizing 
disorders/ 
symptoms1 
(YSR) 
 X 
High score is 
negative 
 X X 
Note: 1Reported in Rigter et al., 2011. 
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Table 11.3: Secondary outcomes - education or vocational involvement 
Study Measurement Dichotomous Continuous Direction Short term Medium term Long term 
Kaminer et al., 
1998a 
 
Kaminer et 
al.,1999 
School problems 
(T-ASI) 
 X 
High score is 
negative 
 X  
School problems 
(T-ASI) 
 X 
High score is 
negative 
  X 
Kaminer et al., 
2002 
School problems 
(T-ASI) 
 X 
High score is 
negative 
X  X 
Latimer et al., 
2003 
Motivation to learn 
(MSLQ) 
 X Unclear  X  
Learning strategies 
(MSLQ) 
 X Unclear  X  
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Table 11.4: Secondary outcomes - retention 
Study Measurement Dichotomous Continuous Direction 
Dennis et al, 2004 Completion X  High score is positive 
Godley et al., 2010 Retention 
(days) 
 X High score is positive 
Attended sessions X  High score is positive 
Hendriks et al., 2011 
 
 
Attended weeks  X High score is positive 
Completion X  High score is positive 
At least 3 month 
treatment1 
X  High score is positive 
Kaminer et al, 1998a, 1999 Completion X  High score is positive 
Kaminer et al., 2002 Completion X  High score is positive 
Latimer et al., 2003 Retention 
(weeks) 
 X High score is positive 
Retention 
(sessions) 
X  High score is positive 
Note: 1Reported in Rigter et al., 2011. 
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Table 11.5: Secondary outcomes - risk behaviour 
Study Measurement Dichotomous Continuous Direction Short term Medium term Long term 
Waldron et al., 
20011 
Delinquency 
(YSR) 
X  
High score is 
negative 
X X  
Hendriks 
et al., 2011 
 
 
Property and violent 
crimes 
 X 
High score is 
negtave 
X X X 
Externalizing 
disorder/symptom2 
(YSR) 
 X 
High score is 
negative 
 X X 
Kaminer et al, 
1998a, 1999 
Legal problems  X 
High score is 
negative 
 X X 
Kaminer et al., 
2002 
Legal problems  X 
High score is 
negative 
X  X 
Note: 1 Note: 1 Reported in French et al., 2008. 2Reported in Rigter et al., 2011. 
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11.3  RISK OF BIAS –  OVERALL JUDGEMENTS 
Table 11.6: Risk of bias - overall judgements 
 Dennis et al., 2004 
Godley et al., 
2010 
Hendriks et al., 
2011 
Kaminer et al., 
1998a, 1999 
Kaminer et al., 
2002 
Latimer et al., 
2003 
Waldron et al., 
2001 
Sequence 
generation 
Low risk Low risk Low risk Unclear Unclear Unclear Low risk 
Allocation 
concealment 
Low risk Low risk Low risk Unclear Unclear Unclear Unclear 
Blinding        
Abstinence or 
reduction of drug 
use 
Unclear 3 1 2 Unclear 3 Unclear 
Social functioning 
and family 
functioning 
Not relevant Not relevant 1 2 Unclear 3 Not relevant 
Education or 
vocational 
involvement 
Not relevant Not relevant Not relevant 2 Unclear 3 Not relevant 
Retention Unclear 4 4 Unclear Unclear Unclear Not relevant 
Risk behavior Not relevant Not relevant 1 2 Unclear Not relevant Unclear 
Other adverse 
effects 
Not relevant Not relevant Not relevant Not relevant Not relevant Not relevant Not relevant 
Incomplete 
outcome data 
       
Abstinence or 
reduction of drug 
use 
2 1 2 3 4 1 1 
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 Dennis et al., 2004 
Godley et al., 
2010 
Hendriks et al., 
2011 
Kaminer et al., 
1998a, 1999 
Kaminer et al., 
2002 
Latimer et al., 
2003 
Waldron et al., 
2001 
Social functioning 
and family 
functioning 
Not relevant Not relevant Unclear 3 4 1 Not relevant 
Education or 
vocational 
involvement 
Not relevant Not relevant Not relevant 3 4 1 Not relevant 
Retention Unclear Unclear Unclear Unclear Unclear Unclear Not relevant 
Risk behavior Not relevant Not relevant 2 3 4 Not relevant Unclear 
Other adverse 
effects 
Not relevant Not relevant Not relevant Not relevant Not relevant Not relevant Not relevant 
Free of selective 
reporting 
       
Abstinence or 
reduction of drug 
use 
1 1 1 2 1 1 1 
Social functioning 
and family 
functioning 
3 Not relevant 3 1 1 1 3 
Education or 
vocational 
involvement 
3 Not relevant 3 1 1 1 Not relevant 
Retention 1 Not relevant 1 1 1 Unclear Not relevant 
Risk behavior 3 3 1 1 1 Not relevant 1 
Other adverse 
effects 
Not relevant Not relevant Not relevant Not relevant Not relevant Not relevant Not relevant 
Free of other bias 1 2 1 1 1 1 1 
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 Dennis et al., 2004 
Godley et al., 
2010 
Hendriks et al., 
2011 
Kaminer et al., 
1998a, 1999 
Kaminer et al., 
2002 
Latimer et al., 
2003 
Waldron et al., 
2001 
A priori protocol Yes Yes Yes Unclear Unclear Unclear Unclear 
A priori analysis 
plan 
Yes Unclear Yes Unclear Unclear Unclear Unclear 
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12 Data and analysis 
12.1  ANALYSIS RESULTS 
Table 12.1: Drug use frequency and recovery, overall results 
 Drug use frequency, SMD [95% CI], (Number of studies included (k)) 
 Short term Medium term  Long term 
Dennis et al., 2004: 
MDFT 
Godley et al. 2010: 
MET/CBT7, CBOP 
(as reported in the main 
text) 
-0.14 [-0.64, 0.36] 
(k=4) 
-0.06 [-0.44, 0.32] 
 (k=4) 
-0.15 [-0.36, 0.06] 
 (k=2) 
Dennis et al., 2004: 
ACRA 
Godley et al. 2010: 
MET/CBT7, CBOP 
-0.07 [-0.59, 0.45] 
 (k=4) 
-0.08 [-0.47, 0.30] 
 (k=4) 
-0.11 [-0.34, 0.13] 
 (k=2) 
Dennis et al., 2004: 
MDFT 
Godley et al. 2010: 
MET/CBT7, CBOP+ACC 
-0.03 [-0.51, 0.44] 
 (k=4) 
-0.02 [-0.45, 0.41] 
 (k=4) 
-0.11 [-0.32, 0.10] 
(k=2) 
Dennis et al., 2004: 
ACRA 
Godley et al. 2010: 
MET/CBT7, CBOP+ACC 
0.03 [-0.43, 0.49] 
 (k=4) 
-0.04 [-0.48, 0.40] 
(k=4) 
-0.07 [-0.27, 0.14] 
 (k=2) 
Dennis et al., 2004: 
MDFT 
Godley et al. 2010: 
MET/CBT7+ACC, 
CBOP+ACC 
-0.02 [-0.50, 0.46] 
(k=4) 
-0.03 [-0.44, 0.39] 
 (k=4) 
-0.02 [-0.23, 0.18] 
 (k=2) 
Dennis et al., 2004: 
ACRA 
Godley et al. 2010: 
MET/CBT7+ACC, 
CBOP+ACC 
0.05 [-0.41, 0.51] 
(k=4) 
-0.05 [-0.48, 0.38] 
 (k=4) 
0.02 [-0.18, 0.23] 
 (k=2) 
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 Drug use frequency, SMD [95% CI], (Number of studies included (k)) 
 Short term Medium term  Long term 
Dennis et al., 2004: 
MDFT 
Godley et al. 2010: 
MET/CBT7, CBOP 
(as reported in the main 
text) 
-0.14 [-0.64, 0.36] 
(k=4) 
-0.06 [-0.44, 0.32] 
 (k=4) 
-0.15 [-0.36, 0.06] 
 (k=2) 
Dennis et al., 2004: 
MDFT 
Godley et al. 2010: 
MET/CBT7+ACC, CBOP 
-0.17 [-0.70, 0.35] 
 (k=4) 
-0.07 [-0.44, 0.30] 
 (k=4) 
-0.04 [-0.24, 0.17] 
 (k=2) 
Dennis et al., 2004: 
ACRA 
Godley et al. 2010: 
MET/CBT7+ACC, CBOP 
-0.11 [-0.67, 0.45] 
 (k=4) 
-0.09 [-0.47, 0.28] 
 (k=4) 
0.01 [-0.20, 0.21] 
 (k=2) 
 
 
12.2  SENSITIVITY ANALYSIS  
Figures 12.1, 12.2 and 12.3 show the results (effect size and confidence interval) for the 
analyses including all studies, as presented in section 4.4.1, and the results (effect size 
and confidence interval) from the analyses with studies with certain characteristics 
removed.   
 
 
 
 
Figure 12.1: Sensitivity analyses, Forest plot, short term, CBT with add-on 
All studies
Removed: Blinding - 3 or 4
Removed: Not reporting on treatment fidelity
Removed: Developer bias
-1 -.5 0 .5 1 1.5
Favours CBT   Favours control
SMD
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Figure 12.2: Sensitivity analyses, Forest plot, medium term, CBT with add-on 
Figure 12.3: Sensitivity analyses, Forest plot, long term, CBT without add-on 
All studies
Removed: Blinding - 3 or 4
Removed: Not reporting on treatment fidelity
Removed: Developer bias
-1 -.5 0 .5 1
Favours CBT   Favours control
SMD
All studies
Removed: Not using intention-to-treat
Removed: Incomplete outcome data - 3 or 4
Removed: Not reporting on treatment fidelity
-1.5 -1 -.5 0 .5
Favours CBT   Favours control
SMD
 
100  The Campbell Collaboration | www.campbellcollaboration.org 
 
12.3  PUBLICATION BIAS 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 12.4: Funnel plot, short term, CBT without add-on 
 
Figure 12.5: Funnel plot, medium term, CBT without add-on 
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Figure 12.6: Funnel plot, medium term, CBT without add-on 
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13 Figures 
13.1  FLOWCHART 
 
Figure 13.1: Flowchart 
Databases 
Medline 1.846 
Embase 2.239 
Cinahl 1.151 
Web of Science 4257 
SocIndex 900 
PsycInfo 1.612 
Cochrane 2.942 
Social Care Online 99 
Eric 651 
Criminal Justice 
Abstract 
505 
Bibliography of Nor-
dic Criminology 
46 
Bibliotek.dk 
Libris 
Bibsys 
 
31 
36 
46 
Total 16.361 
 
Grey literature 
Dissertation 703 
Google 600 
Govermental 
institutions 
800 
Multi-disciplinary 19 
Subject specific 
sites 
488 
  
Total 2.610 
 
 18.514 potential relevant studies to be screened for 
retrieval. (Databases:13.733, Grey: 2.610, 
Handsearch etc.: 2.171). 
394 Full text (primary search:256, update: 138) were 
retrieved for 2. level screening. 
7 studies (17 full text) met the eligibility criteria and 
were included in the review 
 2.628 excluded for being 
duplicates. 
360 excluded for not 
fulfilling second level 
questions. 
18.120 excluded for 
not fulfilling first level 
screening questions. 
Handsearch 
Addiction 1.169 
Journal of Substance 
Abuse Treatment 
Journal of Clinical 
Child and 
Adolescent 
Psychology 
333 
213 
Journal of Consulting 
& Clinical 
Psychology 
Research on Social 
Work Practice 
Snowball 
303 
 
 
74 
 
68 
Expert list 
11 
Total 2.171 
 
4 full texts are 
unobtainable. 
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14 Appendices 
11.1  SEARCH STRATEGY 
Search strategy for MEDLINE on the OVID platform 
 
1 Behavior Therapy/   
2 Cognitive Therapy/   
3 (cognitive adj3 (therap* or train* or techni* or modif* or factor* or question* or 
approach* or experiment* or assess*)).ab,kw,sh,ti.  
4 cbt.ab,kw,sh,ti.   
5 ((psycholog* or social or cognitive) adj1 (skill* adj1  
train*)).ab,kw,sh,ti.   
6 (behavio?r* adj3 (therap* or train* or techni* or modif* or factor* or question* or 
approach* or experiment* or assess*)).ab,kw,sh,ti.  
7 ((cognitive* or mental*) adj3 (map* or model*)).ab,kw,sh,ti.  
8 (cognitive behavio?r* adj1 (factor* or therap*)).ab,kw,sh,ti.  
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8   
10 Adolescent/   
11 (Adolescen* or youth* or teen* or young* or juvenile*).ab,kw,sh,ti.  
12 10 or 11   
13 (misuse or abuse* or use or addict* or depend#n$).ab,kw,sh,ti. 
14 (drug* or substance*or polydrug*).ab,kw,sh,ti.   
15 14 and 15      
16 Marijuana Smoking/   
17 amphetamine-related disorders/ or cocaine-related disorders/ or marijuana 
abuse/ 
18 Narcotic*.ab,kw,sh,ti.   
19 Stimulan*.ab,kw,sh,ti.   
20 (Cannabis or Marijuana or Hashish).ab,kw,sh,ti.  
21 exp Cannabinoids/ or Cannabis/   
22 blunts.ab,kw,sh,ti.   
23 Designer Drugs/   
24 (Designerdrug* or (designer adj1 drug*)).ab,kw,sh,ti.   
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25 Streetdrug*.ab,kw,sh,ti.   
26 N-Methyl-3,4-methylenedioxyamphetamine/   
27 Ecstasy.ab,kw,sh,ti.   
28 Amphetamine/   
29 Methamphetamine/   
30 Fantasy.ab,kw,sh,ti.   
31 (Methamphetamin* or Amphetamin*).ab,kw,sh,ti.   
32 ice.ab,kw,sh,ti.   
33 Flatliner*.ab,kw,sh,ti.   
34 exp cocaine/   
35 (Cocaine or crack).ab,kw,sh,ti.   
36 (free adj1 base).ab,kw,sh,ti.   
37 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 
or 31 or 32 or 33 or 34 or 35 or 36   
38 15 or 37   
39 9 and 12 and 38   
 
Cochrane CBT  
September 2012, update 2010-2012 
 
Search 
number 
Terms Totals 
S21 S16 and s19 (999) 
S20 S16 and S19 (1487) 
S19 S17 and S18 (346232) 
S18 TI ( (free n1 base) or cocaine or crack or flatliner* or ice or 
Methamphetamine$ or Amphetamin*or Fantasy* or Ecstasy or 
Streetdrug* or Designerdrug* or (designer adj1 drug*) or blunt* or 
Cannabis or Marijuana or Hashish or amphetamine-related blunts or 
Stimulan* or narcotic* ) or AB ( (free n1 base) or cocaine or crack or 
flatliner* or ice or Methamphetamine$ or Amphetamin*or Fantasy* or 
Ecstasy or Streetdrug* or Designerdrug* or (designer adj1 drug*) or 
blunt* or Cannabis or Marijuana or Hashi ...   
(19100)   
S17 TI ( Polydrug* or Drug* or substance* or Depend#n* or Addict* ) or AB 
( Polydrug* or Drug* or substance* or Depend#n* or Addict* )  
or SU ( Polydrug* or Drug* or substance* or 
 Depend#n* or Addict* )        
(339852) 
S16 S14 and S15   (5482)    
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Search 
number 
Terms Totals 
S15 TI ( Young n1 men or Young n1 women or Teen* or Juvenile or 
Adolescen* or youth* or young person* or young adult* or Young 
people* or Adolescent/ ) or AB ( Young n1 men or Young n1 women or 
Teen* or Juvenile or Adolescen* or youth* or young person* or young 
adult* or Young people* or Adolescent/ ) or SU ( Young n1 men or 
Young n1 women or Teen* or Juvenile or Adolescen* or youth* or 
young person* or young adult*  
or Young people* or Adolescent/ ) 
(169968) 
S14 S1 or S2 or S3 or S7 or S8 or S9 or S10 or S11 or S12 or S13   (26589) 
S13 TI ( cognitive behavior* factor* or cognitive behavio* therap* ) or AB ( 
cognitive behavior* factor* or cognitive behavio* therap* ) or SU ( 
cognitive behavior* factor* or cognitive behavio* therap* )        
  
(2012) 
S12 TI ( (cognitive* n3 map*) or (cognitive* n3 model*) or ( mental* n3 
map*) or (mental* n3 model*) ) or AB ( (cognitive* n3 map*) or 
(cognitive* n3 model*) or (mental* n3 map*) or (mental* n3 model*) ) 
or SU ( (cognitive* n3 map*) or (cognitive* n3 model*) or ( mental* n3 
map*) or (mental* n3 model*) )   
(1399) 
S11 TI aggression replacement train* or AB aggression replacement train* 
or SU aggression replacement train*   
(0) 
S10 TI cbt or AB cbt or SU cbt   (976)   
S9 TI ( (psycholog* skill* train*) or (cognitive skill*train*) or (social skill* 
train*) ) or AB ( (psycholog* skill* train*) or (cognitive skill*train*) or 
(social skill* train*) ) or SU ( (psycholog* skill* train*) or (cognitive 
skill*train*) or (social skill* train*) )   
(741) 
S8 TI ( (cognitive n3 Therap*) or (cognitive n3 train*) or (cognitive n3 
techni*) or (cognitive n3 modif*) or (cognitive n3 factor*) or (cognitive 
n3 question*) or (cognitive n3 approach*) or (cognitive n3 experiment*) 
or (cognitive n3 assess*) ) or AB ( (cognitive n3 Therap*) or (cognitive 
n3 train*) or (cognitive n3 techni*) or (cognitive n3 modif*) or (cognitive 
n3 factor*) or (cognitive n3 question*) or (cognitive n3 approach*) or 
(cognitive n3 experiment*) or (cognitive n3 assess*) ) or SU ( ( ... 
(9858) 
S7 TI ( (behavio#r* n3 therap*) or (behavio#r* n3 train*) or (behavio#r* n3 
techni*) or (behavio#r* n3 modif*) or (behavio#r* n3 factor*) or 
(behavio#r* n3 question*) or (behavio#r* n3 approach*) or (behavio#r* 
n3 experiment*) or (behavio#r* n3 assess*) ) or AB ( (behavio#r* n3 
therap*) or (behavio#r* n3 train*) or (behavio#r* n3 techni*) or 
(behavio#r* n3 modif*) or (behavio#r* n3 factor*) or (behavio#r* n3 
question*) or (behavio#r* n3 approach*) or (behavio#r* n3 
experiment*) or (behavio#r* n3 as ...   
(17963) 
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Search 
number 
Terms Totals 
S6 TI ( (behavio#r* n3 therap*) or (behavio#r* n3 train*) or (behavio#r* n3 
techni*) or (behavio#r* n3 modif*) or (behavio#r* n3 factor*) or 
(behavio#r* n3 question*) or (behavio#r* n3 approach*) or (behavio#r* 
n3 experiment*) or (behavio#r* n3 assess*) ) or AB ( (behavio#r* n3 
therap*) or (behavio#r* n3 train*) or (behavio#r* n3 techni*) or 
(behavio#r* n3 modif*) or (behavio#r* n3 factor*) or (behavio#r* n3 
question*) or (behavio#r* n3 approach*) or (behavio#r* n3 
experiment*) or (behavio#r* n3 as ...   
(13055) 
S5 TI ( (psycholog* skill* train*) or (cognitive skill*train*) or (social skill* 
train*) ) or AB ( (psycholog* skill* train*) or (cognitive skill*train*) or 
(social skill* train*) )       
(225) 
S4 TI ( (cognitive n3 Therap*) or (cognitive n3 train*) or (cognitive n3 
techni*) or (cognitive n3 modif*) or (cognitive n3 factor*) or (cognitive 
n3 question*) or (cognitive n3 approach*) or (cognitive n3 experiment*) 
or (cognitive n3 assess*) ) or AB ( (cognitive n3 Therap*) or (cognitive 
n3 train*) or (cognitive n3 techni*) or (cognitive n3 modif*) or (cognitive 
n3 factor*) or (cognitive n3 question*) or (cognitive n3 approach*) or 
(cognitive n3 experiment*) or  
(cognitive n3 assess*) )   
(6472) 
S3 TI cbt or AB cbt   (976) 
S2 DE "COGNITIVE therapy"   (5384) 
S1 DE "BEHAVIOR modification"    (945) 
 
Criminal Justice Abstracts Search history 
EBSCO platform, January 2011 
 
Search 
number 
Terms Totals 
S49 (S46 or S47) and (S45 and S48) 419 
S48 S46 or S47 46171 
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Search 
number 
Terms Totals 
S47 TI ( (free n1 base) or cocaine or crack or flatliner* or ice or 
Methamphetamine$ or Amphetamin*or Fantasy* or Ecstasy or 
Streetdrug* or Designerdrug* or (designer adj1 drug*) or blunt* or 
Cannabis or Marijuana or Hashish or amphetamine-related blunts or 
Stimulan* or narcotic* ) or AB ( (free n1 base) or cocaine or crack or 
flatliner* or ice or Methamphetamine$ or Amphetamin*or Fantasy* or 
Ecstasy or Streetdrug* or Designerdrug* or (designer adj1 drug*) or 
blunt* or Cannabis or Marijuana or Hashish or amphetamine-related 
blunts or Stimulan* or narcotic* ) or SU ( (free n1 base) or cocaine or 
crack or flatliner* or ice or Methamphetamine$ or Amphetamin*or 
Fantasy* or Ecstasy or Streetdrug* or Designerdrug* or (designer adj1 
drug*) or blunt* or Cannabis or Marijuana or Hashish or amphetamine-
related blunts or Stimulan* or narcotic* ) 
8846 
S46 TI ( Polydrug* or Drug* or substance* or Depend#n* or Addict* ) or AB 
( Polydrug* or Drug* or substance* or Depend#n* or Addict* ) or SU ( 
Polydrug* or Drug* or substance* or Depend#n* or Addict* ) 
44298 
S45 S43 and S44 1793 
S44 TI ( Young n1 men or Young n1 women or Teen* or Juvenile or 
Adolescen* or youth* or young person* or young adult* or Young 
people* or Adolescent/ ) or AB ( Young n1 men or Young n1 women or 
Teen* or Juvenile or Adolescen* or youth* or young person* or young 
adult* or Young people* or Adolescent/ ) or SU ( Young n1 men or 
Young n1 women or Teen* or Juvenile or Adolescen* or youth* or 
young person* or young adult* or Young people* or Adolescent/ ) 
45246 
S43 S30 or S31 or S32 or S36 or S37 or S38 or S39 or S40 or S41 or S42 6822 
S42 TI ( cognitive behavior* factor* or cognitive behavio* therap* ) or AB ( 
cognitive behavior* factor* or cognitive behavio* therap* ) or SU ( 
cognitive behavior* factor* or cognitive behavio* therap* ) 
312 
S41 TI ( (cognitive* n3 map*) or (cognitive* n3 model*) or ( mental* n3 
map*) or (mental* n3 model*) ) or AB ( (cognitive* n3 map*) or 
(cognitive* n3 model*) or ( mental* n3 map*) or (mental* n3 model*) ) 
or SU ( (cognitive* n3 map*) or (cognitive* n3 model*) or ( mental* n3 
map*) or (mental* n3 model*) ) 
490 
S40 TI aggression replacement train* or AB aggression replacement train* 
or SU aggression replacement train* 
40 
S39 TI cbt or AB cbt or SU cbt 120 
S38 TI ( (psycholog* skill* train*) or (cognitive skill*train*) or (social skill* 
train*) ) or AB ( (psycholog* skill* train*) or (cognitive skill*train*) or 
(social skill* train*) ) or SU ( (psycholog* skill* train*) or (cognitive 
skill*train*) or (social skill* train*) ) 
149 
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Search 
number 
Terms Totals 
S37 TI ( (cognitive n3 Therap*) or (cognitive n3 train*) or (cognitive n3 
techni*) or (cognitive n3 modif*) or (cognitive n3 factor*) or (cognitive 
n3 question*) or (cognitive n3 approach*) or (cognitive n3 experiment*) 
or (cognitive n3 assess*) ) or AB ( (cognitive n3 Therap*) or (cognitive 
n3 train*) or (cognitive n3 techni*) or (cognitive n3 modif*) or (cognitive 
n3 factor*) or (cognitive n3 question*) or (cognitive n3 approach*) or 
(cognitive n3 experiment*) or (cognitive n3 assess*) ) or SU ( 
(cognitive n3 Therap*) or (cognitive n3 train*) or (cognitive n3 techni*) 
or (cognitive n3 modif*) or (cognitive n3 factor*) or (cognitive n3 
question*) or (cognitive n3 approach*) or (cognitive n3 experiment*) or 
(cognitive n3 assess*) ) 
1273 
S36 TI ( (behavio#r* n3 therap*) or (behavio#r* n3 train*) or (behavio#r* n3 
techni*) or (behavio#r* n3 modif*) or (behavio#r* n3 factor*) or 
(behavio#r* n3 question*) or (behavio#r* n3 approach*) or (behavio#r* 
n3 experiment*) or (behavio#r* n3 assess*) ) or AB ( (behavio#r* n3 
therap*) or (behavio#r* n3 train*) or (behavio#r* n3 techni*) or 
(behavio#r* n3 modif*) or (behavio#r* n3 factor*) or (behavio#r* n3 
question*) or (behavio#r* n3 approach*) or (behavio#r* n3 
experiment*) or (behavio#r* n3 assess*) ) or SU ( (behavio#r* n3 
therap*) or (behavio#r* n3 train*) or (behavio#r* n3 techni*) or 
(behavio#r* n3 modif*) or (behavio#r* n3 factor*) or (behavio#r* n3 
question*) or (behavio#r* n3 approach*) or (behavio#r* n3 
experiment*) or (behavio#r* n3 assess*) ) 
5548 
S35 TI ( (behavio#r* n3 therap*) or (behavio#r* n3 train*) or (behavio#r* n3 
techni*) or (behavio#r* n3 modif*) or (behavio#r* n3 factor*) or 
(behavio#r* n3 question*) or (behavio#r* n3 approach*) or (behavio#r* 
n3 experiment*) or (behavio#r* n3 assess*) ) or AB ( (behavio#r* n3 
therap*) or (behavio#r* n3 train*) or (behavio#r* n3 techni*) or 
(behavio#r* n3 modif*) or (behavio#r* n3 factor*) or (behavio#r* n3 
question*) or (behavio#r* n3 approach*) or (behavio#r* n3 
experiment*) or (behavio#r* n3 assess*) ) 
4555 
S34 TI ( (psycholog* skill* train*) or (cognitive skill*train*) or (social skill* 
train*) ) or AB ( (psycholog* skill* train*) or (cognitive skill*train*) or 
(social skill* train*) ) 
149 
S33 TI ( (cognitive n3 Therap*) or (cognitive n3 train*) or (cognitive n3 
techni*) or (cognitive n3 modif*) or (cognitive n3 factor*) or (cognitive 
n3 question*) or (cognitive n3 approach*) or (cognitive n3 experiment*) 
or (cognitive n3 assess*) ) or AB ( (cognitive n3 Therap*) or (cognitive 
n3 train*) or (cognitive n3 techni*) or (cognitive n3 modif*) or (cognitive 
n3 factor*) or (cognitive n3 question*) or (cognitive n3 approach*) or 
(cognitive n3 experiment*) or (cognitive n3 assess*) ) 
1139 
S32 TI cbt or AB cbt 120 
S31 DE "COGNITIVE therapy" 255 
S30 DE "BEHAVIOR modification" 285 
S29 (S21 or S24 or S23 or S20) 804 
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Search 
number 
Terms Totals 
S28 (S23 or S21 or S24 or S20) 804 
S27 (S24 or S21 or S23 or S20) 804 
S26 (S20 or S21 or S23 or S24) 804 
S25 SU "BEHAVIOR modification" 338 
S24 KW (cognitive n3 train*) or (cognitive n3 techni*) or (cognitive n3 
modif*) or (cognitive n3 factor*) or (cognitive n3 question*) or 
(cognitive n3 approach*) or (cognitive n3 experiment*) or (cognitive n3 
assess*) 
22 
S23 AB (cognitive n3 train*) or (cognitive n3 techni*) or (cognitive n3 
modif*) or (cognitive n3 factor*) or (cognitive n3 question*) or 
(cognitive n3 approach*) or (cognitive n3 experiment*) or (cognitive n3 
assess*) 
725 
S22 SU (cognitive n3 train*) or (cognitive n3 techni*) or (cognitive n3 
modif*) or (cognitive n3 factor*) or (cognitive n3 question*) or 
(cognitive n3 approach*) or (cognitive n3 experiment*) or (cognitive n3 
assess*) 
1 
S21 TX (cognitive n3 train*) or (cognitive n3 techni*) or (cognitive n3 
modif*) or (cognitive n3 factor*) or (cognitive n3 question*) or 
(cognitive n3 approach*) or (cognitive n3 experiment*) or (cognitive n3 
assess*) 
804 
S20 (cognitive n3 train*) or (cognitive n3 techni*) or (cognitive n3 modif*) or 
(cognitive n3 factor*) or (cognitive n3 question*) or (cognitive n3 
approach*) or (cognitive n3 experiment*) or (cognitive n3 assess*) 
804 
S19 TX (cognitive n3 train*) or (cognitive n3 techni*) or (cognitive n3 
modif*) or (cognitive n3 factor*) or (cognitive n3 question*) or 
(cognitive n3 approach*) or (cognitive n3 experiment*) or (cognitive n3 
assess*) 
804 
S18 S16 not S15 0 
S17 (S15 or S16) 1313 
S16 TX (cognitive n3 therap*) or (cognitive n3 train*) or (cognitive n3 
techni*) or (cognitive n3 modif*) or (cognitive n3 factor*) or (cognitive 
n3 question*) or (cognitive n3 approach*) or (cognitive n3 experiment*) 
or (cognitive n3 assess*) 
1313 
S15 (cognitive n3 therap*) or (cognitive n3 train*) or (cognitive n3 techni*) 
or (cognitive n3 modif*) or (cognitive n3 factor*) or (cognitive n3 
question*) or (cognitive n3 approach*) or (cognitive n3 experiment*) or 
(cognitive n3 assess*) 
1313 
S14 (cognitive behavio#r* n1 factor*) or (cognitive behavio#r* n1 therap*) 315 
S13 TX (cognitive behavio#r* n1 factor*) or (cognitive behavio#r* n1 
therap*) 
315 
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Search 
number 
Terms Totals 
S12 (cognitive behavio#r* n1 factor*) or (cognitive behavio#r* n1 therap*) 315 
S11 TX (cognitive* n3 map*) or (cognitive* n3 mental*) or (mental* n3 
map*) or (mental* n3 model*) 
301 
S10 (cognitive behavio#r* n1 factor*) or (cognitive behavio#r* n1 therap*) 315 
S9 (cognitive behavio#r n1 factor*) or (cognitive behavio#r n1 therap*) 71 
S8 (cognitive* n3 map*) or (cognitive* n3 mental*) or (mental* n3 map*) or 
(mental* n3 model*) 
301 
S7 TX (behavio#r* n3 train*) or (behavio#r* n3 techni*) or (behavio#r* n3 
modif*) or (behavio#r* n3 factor*) or (behavio#r* n3 question*) or 
(behavio#r* n3 approach*) or (behavio#r* n3 experiment*) or 
(behavio#r* n3 assess*) 
5251 
S6 TX social skill* train* 150 
S5 TX psycholog* skill* train* 5 
S4 TX cbt 132 
S3 TX (cognitive n3 train*) or (cognitive n3 techni*) or (cognitive n3 
modif*) or (cognitive n3 factor*) or (cognitive n3 question*) or 
(cognitive n3 approach*) or (cognitive n3 experiment*) or (cognitive n3 
assess*) 
804 
S2 DE "COGNITIVE therapy" 255 
S1 DE "BEHAVIOR modification" 285 
 
EMBASE 1980 to 2010 Week 50 
Ovid platform 
 
Search 
number 
Terms Totals 
1 Behavior Therapy/ 32493 
2 Cognitive Therapy/ 22734 
3 (cognitive adj3 (therap$ or train$ or techni$ or modif$ or factor$ or 
question$ or approach$ or experiment$ or assess$)).ab,kw,sh,ti. 
26295 
4 cbt.ab,kw,sh,ti. 4252 
5 ((psycholog$ or social or cognitive) adj1 (skill$ adj1 
train$)).ab,kw,sh,ti. 
1051 
6 (behavio?r$ adj3 (therap$ or train$ or techni$ or modif$ or factor$ or 
question$ or approach$ or experiment$ or assess$)).ab,kw,sh,ti. 
74492 
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Search 
number 
Terms Totals 
7 ((cognitive$ or mental$) adj3 (map$ or model$)).ab,kw,sh,ti. 9968 
8 (cognitive behavio?r$ adj1 (factor$ or therap$)).ab,kw,sh,ti. 7363 
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 125380 
10 Adolescent/ 1067149 
11 (Adolescen$ or youth$ or teen$ or young$).ab,kw,sh,ti. 1429584 
12 10 or 11 1429584 
13 9 and 12 20763 
14 (misuse or abuse$ or addict$ or depend#n$).ab,kw,sh,ti. 1330823 
15 (drug$ or substance$).ab,kw,sh,ti. 3614837 
16 14 and 15 385847 
17 ((polydrug$ or drug$ or substance$) adj2 (misuse or abuse$ or addict$ 
or depend#n$)).ab,kw,sh,ti. 
65325 
18 13 and 16 1200 
19 13 and 17 752 
20 18 or 19 1200 
21 Marijuana Smoking/ 962 
22 amphetamine-related disorders/ or cocaine-related disorders/ or 
marijuana abuse/ 
44678 
23 Narcotic$.ab,kw,sh,ti. 30070 
24 Stimulan$.ab,kw,sh,ti. 17981 
25 (Cannabis or Marijuana or Hashish).ab,kw,sh,ti. 21244 
26 exp Cannabinoids/ or Cannabis/ 29554 
27 blunts.ab,kw,sh,ti. 1488 
28 Designer Drugs/ 486 
29 (Designerdrug$ or (designer adj1 drug$)).ab,kw,sh,ti. 565 
30 Streetdrug$.ab,kw,sh,ti. 2 
31 N-Methyl-3,4-methylenedioxyamphetamine/ 5121 
32 Ecstasy.ab,kw,sh,ti. 2845 
33 Amphetamine/ 21872 
34 Methamphetamine/ 9228 
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Search 
number 
Terms Totals 
35 Fantasy.ab,kw,sh,ti. 5112 
36 (Methamphetamin$ or Amphetamin$).ab,kw,sh,ti. 39365 
37 ice.ab,kw,sh,ti. 17646 
38 flatliner$.ab,kw,sh,ti. 9 
39 exp cocaine/ 35000 
40 (Cocaine or crack).ab,kw,sh,ti. 42906 
41 (free adj1 base).ab,kw,sh,ti. 1718 
42 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 
33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 
192579 
43 20 or 42 193364 
44 19 or 42 193054 
45 13 and 43 1862 
46 limit 45 to humans downloaded 1676 
47 13 and 44 1552 
48 limit 47 to humans 1414 
 
ERIC search history 
Ebsco platform, December 2010 
 
Search 
number 
Terms Totals 
S49 (S46 or S47) and (S45 and S48) 589 
S48 S46 or S47 48,213 
S47 TI ( (free n1 base) or cocaine or crack or flatliner* or ice or 
Methamphetamine$ or Amphetamin*or Fantasy* or Ecstasy or 
Streetdrug* or Designerdrug* or (designer adj1 drug*) or blunt* or 
Cannabis or Marijuana or Hashish or amphetamine-related blunts or 
Stimulan* or narcotic* ) or AB ( (free n1 base) or cocaine or crack or 
flatliner* or ice or Methamphetamine$ or Amphetamin*or Fantasy* or 
Ecstasy or Streetdrug* or Designerdrug* or (designer adj1 drug*) or 
blunt* or Cannabis or Marijuana or Hashish or amphetamine-related 
blunts or Stimulan* or narcotic* ) or SU ( (free n1 base) or cocaine or 
crack or flatliner* or ice or Methamphetamine$ or Amphetamin*or 
Fantasy* or Ecstasy or Streetdrug* or Designerdrug* or (designer adj1 
drug*) or blunt* or Cannabis or Marijuana or Hashish or amphetamine-
related blunts or Stimulan* or narcotic* ) 
4,753 
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Search 
number 
Terms Totals 
S46 TI ( Polydrug* or Drug* or substance* or Depend#n* or Addict* ) or AB 
( Polydrug* or Drug* or substance* or Depend#n* or Addict* ) or SU ( 
Polydrug* or Drug* or substance* or Depend#n* or Addict* ) 
46,491 
S45 S43 and S44 4,660 
S44 TI ( Young n1 men or Young n1 women or Teen* or Juvenile or 
Adolescen* or youth* or young person* or young adult* or Young 
people* or Adolescent/ ) or AB ( Young n1 men or Young n1 women or 
Teen* or Juvenile or Adolescen* or youth* or young person* or young 
adult* or Young people* or Adolescent/ ) or SU ( Young n1 men or 
Young n1 women or Teen* or Juvenile or Adolescen* or youth* or 
young person* or young adult* or Young people* or Adolescent/ ) 
119,012 
S43 S30 or S31 or S32 or S36 or S37 or S38 or S39 or S40 or S41 or S42 32,374 
S42 TI ( cognitive behavior* factor* or cognitive behavio* therap* ) or AB ( 
cognitive behavior* factor* or cognitive behavio* therap* ) or SU ( 
cognitive behavior* factor* or cognitive behavio* therap* ) 
1,074 
S41 TI ( (cognitive* n3 map*) or (cognitive* n3 model*) or ( mental* n3 
map*) or (mental* n3 model*) ) or AB ( (cognitive* n3 map*) or 
(cognitive* n3 model*) or ( mental* n3 map*) or (mental* n3 model*) ) 
or SU ( (cognitive* n3 map*) or (cognitive* n3 model*) or ( mental* n3 
map*) or (mental* n3 model*) ) 
4,312 
S40 TI aggression replacement train* or AB aggression replacement train* 
or SU aggression replacement train* 
30 
S39 TI cbt or AB cbt or SU cbt 673 
S38 TI ( (psycholog* skill* train*) or (cognitive skill*train*) or (social skill* 
train*) ) or AB ( (psycholog* skill* train*) or (cognitive skill*train*) or 
(social skill* train*) ) or SU ( (psycholog* skill* train*) or (cognitive 
skill*train*) or (social skill* train*) ) 
1,063 
S37 TI ( (cognitive n3 Therap*) or (cognitive n3 train*) or (cognitive n3 
techni*) or (cognitive n3 modif*) or (cognitive n3 factor*) or (cognitive 
n3 question*) or (cognitive n3 approach*) or (cognitive n3 experiment*) 
or (cognitive n3 assess*) ) or AB ( (cognitive n3 Therap*) or (cognitive 
n3 train*) or (cognitive n3 techni*) or (cognitive n3 modif*) or (cognitive 
n3 factor*) or (cognitive n3 question*) or (cognitive n3 approach*) or 
(cognitive n3 experiment*) or (cognitive n3 assess*) ) or SU ( 
(cognitive n3 Therap*) or (cognitive n3 train*) or (cognitive n3 techni*) 
or (cognitive n3 modif*) or (cognitive n3 factor*) or (cognitive n3 
question*) or (cognitive n3 approach*) or (cognitive n3 experiment*) or 
(cognitive n3 assess*) ) 
7,184 
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S36 TI ( (behavio#r* n3 therap*) or (behavio#r* n3 train*) or (behavio#r* n3 
techni*) or (behavio#r* n3 modif*) or (behavio#r* n3 factor*) or 
(behavio#r* n3 question*) or (behavio#r* n3 approach*) or (behavio#r* 
n3 experiment*) or (behavio#r* n3 assess*) ) or AB ( (behavio#r* n3 
therap*) or (behavio#r* n3 train*) or (behavio#r* n3 techni*) or 
(behavio#r* n3 modif*) or (behavio#r* n3 factor*) or (behavio#r* n3 
question*) or (behavio#r* n3 approach*) or (behavio#r* n3 
experiment*) or (behavio#r* n3 assess*) ) or SU ( (behavio#r* n3 
therap*) or (behavio#r* n3 train*) or (behavio#r* n3 techni*) or 
(behavio#r* n3 modif*) or (behavio#r* n3 factor*) or (behavio#r* n3 
question*) or (behavio#r* n3 approach*) or (behavio#r* n3 
experiment*) or (behavio#r* n3 assess*) ) 
22,117 
S35 TI ( (behavio#r* n3 therap*) or (behavio#r* n3 train*) or (behavio#r* n3 
techni*) or (behavio#r* n3 modif*) or (behavio#r* n3 factor*) or 
(behavio#r* n3 question*) or (behavio#r* n3 approach*) or (behavio#r* 
n3 experiment*) or (behavio#r* n3 assess*) ) or AB ( (behavio#r* n3 
therap*) or (behavio#r* n3 train*) or (behavio#r* n3 techni*) or 
(behavio#r* n3 modif*) or (behavio#r* n3 factor*) or (behavio#r* n3 
question*) or (behavio#r* n3 approach*) or (behavio#r* n3 
experiment*) or (behavio#r* n3 assess*) ) 
16,440 
S34 TI ( (psycholog* skill* train*) or (cognitive skill*train*) or (social skill* 
train*) ) or AB ( (psycholog* skill* train*) or (cognitive skill*train*) or 
(social skill* train*) ) 
1,063 
S33 TI ( (cognitive n3 Therap*) or (cognitive n3 train*) or (cognitive n3 
techni*) or (cognitive n3 modif*) or (cognitive n3 factor*) or (cognitive 
n3 question*) or (cognitive n3 approach*) or (cognitive n3 experiment*) 
or (cognitive n3 assess*) ) or AB ( (cognitive n3 Therap*) or (cognitive 
n3 train*) or (cognitive n3 techni*) or (cognitive n3 modif*) or (cognitive 
n3 factor*) or (cognitive n3 question*) or (cognitive n3 approach*) or 
(cognitive n3 experiment*) or (cognitive n3 assess*) ) 
7,183 
S32 TI cbt or AB cbt 673 
S31 DE "COGNITIVE therapy" 0 
S30 DE "BEHAVIOR modification" 8,326 
S29 (S21 or S24 or S23 or S20) 6,287 
S28 (S23 or S21 or S24 or S20) 6,287 
S27 (S24 or S21 or S23 or S20) 6,287 
S26 (S20 or S21 or S23 or S24) 6,287 
S25 SU "BEHAVIOR modification" 8,327 
S24 KW (cognitive n3 train*) or (cognitive n3 techni*) or (cognitive n3 
modif*) or (cognitive n3 factor*) or (cognitive n3 question*) or 
(cognitive n3 approach*) or (cognitive n3 experiment*) or (cognitive n3 
assess*) 
162 
 
115  The Campbell Collaboration | www.campbellcollaboration.org 
 
Search 
number 
Terms Totals 
S23 AB (cognitive n3 train*) or (cognitive n3 techni*) or (cognitive n3 
modif*) or (cognitive n3 factor*) or (cognitive n3 question*) or 
(cognitive n3 approach*) or (cognitive n3 experiment*) or (cognitive n3 
assess*) 
5,417 
S22 SU (cognitive n3 train*) or (cognitive n3 techni*) or (cognitive n3 
modif*) or (cognitive n3 factor*) or (cognitive n3 question*) or 
(cognitive n3 approach*) or (cognitive n3 experiment*) or (cognitive n3 
assess*) 
2 
S21 TX (cognitive n3 train*) or (cognitive n3 techni*) or (cognitive n3 
modif*) or (cognitive n3 factor*) or (cognitive n3 question*) or 
(cognitive n3 approach*) or (cognitive n3 experiment*) or (cognitive n3 
assess*) 
6,287 
S20 (cognitive n3 train*) or (cognitive n3 techni*) or (cognitive n3 modif*) or 
(cognitive n3 factor*) or (cognitive n3 question*) or (cognitive n3 
approach*) or (cognitive n3 experiment*) or (cognitive n3 assess*) 
6,287 
S19 TX (cognitive n3 train*) or (cognitive n3 techni*) or (cognitive n3 
modif*) or (cognitive n3 factor*) or (cognitive n3 question*) or 
(cognitive n3 approach*) or (cognitive n3 experiment*) or (cognitive n3 
assess*) 
6,287 
S18 S16 not S15 0 
S17 (S15 or S16) 7,262 
S16 TX (cognitive n3 therap*) or (cognitive n3 train*) or (cognitive n3 
techni*) or (cognitive n3 modif*) or (cognitive n3 factor*) or (cognitive 
n3 question*) or (cognitive n3 approach*) or (cognitive n3 experiment*) 
or (cognitive n3 assess*) 
7,262 
S15 (cognitive n3 therap*) or (cognitive n3 train*) or (cognitive n3 techni*) 
or (cognitive n3 modif*) or (cognitive n3 factor*) or (cognitive n3 
question*) or (cognitive n3 approach*) or (cognitive n3 experiment*) or 
(cognitive n3 assess*) 
7,262 
S14 (cognitive behavio#r* n1 factor*) or (cognitive behavio#r* n1 therap*) 951 
S13 TX (cognitive behavio#r* n1 factor*) or (cognitive behavio#r* n1 
therap*) 
951 
S12 (cognitive behavio#r* n1 factor*) or (cognitive behavio#r* n1 therap*) 951 
S11 TX (cognitive* n3 map*) or (cognitive* n3 mental*) or (mental* n3 
map*) or (mental* n3 model*) 
2,676 
S10 (cognitive behavio#r* n1 factor*) or (cognitive behavio#r* n1 therap*) 951 
S9 (cognitive behavio#r n1 factor*) or (cognitive behavio#r n1 therap*) 277 
S8 (cognitive* n3 map*) or (cognitive* n3 mental*) or (mental* n3 map*) or 
(mental* n3 model*) 
2,676 
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S7 TX (behavio#r* n3 train*) or (behavio#r* n3 techni*) or (behavio#r* n3 
modif*) or (behavio#r* n3 factor*) or (behavio#r* n3 question*) or 
(behavio#r* n3 approach*) or (behavio#r* n3 experiment*) or 
(behavio#r* n3 assess*) 
22,567 
S6 TX social skill* train* 1,174 
S5 TX psycholog* skill* train* 69 
S4 TX cbt 675 
S3 TX (cognitive n3 train*) or (cognitive n3 techni*) or (cognitive n3 
modif*) or (cognitive n3 factor*) or (cognitive n3 question*) or 
(cognitive n3 approach*) or (cognitive n3 experiment*) or (cognitive n3 
assess*) 
6,287 
S2 DE "COGNITIVE therapy" 0 
S1 DE "BEHAVIOR modification" 8,326 
 
 
MEDLINE(R) 1950 to December Week 2 2010 
Ovid platform 
 
Search 
number 
Terms Totals 
1 Behavior Therapy/ 21452 
2 Cognitive Therapy/ 11067 
3 (cognitive adj3 (therap* or train* or techni* or modif* or factor* or 
question* or approach* or experiment* or assess*)).ab,kw,sh,ti. 
18804 
4 cbt.ab,kw,sh,ti. 2778 
5 ((psycholog$ or social or cognitive) adj1 (skill$ adj1 
train$)).ab,kw,sh,ti. 
651 
6 (behavio?r* adj3 (therap* or train* or techni* or modif* or factor* or 
question* or approach* or experiment* or assess*)).ab,kw,sh,ti. 
51635 
7 ((cognitive* or mental*) adj3 (map* or model*)).ab,kw,sh,ti. 11550 
8 (cognitive behavio?r* adj1 (factor* or therap*)).ab,kw,sh,ti. 4610 
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 95090 
10 Adolescent/ 1383699 
11 (Adolescen* or youth* or teen* or young* or juvenile*).ab,kw,sh,ti. 1705917 
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12 10 or 11 1705917 
13 9 and 12 21534 
14 (misuse or abuse* or use or addict* or depend#n$).ab,kw,sh,ti. 1189904 
15 (drug* or substance*).ab,kw,sh,ti. 1650851 
16 14 and 15 208181 
17 ((polydrug* or drug* or substance*) adj2 (misuse or use or abuse* 
or addict* or depend#n*)).ab,kw,sh,ti. 
47479 
18 13 and 16 1010 
19 13 and 17 673 
20 18 or 19 1010 
21 Marijuana Smoking/ 1829 
22 amphetamine-related disorders/ or cocaine-related disorders/ or 
marijuana abuse/ 
9423 
23 Narcotic*.ab,kw,sh,ti. 29571 
24 Stimulan*.ab,kw,sh,ti. 16596 
25 (Cannabis or Marijuana or Hashish).ab,kw,sh,ti. 14435 
26 exp Cannabinoids/ or Cannabis/ 12797 
27 blunts.ab,kw,sh,ti. 1320 
28 Designer Drugs/ 537 
29 (Designerdrug* or (designer adj1 drug*)).ab,kw,sh,ti. 423 
30 Streetdrug*.ab,kw,sh,ti. 1 
31 N-Methyl-3,4-methylenedioxyamphetamine/ 2874 
32 Ecstasy.ab,kw,sh,ti. 2308 
33 Amphetamine/ 10641 
34 Methamphetamine/ 5706 
35 Fantasy.ab,kw,sh,ti. 4787 
36 (Methamphetamin* or Amphetamin*).ab,kw,sh,ti. 30627 
37 ice.ab,kw,sh,ti. 14205 
38 Flatliner*.ab,kw,sh,ti. 9 
39 exp cocaine/ 20440 
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40 (Cocaine or crack).ab,kw,sh,ti. 30962 
41 (free adj1 base).ab,kw,sh,ti. 1336 
42 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 
or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 
137037 
43 20 or 42 137819 
44 19 or 42 137568 
45 13 and 43 1494 
46 limit 45 to humans downloaded 1440 
47 13 and 44 1243 
48 limit 47 to humans 1204 
 
 
PsycINFO search history 
Ebsco platform, December 2010 
 
Search 
number 
Terms Totals 
S49 (S46 or S47) and (S45 and S48) 1371 
S48 S46 or S47 458,655 
S47 TI ( (free n1 base) or cocaine or crack or flatliner* or ice or 
Methamphetamine$ or Amphetamin*or Fantasy* or Ecstasy or 
Streetdrug* or Designerdrug* or (designer adj1 drug*) or blunt* or 
Cannabis or Marijuana or Hashish or amphetamine-related blunts or 
Stimulan* or narcotic* ) or AB ( (free n1 base) or cocaine or crack or 
flatliner* or ice or Methamphetamine$ or Amphetamin*or Fantasy* or 
Ecstasy or Streetdrug* or Designerdrug* or (designer adj1 drug*) or 
blunt* or Cannabis or Marijuana or Hashish or amphetamine-related 
blunts or Stimulan* or narcotic* ) or SU ( (free n1 base) or cocaine or 
crack or flatliner* or ice or Methamphetamine$ or Amphetamin*or 
Fantasy* or Ecstasy or Streetdrug* or Designerdrug* or (designer adj1 
drug*) or blunt* or Cannabis or Marijuana or Hashish or amphetamine-
related blunts or Stimulan* or narcotic* ) 
45,344 
S46 TI ( Polydrug* or Drug* or substance* or Depend#n* or Addict* ) or AB 
( Polydrug* or Drug* or substance* or Depend#n* or Addict* ) or SU ( 
Polydrug* or Drug* or substance* or Depend#n* or Addict* ) 
448,415 
S45 S43 and S44 17,120 
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S44 TI ( Young n1 men or Young n1 women or Teen* or Juvenile or 
Adolescen* or youth* or young person* or young adult* or Young 
people* or Adolescent/ ) or AB ( Young n1 men or Young n1 women or 
Teen* or Juvenile or Adolescen* or youth* or young person* or young 
adult* or Young people* or Adolescent/ ) or SU ( Young n1 men or 
Young n1 women or Teen* or Juvenile or Adolescen* or youth* or 
young person* or young adult* or Young people* or Adolescent/ ) 
271,349 
S43 S30 or S31 or S32 or S36 or S37 or S38 or S39 or S40 or S41 or S42 184,698 
S42 TI ( cognitive behavior* factor* or cognitive behavio* therap* ) or AB ( 
cognitive behavior* factor* or cognitive behavio* therap* ) or SU ( 
cognitive behavior* factor* or cognitive behavio* therap* ) 
19,842 
S41 TI ( (cognitive* n3 map*) or (cognitive* n3 model*) or ( mental* n3 
map*) or (mental* n3 model*) ) or AB ( (cognitive* n3 map*) or 
(cognitive* n3 model*) or ( mental* n3 map*) or (mental* n3 model*) ) 
or SU ( (cognitive* n3 map*) or (cognitive* n3 model*) or ( mental* n3 
map*) or (mental* n3 model*) ) 
21,946 
S40 TI aggression replacement train* or AB aggression replacement train* 
or SU aggression replacement train* 
61 
S39 TI cbt or AB cbt or SU cbt 6,952 
S38 TI ( (psycholog* skill* train*) or (cognitive skill*train*) or (social skill* 
train*) ) or AB ( (psycholog* skill* train*) or (cognitive skill*train*) or 
(social skill* train*) ) or SU ( (psycholog* skill* train*) or (cognitive 
skill*train*) or (social skill* train*) ) 
5,638 
S37 TI ( (cognitive n3 Therap*) or (cognitive n3 train*) or (cognitive n3 
techni*) or (cognitive n3 modif*) or (cognitive n3 factor*) or (cognitive 
n3 question*) or (cognitive n3 approach*) or (cognitive n3 experiment*) 
or (cognitive n3 assess*) ) or AB ( (cognitive n3 Therap*) or (cognitive 
n3 train*) or (cognitive n3 techni*) or (cognitive n3 modif*) or (cognitive 
n3 factor*) or (cognitive n3 question*) or (cognitive n3 approach*) or 
(cognitive n3 experiment*) or (cognitive n3 assess*) ) or SU ( 
(cognitive n3 Therap*) or (cognitive n3 train*) or (cognitive n3 techni*) 
or (cognitive n3 modif*) or (cognitive n3 factor*) or (cognitive n3 
question*) or (cognitive n3 approach*) or (cognitive n3 experiment*) or 
(cognitive n3 assess*) ) 
63,319 
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S36 TI ( (behavio#r* n3 therap*) or (behavio#r* n3 train*) or (behavio#r* 
n3 techni*) or (behavio#r* n3 modif*) or (behavio#r* n3 factor*) or 
(behavio#r* n3 question*) or (behavio#r* n3 approach*) or (behavio#r* 
n3 experiment*) or (behavio#r* n3 assess*) ) or AB ( (behavio#r* n3 
therap*) or (behavio#r* n3 train*) or (behavio#r* n3 techni*) or 
(behavio#r* n3 modif*) or (behavio#r* n3 factor*) or (behavio#r* n3 
question*) or (behavio#r* n3 approach*) or (behavio#r* n3 
experiment*) or (behavio#r* n3 assess*) ) or SU ( (behavio#r* n3 
therap*) or (behavio#r* n3 train*) or (behavio#r* n3 techni*) or 
(behavio#r* n3 modif*) or (behavio#r* n3 factor*) or (behavio#r* n3 
question*) or (behavio#r* n3 approach*) or (behavio#r* n3 
experiment*) or (behavio#r* n3 assess*) ) 
124,902 
S35 TI ( (behavio#r* n3 therap*) or (behavio#r* n3 train*) or (behavio#r* 
n3 techni*) or (behavio#r* n3 modif*) or (behavio#r* n3 factor*) or 
(behavio#r* n3 question*) or (behavio#r* n3 approach*) or (behavio#r* 
n3 experiment*) or (behavio#r* n3 assess*) ) or AB ( (behavio#r* n3 
therap*) or (behavio#r* n3 train*) or (behavio#r* n3 techni*) or 
(behavio#r* n3 modif*) or (behavio#r* n3 factor*) or (behavio#r* n3 
question*) or (behavio#r* n3 approach*) or (behavio#r* n3 
experiment*) or (behavio#r* n3 assess*) ) 
100,511 
S34 TI ( (psycholog* skill* train*) or (cognitive skill*train*) or (social skill* 
train*) ) or AB ( (psycholog* skill* train*) or (cognitive skill*train*) or 
(social skill* train*) ) 
3,522 
S33 TI ( (cognitive n3 Therap*) or (cognitive n3 train*) or (cognitive n3 
techni*) or (cognitive n3 modif*) or (cognitive n3 factor*) or (cognitive 
n3 question*) or (cognitive n3 approach*) or (cognitive n3 experiment*) 
or (cognitive n3 assess*) ) or AB ( (cognitive n3 Therap*) or (cognitive 
n3 train*) or (cognitive n3 techni*) or (cognitive n3 modif*) or (cognitive 
n3 factor*) or (cognitive n3 question*) or (cognitive n3 approach*) or 
(cognitive n3 experiment*) or (cognitive n3 assess*) ) 
52,454 
S32 TI cbt or AB cbt 6,933 
S31 DE "COGNITIVE therapy" 11,416 
S30 DE "BEHAVIOR modification" 9,891 
S29 (S21 or S24 or S23 or S20) 46,023 
S28 (S23 or S21 or S24 or S20) 46,023 
S27 (S24 or S21 or S23 or S20) 46,023 
S26 (S20 or S21 or S23 or S24) 46,023 
S25 SU "BEHAVIOR modification" 12,712 
S24 KW (cognitive n3 train*) or (cognitive n3 techni*) or (cognitive n3 
modif*) or (cognitive n3 factor*) or (cognitive n3 question*) or 
(cognitive n3 approach*) or (cognitive n3 experiment*) or (cognitive n3 
assess*) 
9,160 
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S23 AB (cognitive n3 train*) or (cognitive n3 techni*) or (cognitive n3 
modif*) or (cognitive n3 factor*) or (cognitive n3 question*) or 
(cognitive n3 approach*) or (cognitive n3 experiment*) or (cognitive n3 
assess*) 
32,791 
S22 SU (cognitive n3 train*) or (cognitive n3 techni*) or (cognitive n3 
modif*) or (cognitive n3 factor*) or (cognitive n3 question*) or 
(cognitive n3 approach*) or (cognitive n3 experiment*) or (cognitive n3 
assess*) 
12,369 
S21 TX (cognitive n3 train*) or (cognitive n3 techni*) or (cognitive n3 
modif*) or (cognitive n3 factor*) or (cognitive n3 question*) or 
(cognitive n3 approach*) or (cognitive n3 experiment*) or (cognitive n3 
assess*) 
46,023 
S20 (cognitive n3 train*) or (cognitive n3 techni*) or (cognitive n3 modif*) or 
(cognitive n3 factor*) or (cognitive n3 question*) or (cognitive n3 
approach*) or (cognitive n3 experiment*) or (cognitive n3 assess*) 
43,253 
S19 TX (cognitive n3 train*) or (cognitive n3 techni*) or (cognitive n3 
modif*) or (cognitive n3 factor*) or (cognitive n3 question*) or 
(cognitive n3 approach*) or (cognitive n3 experiment*) or (cognitive n3 
assess*) 
43,316 
S18 S16 not S15 3,959 
S17 (S15 or S16) 72,108 
S16 TX (cognitive n3 therap*) or (cognitive n3 train*) or (cognitive n3 
techni*) or (cognitive n3 modif*) or (cognitive n3 factor*) or (cognitive 
n3 question*) or (cognitive n3 approach*) or (cognitive n3 experiment*) 
or (cognitive n3 assess*) 
72,108 
S15 (cognitive n3 therap*) or (cognitive n3 train*) or (cognitive n3 techni*) 
or (cognitive n3 modif*) or (cognitive n3 factor*) or (cognitive n3 
question*) or (cognitive n3 approach*) or (cognitive n3 experiment*) or 
(cognitive n3 assess*) 
68,149 
S14 (cognitive behavio#r* n1 factor*) or (cognitive behavio#r* n1 therap*) 20,091 
S13 TX (cognitive behavio#r* n1 factor*) or (cognitive behavio#r* n1 
therap*) 
21,517 
S12 (cognitive behavio#r* n1 factor*) or (cognitive behavio#r* n1 therap*) 20,091 
S11 TX (cognitive* n3 map*) or (cognitive* n3 mental*) or (mental* n3 
map*) or (mental* n3 model*) 
12,818 
S10 (cognitive behavio#r* n1 factor*) or (cognitive behavio#r* n1 therap*) 20,091 
S9 (cognitive behavio#r n1 factor*) or (cognitive behavio#r n1 therap*) 14,501 
S8 (cognitive* n3 map*) or (cognitive* n3 mental*) or (mental* n3 map*) or 
(mental* n3 model*) 
12,363 
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S7 TX (behavio#r* n3 train*) or (behavio#r* n3 techni*) or (behavio#r* n3 
modif*) or (behavio#r* n3 factor*) or (behavio#r* n3 question*) or 
(behavio#r* n3 approach*) or (behavio#r* n3 experiment*) or 
(behavio#r* n3 assess*) 
120,113 
S6 TX social skill* train* 5,381 
S5 TX psycholog* skill* train* 499 
S4 TX cbt 7,092 
S3 TX (cognitive n3 train*) or (cognitive n3 techni*) or (cognitive n3 
modif*) or (cognitive n3 factor*) or (cognitive n3 question*) or 
(cognitive n3 approach*) or (cognitive n3 experiment*) or (cognitive n3 
assess*) 
46,023 
S2 DE "COGNITIVE therapy" 11,416 
S1 DE "BEHAVIOR modification" 9,891 
 
 
Social Care Online Search history 
January 2011 
 
Search 
number 
Terms Totals 
 (freetext="cognitive* therapy" or   freetext="behavior* therap*" or  
freetext="behaviour therap*"  freetext="social skill* train*” or freetext=" 
psycholog* skill* train*") 
 and  
(freetext="drug"  or  freetext="substance*" or  freetext="abuse" or 
freetext="misuse"  or freetext=" Dependen*" or  freetext="Addict*")  
and  
 (freetext="teen*"  or freetext="juvenile" or  freetext="adolescen* or 
" freetext="youth*" or  freetext="young person*" or  freetext="young 
adult*" or  freetext="young people*" ) 
 
 
 
SocINDEX Search History  06-12-2010 
Ebsco host 
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S49 (S46 or S47) and (S45 and S48) 441 
S48 S46 or S47 68,396 
S47 TI ( (free n1 base) or cocaine or crack or flatliner* or ice or 
Methamphetamine$ or Amphetamin*or Fantasy* or Ecstasy or 
Streetdrug* or Designerdrug* or (designer adj1 drug*) or blunt* or 
Cannabis or Marijuana or Hashish or amphetamine-related blunts or 
Stimulan* or narcotic* ) or AB ( (free n1 base) or cocaine or crack or 
flatliner* or ice or Methamphetamine$ or Amphetamin*or Fantasy* or 
Ecstasy or Streetdrug* or Designerdrug* or (designer adj1 drug*) or 
blunt* or Cannabis or Marijuana or Hashish or amphetamine-related 
blunts or Stimulan* or narcotic* ) or SU ( (free n1 base) or cocaine or 
crack or flatliner* or ice or Methamphetamine$ or Amphetamin*or 
Fantasy* or Ecstasy or Streetdrug* or Designerdrug* or (designer adj1 
drug*) or blunt* or Cannabis or Marijuana or Hashish or amphetamine-
related blunts or Stimulan* or narcotic* ) 
8,188 
S46 TI ( Polydrug* or Drug* or substance* or Depend#n* or Addict* ) or AB 
( Polydrug* or Drug* or substance* or Depend#n* or Addict* ) or SU ( 
Polydrug* or Drug* or substance* or Depend#n* or Addict* ) 
66,161 
S45 S43 and S44 2,430 
S44 TI ( Young n1 men or Young n1 women or Teen* or Juvenile or 
Adolescen* or youth* or young person* or young adult* or Young 
people* or Adolescent/ ) or AB ( Young n1 men or Young n1 women or 
Teen* or Juvenile or Adolescen* or youth* or young person* or young 
adult* or Young people* or Adolescent/ ) or SU ( Young n1 men or 
Young n1 women or Teen* or Juvenile or Adolescen* or youth* or 
young person* or young adult* or Young people* or Adolescent/ ) 
82,403 
S43 S30 or S31 or S32 or S36 or S37 or S38 or S39 or S40 or S41 or S42 15,454 
S42 TI ( cognitive behavior* factor* or cognitive behavio* therap* ) or AB ( 
cognitive behavior* factor* or cognitive behavio* therap* ) or SU ( 
cognitive behavior* factor* or cognitive behavio* therap* ) 
737 
S41 TI ( (cognitive* n3 map*) or (cognitive* n3 model*) or ( mental* n3 
map*) or (mental* n3 model*) ) or AB ( (cognitive* n3 map*) or 
(cognitive* n3 model*) or ( mental* n3 map*) or (mental* n3 model*) ) 
or SU ( (cognitive* n3 map*) or (cognitive* n3 model*) or ( mental* n3 
map*) or (mental* n3 model*) ) 
1,398 
S40 TI aggression replacement train* or AB aggression replacement train* 
or SU aggression replacement train* 
31 
S39 TI cbt or AB cbt or SU cbt 257 
S38 TI ( (psycholog* skill* train*) or (cognitive skill*train*) or (social skill* 
train*) ) or AB ( (psycholog* skill* train*) or (cognitive skill*train*) or 
(social skill* train*) ) or SU ( (psycholog* skill* train*) or (cognitive 
skill*train*) or (social skill* train*) ) 
236 
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S37 TI ( (cognitive n3 Therap*) or (cognitive n3 train*) or (cognitive n3 
techni*) or (cognitive n3 modif*) or (cognitive n3 factor*) or (cognitive 
n3 question*) or (cognitive n3 approach*) or (cognitive n3 experiment*) 
or (cognitive n3 assess*) ) or AB ( (cognitive n3 Therap*) or (cognitive 
n3 train*) or (cognitive n3 techni*) or (cognitive n3 modif*) or (cognitive 
n3 factor*) or (cognitive n3 question*) or (cognitive n3 approach*) or 
(cognitive n3 experiment*) or (cognitive n3 assess*) ) or SU ( 
(cognitive n3 Therap*) or (cognitive n3 train*) or (cognitive n3 techni*) 
or (cognitive n3 modif*) or (cognitive n3 factor*) or (cognitive n3 
question*) or (cognitive n3 approach*) or (cognitive n3 experiment*) or 
(cognitive n3 assess*) ) 
3,186 
S36 TI ( (behavio#r* n3 therap*) or (behavio#r* n3 train*) or (behavio#r* n3 
techni*) or (behavio#r* n3 modif*) or (behavio#r* n3 factor*) or 
(behavio#r* n3 question*) or (behavio#r* n3 approach*) or (behavio#r* 
n3 experiment*) or (behavio#r* n3 assess*) ) or AB ( (behavio#r* n3 
therap*) or (behavio#r* n3 train*) or (behavio#r* n3 techni*) or 
(behavio#r* n3 modif*) or (behavio#r* n3 factor*) or (behavio#r* n3 
question*) or (behavio#r* n3 approach*) or (behavio#r* n3 
experiment*) or (behavio#r* n3 assess*) ) or SU ( (behavio#r* n3 
therap*) or (behavio#r* n3 train*) or (behavio#r* n3 techni*) or 
(behavio#r* n3 modif*) or (behavio#r* n3 factor*) or (behavio#r* n3 
question*) or (behavio#r* n3 approach*) or (behavio#r* n3 
experiment*) or (behavio#r* n3 assess*) ) 
11,845 
S35 TI ( (behavio#r* n3 therap*) or (behavio#r* n3 train*) or (behavio#r* 
n3 techni*) or (behavio#r* n3 modif*) or (behavio#r* n3 factor*) or 
(behavio#r* n3 question*) or (behavio#r* n3 approach*) or (behavio#r* 
n3 experiment*) or (behavio#r* n3 assess*) ) or AB ( (behavio#r* n3 
therap*) or (behavio#r* n3 train*) or (behavio#r* n3 techni*) or 
(behavio#r* n3 modif*) or (behavio#r* n3 factor*) or (behavio#r* n3 
question*) or (behavio#r* n3 approach*) or (behavio#r* n3 
experiment*) or (behavio#r* n3 assess*) ) 
8,888 
S34 TI ( (psycholog* skill* train*) or (cognitive skill*train*) or (social skill* 
train*) ) or AB ( (psycholog* skill* train*) or (cognitive skill*train*) or 
(social skill* train*) ) 
236 
S33 TI ( (cognitive n3 Therap*) or (cognitive n3 train*) or (cognitive n3 
techni*) or (cognitive n3 modif*) or (cognitive n3 factor*) or (cognitive 
n3 question*) or (cognitive n3 approach*) or (cognitive n3 experiment*) 
or (cognitive n3 assess*) ) or AB ( (cognitive n3 Therap*) or (cognitive 
n3 train*) or (cognitive n3 techni*) or (cognitive n3 modif*) or (cognitive 
n3 factor*) or (cognitive n3 question*) or (cognitive n3 approach*) or 
(cognitive n3 experiment*) or (cognitive n3 assess*) ) 
2,817 
S32 TI cbt or AB cbt 257 
S31 DE "COGNITIVE therapy" 768 
S30 DE "BEHAVIOR modification" 1,061 
S29 (S21 or S24 or S23 or S20) 15,767 
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S28 (S23 or S21 or S24 or S20) 15,767 
S27 (S24 or S21 or S23 or S20) 15,767 
S26 (S20 or S21 or S23 or S24) 15,767 
S25 SU "BEHAVIOR modification" 1,091 
S24 KW (cognitive n3 train*) or (cognitive n3 techni*) or (cognitive n3 
modif*) or (cognitive n3 factor*) or (cognitive n3 question*) or 
(cognitive n3 approach*) or (cognitive n3 experiment*) or (cognitive n3 
assess*) 
29 
S23 AB (cognitive n3 train*) or (cognitive n3 techni*) or (cognitive n3 
modif*) or (cognitive n3 factor*) or (cognitive n3 question*) or 
(cognitive n3 approach*) or (cognitive n3 experiment*) or (cognitive n3 
assess*) 
1,900 
S22 SU (cognitive n3 train*) or (cognitive n3 techni*) or (cognitive n3 
modif*) or (cognitive n3 factor*) or (cognitive n3 question*) or 
(cognitive n3 approach*) or (cognitive n3 experiment*) or (cognitive n3 
assess*) 
5 
S21 TX (cognitive n3 train*) or (cognitive n3 techni*) or (cognitive n3 
modif*) or (cognitive n3 factor*) or (cognitive n3 question*) or 
(cognitive n3 approach*) or (cognitive n3 experiment*) or (cognitive n3 
assess*) 
15,767 
S20 (cognitive n3 train*) or (cognitive n3 techni*) or (cognitive n3 modif*) or 
(cognitive n3 factor*) or (cognitive n3 question*) or (cognitive n3 
approach*) or (cognitive n3 experiment*) or (cognitive n3 assess*) 
2,090 
S19 TX (cognitive n3 train*) or (cognitive n3 techni*) or (cognitive n3 
modif*) or (cognitive n3 factor*) or (cognitive n3 question*) or 
(cognitive n3 approach*) or (cognitive n3 experiment*) or (cognitive n3 
assess*) 
3,264 
S18 S16 not S15 17,463 
S17 (S15 or S16) 20,728 
S16 TX (cognitive n3 therap*) or (cognitive n3 train*) or (cognitive n3 
techni*) or (cognitive n3 modif*) or (cognitive n3 factor*) or (cognitive 
n3 question*) or (cognitive n3 approach*) or (cognitive n3 experiment*) 
or (cognitive n3 assess*) 
20,728 
S15 (cognitive n3 therap*) or (cognitive n3 train*) or (cognitive n3 techni*) 
or (cognitive n3 modif*) or (cognitive n3 factor*) or (cognitive n3 
question*) or (cognitive n3 approach*) or (cognitive n3 experiment*) or 
(cognitive n3 assess*) 
3,265 
S14 (cognitive behavio#r* n1 factor*) or (cognitive behavio#r* n1 therap*) 710 
S13 TX (cognitive behavio#r* n1 factor*) or (cognitive behavio#r* n1 
therap*) 
4,860 
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S12 (cognitive behavio#r* n1 factor*) or (cognitive behavio#r* n1 therap*) 710 
S11 TX (cognitive* n3 map*) or (cognitive* n3 mental*) or (mental* n3 
map*) or (mental* n3 model*) 
8,801 
S10 (cognitive behavio#r* n1 factor*) or (cognitive behavio#r* n1 therap*) 710 
S9 (cognitive behavio#r n1 factor*) or (cognitive behavio#r n1 therap*) 182 
S8 (cognitive* n3 map*) or (cognitive* n3 mental*) or (mental* n3 map*) or 
(mental* n3 model*) 
918 
S7 TX (behavio#r* n3 train*) or (behavio#r* n3 techni*) or (behavio#r* n3 
modif*) or (behavio#r* n3 factor*) or (behavio#r* n3 question*) or 
(behavio#r* n3 approach*) or (behavio#r* n3 experiment*) or 
(behavio#r* n3 assess*) 
47,887 
S6 TX social skill* train* 2,536 
S5 TX psycholog* skill* train* 278 
S4 TX cbt 1,463 
S3 TX (cognitive n3 train*) or (cognitive n3 techni*) or (cognitive n3 
modif*) or (cognitive n3 factor*) or (cognitive n3 question*) or 
(cognitive n3 approach*) or (cognitive n3 experiment*) or (cognitive n3 
assess*) 
15,767 
S2 DE "COGNITIVE therapy" 768 
S1 DE "BEHAVIOR modification" 1,061 
 
Web of Science December 2010 
Social Science Citation Index, Science Citation Index 
 
Search 
number 
Terms Totals 
# 19 #18 AND #9  
Databases=SCI-EXPANDED, SSCI Timespan=All Years 
2,270 
# 18 #16 OR #12  
Databases=SCI-EXPANDED, SSCI Timespan=All Years 
>100,000 
# 17 #16 OR #13  
Databases=SCI-EXPANDED, SSCI Timespan=All Years 
>100,000 
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number 
Terms Totals 
# 16 Topic=(Narcotic* or Stimulan* or Cannabis or Marijuana or Hashish or 
blunts or Designerdrug* or "designer drug*" or Streetdrug* or N-
Methyl-3,4-methylenedioxyamphetamine or Ecstasy or Fantasy or 
Methamphetamin* or Amphetamin* or ice or flatliner* or Cocaine or 
crack or "free base")  
Databases=SCI-EXPANDED, SSCI Timespan=All Years 
>100,000 
# 15 #13 AND #9 
Databases=SCI-EXPANDED, SSCI Timespan=All Years 
1,215 
# 14 #12 AND #9  
Databases=SCI-EXPANDED, SSCI Timespan=All Years 
1,678 
# 13 Topic=((polydrug* or drug* or substance*) same (misuse or abuse* or 
addict* or dependen* or dependan*))  
Databases=SCI-EXPANDED, SSCI Timespan=All Years 
71,024 
# 12 #11 AND #10  
Databases=SCI-EXPANDED, SSCI Timespan=All Years 
>100,000 
# 11 Topic=(misuse or abuse* or addict* or dependen* or dependan*)  
Databases=SCI-EXPANDED, SSCI Timespan=All Years 
>100,000 
# 10 Topic=(polydrug* or drug* or substance*)  
Databases=SCI-EXPANDED, SSCI Timespan=All Years 
>100,000 
# 9 #8 AND #7  
Databases=SCI-EXPANDED, SSCI Timespan=All Years 
22,083 
# 8 Topic=(Adolescen* or youth* or teen* or young*or juvenile)  
Databases=SCI-EXPANDED, SSCI Timespan=All Years 
>100,000 
# 7 #6 OR #5 OR #4 OR #3 OR #2 OR #1  
Databases=SCI-EXPANDED, SSCI Timespan=All Years 
>100,000 
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# 6 Topic=(("cognitive behavior*" or "cognitive behaviour*") same (factor* 
or therap*))  
Databases=SCI-EXPANDED, SSCI Timespan=All Years 
9,219 
# 5 Topic=(((cognitive* or mental*) same (map* or model*)))  
Databases=SCI-EXPANDED, SSCI Timespan=All Years 
22,947 
# 4 Topic=((psycholog* or social or cognitive) same (skill* same train*))  
Databases=SCI-EXPANDED, SSCI Timespan=All Years 
2,128 
# 3 Topic=(cbt)  
Databases=SCI-EXPANDED, SSCI Timespan=All Years 
3,735 
# 2 Topic=((cognitive same (therap* or train* or techni* or modif* or factor* 
or question* or approach* or experiment* or asses*)))  
Databases=SCI-EXPANDED, SSCI Timespan=All Years 
52,514 
# 1 Topic=((behavi$r* same (therap* or train* or techni* or modif* or 
factor* or question* or approach* or experiment* or asses*)))  
Databases=SCI-EXPANDED, SSCI Timespan=All Years 
>100,000 
 
Nordic Databases 
Bibliography of Nordic Criminology (up to summer 2008)  
 
Search 
number 
Terms Totals 
 (CBT OR Cognitiv? OR kognitiv?) AND (barn? OR Børn? OR Unge 
OR Unga OR Teen? OR Tonår?) 
46 
 
Bibliotek.dk search history 
January 2011 
 
Search 
number 
Terms Totals 
 ma=(ap eller tr eller (fag1 og bå)) OG (KE=Adfærdsterapi) 285 
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 Ma=(ap eller tr eller (fag1 og bå)) OG KE=Kognitiv terapi 354 
 Ma=(ap eller tr eller (fag1 og bå)) OG (kognitiv? OG (terapi? ELLER 
træning ELLER teknik? ELLER ændring? ELLER spørgsmål ELLER 
tilgang ELLER eksperiment?)) 
726 
 Ma=(ap eller tr eller (fag1 og bå)) OG CBT 94 
 Ma=(ap eller tr eller (fag1 og bå)) OG (træn? OG (psyk? færdighed?)) 1 
 Ma=(ap eller tr eller (fag1 og bå)) OG (træn? OG (social? færdighed?)) 33 
 Ma=(ap eller tr eller (fag1 og bå)) OG (træn? OG (kogniv? 
færdighed?)) 
0 
 Ma=(ap eller tr eller (fag1 og bå)) OG (adfærd? OG (terapi? ELLER 
træning ELLER teknik? ELLER ændring? ELLER spørgsmål ELLER 
tilgang ELLER eksperiment?)) 
885 
 Ma=(ap eller tr eller (fag1 og bå)) OG vredeshåndtering 0 
 Ma=(ap eller tr eller (fag1 og bå)) OG ((kognitiv? ELLER mental?) OG 
(map ELLER kort ELLER model)) 
485 
 Ma=(ap eller tr eller (fag1 og bå)) OG (kognitiv adfærdsterapi) 138 
 Ma=(ap eller tr eller (fag1 og bå)) OG (kognitiv? adfærdsfaktor?) 0 
 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 2053 
 Ma=(ap eller tr eller (fag1 og bå)) OG (KE=(ungdom? ELLER 
pubertet? ELLER teenager? ELLER adolescens)) 
13025 
 Ma=(ap eller tr eller (fag1 og bå)) OG (unge mennesker) 236 
 Ma=(ap eller tr eller (fag1 og bå)) OG (unge voksne) 126 
 Ma=(ap eller tr eller (fag1 og bå)) OG (unge personer) 20 
 Ma=(ap eller tr eller (fag1 og bå)) OG Ungdom? 36582 
 Ma=(ap eller tr eller (fag1 og bå)) OG (ung? ELLER pubertet? ELLER 
teenager?) 
84012 
 Ma=(ap eller tr eller (fag1 og bå)) OG mindreårig? 86 
 Ma=(ap eller tr eller (fag1 og bå)) OG teen? 2351 
 Ma=(ap eller tr eller (fag1 og bå)) OG (ung? OG (m#nd ELLER 
kvinde?)) 
2909 
  84905 
  168 
 Ma=(ap eller tr eller (fag1 og bå)) OG (afhængig ELLER misbrug? 
Eller afhængighed) 
4054 
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 Ma=(ap eller tr eller (fag1 og bå)) OG (afhængig?) 1544 
 Ma=(ap eller tr eller (fag1 og bå)) OG substans 86 
 Ma=(ap eller tr eller (fag1 og bå)) OG (drug? ELLER stof?) 23420 
 Ma=(ap eller tr eller (fag1 og bå)) OG (polydrug? ELLER 
blandingsmisbrug) 
18 
  23513 
 Ma=(ap eller tr eller (fag1 og bå)) OG KE=marijuana 32 
 -  
 Ma=(ap eller tr eller (fag1 og bå)) OG narko? 3562 
 Ma=(ap eller tr eller (fag1 og bå)) OG (stimulans ELLER 
nydelsesmiddel) 
77 
 Ma=(ap eller tr eller (fag1 og bå)) OG (cannabis ELLER marijuana 
ELLER hash?) 
1726 
 Ma=(ap eller tr eller (fag1 og bå)) OG (KE=cannabinoids ELLER 
KE=cannabis) 
71 
 Ma=(ap eller tr eller (fag1 og bå)) OG (hashish ELLER hash) 432 
 Ma=(ap eller tr eller (fag1 og bå)) OG (sløv? mid?) 0 
 Ma=(ap eller tr eller (fag1 og bå)) OG KE=designer drugs 24 
 Ma=(ap eller tr eller (fag1 og bå)) OG (Designerdrug? ELLER 
(designer OG drug?)) 
53 
 Ma=(ap eller tr eller (fag1 og bå)) OG (streetdrug ELLER (gade OG 
(stof? ELLER drug?))) 
12 
 -  
 Ma=(ap eller tr eller (fag1 og bå)) OG ecstasy 347 
 Ma=(ap eller tr eller (fag1 og bå)) OG KE=amfetamin 42 
 -  
 Ma=(ap eller tr eller (fag1 og bå)) OG Fantasy 2271 
 Ma=(ap eller tr eller (fag1 og bå)) OG (metamfetamin? ELLER 
amfetamin?) 
104 
 Ma=(ap eller tr eller (fag1 og bå)) OG (ice ELLER is) 51561 
 Ma=(ap eller tr eller (fag1 og bå)) OG flatliner 0 
 Ma=(ap eller tr eller (fag1 og bå)) OG KE=kokain 86 
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 Ma=(ap eller tr eller (fag1 og bå)) OG (cocain ELLER kokain ELLER 
crack) 
461 
 Ma=(ap eller tr eller (fag1 og bå)) OG (free OG base) 38 
  146 
  83345 
  24 
 
 
 
 
Bibsys search history 
January 2011 
 
Search 
number 
Terms Totals 
 (emne = "atferdsterapi") OR (emne = "atferd terapi") OR (emne = 
"atferdsbehandling") 
739 
 emne = "kognitiv terapi" OR emne = "cognitiv therapy" 598 
 ((bd = "terapi") OR (bd = "metode") OR (bd = "faktor?") OR (bd = 
"forhold") OR (bd = "spørsmål?") OR (bd = "tilnærm?") OR (bd = 
"eksperiment") OR (bd = "forsøk") OR (bd = "vurder?")) AND (bd = 
"kognitiv") 
835 
 ((bd = "terapi") OR (bd = "metode") OR (bd = "faktor?") OR (bd = 
"forhold") OR (bd = "spørsmål?") OR (bd = "tilnærm?") OR (bd = 
"eksperiment") OR (bd = "forsøk") OR (bd = "vurder?")) AND (bd = 
"atferd?") 
1033 
 (bd = "cognitive behavio?r? therap?") OR (bd = "kognitiv? 
atferdsterapi?") OR (bd = "kognitiv? atferd terapi") OR (bd = "kognitiv? 
atferdsbehandling?") 
794 
 1 or 2 or 3 or 4 or 5 2465 
 (emne = "adolescen?") OR (emne = "ungdom?") 26365 
 (bd = "unge voksne") 419 
 (bd = "teen?") OR (bd = "tenåring?") 2361 
 ((bd = "ung?") AND ((bd = "m?nn") OR (bd = "kvinne?"))) 29788 
 7 or 8 or 9 or 10 44087 
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 6 and 11 307 
 (bd = "addict?") OR (bd = "rusmiddelmisbruk?") 3183 
 (bd = "avhengig?") 1473 
 (bd = "drug?") OR (bd = "stof?") 22596 
 14 and 15 243 
 13 or 15 or 16 24635 
 6 and 11 and 17 21 
 
 
 
 
Librisk search history 
January 2011 
 
Search 
number 
Terms Totals 
 WAMK:"Behavio*r Therapy" OR WAMK:"beteendeterapi" 507 
 WAMK:"Cognitive Therapy" OR WAMK:"kognitiv terapi" 590 
 (kognitiv* SAME (terapi* OR utbilding* OR teknik* OR faktor* OR  
fråga* OR metod* OR försök OR bedömning)) 
348 
 CBT 82 
 utbild* SAME (psycholog* OR psykolog*) SAME färdighet* 0 
 (utbild* OR trän*) SAME "social* färdighet*" 3 
 (utbild* OR trän*) SAME "kognitiv* färdighet*" 0 
 (Behavior?r* SAME therap*) OR (beteende SAME (terapi* OR 
utbilding* OR teknik* OR faktor* OR  fråga* OR metod* OR försök OR 
bedömning)) 
52 
 Aggression ADJ replacement ADJ train* 17 
 ((cognitive* OR mental) SAME (map* OR model*)) OR ((kognitiv* OR 
mental) SAME (model* OR kart*)) 
638 
 (cognitive ADJ behavior?r ADJ therapy) OR (kognitiv* SAME 
beteendeterapi*) 
220 
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 (cognitive ADJ behavior?r ADJ factor*) OR (kognitiv* SAME beteende 
SAME factor*) 
0 
  1727 
 (WAMK:"adolescen*" OR WAMK:"ungdom*") 11983 
 Ungdom* 80074 
 (Unga ADJ vuxna) 420 
 Adolescen* 6851 
 (Teen* OR tonåring*) 4291 
 (ung* ADJ ( män OR man* OR kvinn*)) 1223 
  87666 
  154 
 (Addict* OR misbruk*) 2149 
 Bero* 4005 
 (Drug* OR drog*) 25861 
  142 
  26921 
  13 
   
 (WAMK:"Marijuana Smoking") 7 
 (WAMK:"amphetamine-related disorders*") OR (WAMK:"cocaine-
related disorders*") OR (WAMK:"marijuana abuse") 
41 
 Narko* 6380 
 Stimulan* 664 
 (Cannabis OR Marijuana OR Hashish OR hasch) 416 
 ((WAMK:"canabinoids") OR (WAMK:”cannabis”)) 164 
 wamk:"designer drug*" 10 
 (”Designer Drug*” OR (designer SAME drug*)) 18 
 Streetdrug* 0 
 Ecstasy 269 
 (wamk:"amphetamine" OR wamk:"amfetamin*") 36 
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 (Metaamphetamin OR amfetamin OR metamfetamin) 27 
 (wamk:"cocaine" OR wamk:"kokain") 131 
 (cocain OR crack) 679 
  9945 
  14 
 
 
11.2  STUDY ELIGIBILITY SCREENING (LEVEL ONE & TWO) 
Screening level one (on the basis of titles and abstracts) 
 
Reference id.no.  
Study id. no.  
Reviewer’s initials 
Year of publication: 
Author: 
 
1. Is the report about a CBT intervention? 
Yes 
No (if no stop here and exclude) 
Uncertain 
 
2. Are the participants 13 to 21 years of age? 
Yes 
No (if no stop here and exclude) 
Uncertain 
 
3. Are the participants in outpatient drug treatment for non- opioid drug use?  
Yes 
No (if no stop here and exclude) 
Uncertain 
 
The report reference is excluded if one of the answers to question 1 to 3 are no. 
If the answers are yes or uncertain the full report is retrieved for second level screening. All uncertain 
questions for 1-3 need to be posed again based on the full text. If information is not available or the report is 
unclear report authors will be contacted to clarify study eligibility. 
Additional questions for second level screening, questions 4 - 7  
 
 
4. Is the report a ? 
Primary study (that is a CBT outcome evaluation) 
Review  
Descriptive or case study 
Theoretical or position paper editorial or book review 
Treatment manual or guidelines for practice 
Other 
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5. Is the report a RCT study (with a control groups that is TAU, alternative intervention 
or no intervention)?  
Yes 
No  
Uncertain  
 
6. Is the report a non-randomised controlled study (with a control group that is TAU, 
alternative intervention, or no intervention)? 
Yes 
No  
Uncertain 
 
 
7. Is the study? 
Included 
Excluded 
Uncertain (state reason) 
 
11.3  DATA EXTRACTION 
Study design 
1. How were comparison/control groups formed?  
Random assignment  
Other (specify) 
 
2. If random assignment, specify design 
Simple/systematic (individuals/families) 
Stratified/blocked (identify stratifying variables) 
Yoked pairs (created by timing of enrolment into the study) 
Matched pairs (identify matching variables) 
Cluster (group) randomised 
Other (specify) 
Can't tell 
 
3. Who performed group assignment? 
Research staff 
Clinical staff 
Can’t tell 
Other (specify) 
 
4. How was random assignment performed? 
Computer generated  
Random numbers table  
Coins or dice  
Other (describe) 
Can't tell 
 
5. How many separate sites were included in the study? 
One 
Two 
Three 
Specify number 
 
6. Was random assignment performed in the same way in all sites 
Yes 
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No (explain) 
Can’t tell  
 
7. How many intervention groups were there? (CBT counts as one) 
One (CBT) 
Two (CBT plus what?) 
Three (CBT plus what?) 
 
8. How many intervention groups are relevant for this review? 
One (CBT) 
More than one (explain) 
 
9. How many different control/comparison groups were there? (i.e., groups that 
received different treatments, not counting multiple sites) 
One 
Two or more (explain) 
 
10. How many control/comparison groups are relevant for this review? 
One  
More than one (explain) 
 
11. Study sample size  
N’s CBT1* COMPARISON1* TOTAL  Pg. # & NOTES 
Referred to study      
Consented     
Completed base 
line measures 
    
Randomly 
assigned 
Or non randomly 
allocated  
    
Started treatment      
Completed 
treatment 
    
Completed  first 
measure after 
baseline 
    
Completed 1st 
follow  
 up   
    
Completed 2nd 
follow up(add 
rows for as 
required for 
additional follow 
ups) 
    
* Add columns for additional intervention and control/comparison groups. 
 
Participant/sample Characteristics: 
12. Was participant inclusion criteria mentioned? 
No 
Yes (describe & cite pg#) 
 
13. Was participant exclusion criteria mentioned? 
No 
Yes (describe & cite pg#) 
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14. Participant Characteristics  
 CBT* CONTROL* TOTAL  Pg. # & NOTES 
Gender (e.g. % male)      
Youth Ages      
Race/ethnicity      
Socioeconomic status     
Profession       
Family composition     
Other characteristics      
* Add columns for additional intervention and control/comparison groups. 
 
15. Specify and describe type of drug use 
Cannabis   
Cocaine  
Amphetamine 
Combination (specify, pg. #)  
Other (specify, pg. #) 
 
16. Were there any differences between intervention and comparison groups at baseline 
(For NRCT only)? 
No 
Yes (describe differences & cite pg#) 
Unclear 
 
17. Was there any analysis of differences between completers and dropouts in the 
intervention group and/or comparison group?  
No 
Yes (describe differences & cite pg#) 
Unclear 
 
18. Was there any analysis of differences between completers and dropouts in the 
intervention group and/or comparison group?  
No 
Yes (pg. # & describe) 
Unclear 
 
19. Was intention to treat analysis used? 
No 
Yes (pg. # & describe) 
If yes is this a true ITT analysis  
Unclear 
 
Settings 
20. Location of interventions (check all that apply) 
Urban 
Suburban 
Rural 
Can’t tell 
 
21. Location details (city, state, country) 
Primary service sector 
Mental Health 
Child Welfare 
Other (specify) 
 
21. A Referred by? 
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School 
Social worker 
Juvenile justice system 
Family 
Other (specify)  
 
 
 
 
22.  CBT  Characteristics 
 Min Max Mean SD Pg# & Notes 
Duration in 
Days 
Weeks 
Months 
     
Hours of contact 
Per week 
Per month 
Other (explain) 
     
Total hours of contact      
 
 
23.  Was the CBT? 
Group based 
Individual  
Combination  
 
24.  Other characteristics of CBT 
 
25.  Characteristics of treatment staff (education, demographics, etc.) 
 
26.  Describe methods used to insure quality of CBT (supervision, training, 
consultation) 
 
27.  Is there any information on adherence (fidelity) to CBT? 
Yes (describe) 
No 
Not sure 
 
28.  If multiple sites, were there any implementation differences between sites?  
Yes (describe differences) 
No (how do we know?) 
Can’t tell 
 
Services provided to control cases 
29. Type of control group 
Usual services (treatment as usual) 
Alternative service (describe) 
No service 
 
30. Describe services provided to control group 
 
31. Characteristics of staff that provided services to control/comparison 
groups (education, demographics, etc.)  
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Outcome measures 
32.  When were data collected? (check all that apply) 
Baseline 
Post-tx 
1st follow-up (when?) 
2nd follow-up (when?) 
3rd follow-up (when?) 
4th follow-up (when?) 
5th follow-up (when?) 
Other 
 
33. Who conducted interviews? 
Research staff 
Clinical staff 
Both 
No interviews 
 
34.  Were data collected in the same manner for CBT and control groups? 
Yes 
No (what were the differences?) 
Can’t tell 
 
35.  Analysis  
Describe how the authors deal with ITT? 
Did they use ITT and if yes was the approach used adequate (i.e., was it a true ITT) (specify) ? 
Yes 
No 
Can’t tell 
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Outcome measures 
Instructions: Please enter outcome measures in the order in which they are described in the report. Note that a single outcome measure can be completed by multiple sources and at 
multiple points in time (data from specific sources and time-points will be entered later). 
 
# 
Outcome  
& measure 
Reliability & Validity Format Direction Source Mode Admin 
Blind 
(outcome 
assessors)? 
Pg# & notes 
  
Info from: 
Other samples 
This sample 
Unclear 
 
Info provided: 
 
 
Dichotomy 
Continuous 
 
 
High score or 
event is 
 
Positive 
Negative 
Can’t tell 
 
Youth 
Parent 
Teacher 
Clinician 
Admin data 
Other 
Unclear 
Self-admin 
Interview 
Other 
 
 
Yes 
No 
Can’t tell 
 
 
 
* Repeat as needed 
 
DICHOTOMOUS OUTCOME DATA  
OUTCOME 
TIME POINT (record exact 
time taken from baseline  
SOURCE 
 
VALID Ns N W/ EVENT % WITH EVENT  STATISTICS Pg. # & NOTES 
 
•1st measure after baseline 
•1st follow-up 
• 2nd follow-up 
• 3rd follow-up 
•4th  follow-up 
• other 
• youth 
• parent 
• teacher 
• clinician 
• admin data 
• other (specify) 
 
CBT CBT CBT Risk ratio 
OR (odd ratio) 
95% CI 
DF 
 
P- value (enter exact p value 
if available) 
Chi2 
Other 
Covariates (control 
variables) 
 
 
 
 
 
  
Comparison  Comparison Comparison 
 
 
 
  
* Repeat as needed 
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CONTINUOUS OUTCOME DATA 
Enter change and gain scores under Statistics (Other)   
 
OUTCOME 
TIME POINT (record exact 
time taken from baseline 
SOURCE 
(specify) 
VALID Ns Means SDs STATISTICS Pg. # & NOTES 
 
•1st measure after baseline 
•1st follow-up 
• 2nd follow-up 
• 3rd follow-up 
•4th  follow-up 
• other  
 
• youth 
• parent 
• teacher 
• clinician 
•admin data 
• other (specify) 
 
CBT CBT CBT 
P   
t 
F 
Df 
ES 
Covariates 
Other  
 
 
 
 
 
 
 
 
 
 
 
Comparison  Comparison Comparison 
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11.4  RISK OF BIAS TOOL 
Item Judgementa Description (quote from paper, or 
describekey information) 
1. Sequence generation 
 Automatically high for NRCT 
2. Allocation concealment 
  
3. Confoundingb, 
  
4. Blinding?b 
  
5. Incomplete outcome data 
addressed?b 
  
6. Free of selective reporting?b 
  
7. Free of other bias? 
  
8. A prioriprotocol?d 
  
9. A priori analysis plan?e 
  
 
a Some items on low/high risk/unclear scale (double-line border), some on 5 point scale/unclear 
(single line border), some on yes/no/unclear scale (dashed border). For all items, record 
“unclear” if inadequate reporting prevents a judgement being made. 
b For each outcome in the study. 
c This item is based on list of confounders considered important at the outset and defined in the 
protocol for the review (assessment against worksheet).  
d Did the researchers write a protocol defining the study population, intervention and comparator, 
primary and other outcomes, data collection methods, etc. in advance of starting the study? 
e Did the researchers have an analysis plan defining the primary and other outcomes, statistical 
methods, subgroup analyses, etc. in advance of starting the study? 
Risk of bias tool 
Studies for which RoB tool is intended 
The risk of bias model is developed by Prof. Barnaby Reeves in association with the Cochrane Non-
Randomised Studies Methods Group.25 This model, an extension of the Cochrane Collaboration’s risk 
of bias tool, covers both risk of bias in randomised controlled trials (RCTs and QRCTs), but also risk of 
bias in non-randomised studies (in this case non-randomised controlled trials NRCTs).   
The point of departure for the risk of bias model is the Cochrane Handbook for Systematic Reviews of 
interventions (Higgins & Green, 2008). The existing Cochrane risk of bias tool needs elaboration when 
assessing non-randomised studies because, for non-randomised studies, particular attention should be 
paid to selection bias / risk of confounding.   
                                                          
25This risk of bias model was introduced by Prof. Reeves at a workshop on risk of bias in non-
randomised studies at SFI Campbell, February 2011. The model is a further development of work 
carried out in the Cochrane Non-Randomised Studies Method Group (NRSMG). 
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Assessment of risk of bias 
Issues when using modified RoB tool to assess included non-randomised studies: 
 Use existing principle: score judgement and provide information (preferably direct quote) to 
support judgement 
 Additional item on confounding used for RCTs and NRCTs. 
 5-point scale for some items (distinguish “unclear” from intermediate risk of bias). 
 Keep in mind the general philosophy – assessment is not about whether researchers could 
have done better but about risk of bias; the assessment tool must be used in a standard way 
whatever the difficulty / circumstances of investigating the research question of interest and 
whatever the study design used. 
 Anchors: “1/No/low risk” of bias should correspond to a high quality RCT. “5/high risk” of 
bias should correspond to a risk of bias that means the findings should not be considered (too 
risky, too much bias, more likely to mislead than inform) 
 
1. Sequence generation 
 Low/high/unclear RoB item 
 Always high RoB (not random) for a non-randomised study 
 Might argue that this item redundant for NRS since always high – but important to include in 
RoB table (‘level playing field’ argument) 
 
2. Allocation concealment 
 Low/high/unclear RoB item 
 Potentially lowRoB for a non-randomised study, e.g. quasi-randomised (so high RoB to 
sequence generation) but concealed (reviewer judges that the people making decisions about 
including participants didn’t know how allocation was being done, e.g. odd/even date of 
birth/hospital number) 
 
3. RoB from confounding (assess for each outcome) 
 Assumes a pre-specified list of potential confounders defined in the protocol 
 Low(1) / 2 / 3 / 4 / high(5) / unclear RoB item 
 Judgement needs to factor in: 
o proportion of confounders (from pre-specified list) that were considered 
o whether most important confounders (from pre-specified list) were considered 
o resolution/precision with which confounders were measured 
o extent of imbalance between groups at baseline 
o care with which adjustment was done (typically a judgement about the statistical 
modeling carried out by authors) 
 Low RoB requires that all important confounders are balanced at baseline (not primarily/not 
only a statistical judgement OR measured ‘well’ and ‘carefully’ controlled for in the analysis. 
 
Assess against pre-specified worksheet. Reviewers will make a RoB judgement about each factor first 
and then ‘eyeball’ these for the judgement RoB table. 
 
4. RoB from lack of blinding (assess for each outcome, as per existing RoB tool) 
 Low(1) / 2 / 3 / 4 / high(5) / unclear RoB item 
 Judgement needs to factor in: 
o nature of outcome (subjective / objective; source of information) 
o who was / was not blinded and the risk that those who were not blinded could 
introduce performance or detection bias 
o see Ch.8 
 
5. RoB from incomplete outcome data (assess for each outcome, as per existing RoB tool) 
 Low(1) / 2 / 3 / 4 / high(5) / unclear RoB item 
 Judgement needs to factor in: 
o reasons for missing data 
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o whether amount of missing data balanced across groups, with similar reasons 
o see Ch.8 
 
6. RoB from selective reporting (assess for each outcome, NB different to existing Ch.8 
recommendation) 
 Low(1) / 2 / 3 / 4 / high(5) /unclear RoB item 
 Judgement needs to factor in: 
o existing RoB guidance on selective outcome reporting 
o see Ch.8 
o also, extent to which analyses (and potentially other choices) could have been 
manipulated to bias the findings reported, e.g. choice of method of model fitting, 
potential confounders considered / included    
o look for evidence that there was a protocol in advance of doing any analysis / 
obtaining the data (difficult unless explicitly reported); NRS very different from 
RCTs. RCTs must have a protocol in advance of starting to recruit (for 
REC/IRB/other regulatory approval); NRS need not (especially older studies) 
o Hence, separate yes/no items asking reviewers whether they think the researchers 
had a pre-specified protocol and analysis plan.  
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Confounding Worksheet 
Assessment of how researchers dealt with confounding  
Method for identifying relevant confounders described by researchers:                          yes 
                                                                                                                                                            no                                                                                                                            
If yes, describe the method used: 
 
 
Relevant confounders described:                                                                                               yes 
                                                                                                                                                            no 
List confounders described on next page 
 
Method used for controlling for confounding 
At design stage (e.g. matching, regression discontinuity, instrument variable):  
………………………………………………..      
………………………………………………..  
………………………………………………..            
 
At analysis stage (e.g. stratification, multivariate regression, difference-indifference):    
………………………………………………..      
………………………………………………..  
………………………………………………..            
 
 
Describe confounders controlled for below 
 
 
 
Confounders described by researchers 
Tick (yes[0]/no[1] judgement) if confounder considered by the researchers [Cons’d?] 
Score (1[good precision] to 5[poor precision]) precision with which confounder measured 
Score (1[balanced] to 5[major imbalance]) imbalance between groups 
Score (1[very careful] to 5[not at all careful]) care with which adjustment for confounder was carried 
out 
 
Confounder Considered Precision Imbalance Adjustment 
Gender     
Age     
History of drug use      
Other      
Other:     
Other:     
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11.5  RISK OF BIAS JUDGEMENT, INDIVIDUAL STUDIES 
Table 14.1: Dennis et al., 2004 
Bias Author’s judgement 
 
Support for judgement 
Sequence 
generation 
Low risk "Within each site, eligible adolescents were 
assigned to one of the three local conditions 
using a randomly ordered list that was 
generated by independent research staff at the 
coordinating center using Microsoft Excel." 
(p.206) 
 
"Within each site, eligible adolescents were 
assigned randomly (...) based on their sequence 
of admission using a randomly ordered list of 
assignments. This was undertaken instead of 
simple random assignment in order to allow 
rapid group formation and to counterbalance 
any temporal shifts in recruitment strategies or 
casemix." (Protocol, p. 25) 
Allocation 
concealment 
Low risk 
" Assignment logs were kept in a locked file cabinet 
and were never accessible to clinical staff." (p. 206) 
Blinding – 
outcome 
assessors? 
 “Intake and 3,-6, -9, and 12 month follow-up 
interviews were conducted by research staff” (p. 
206) 
 
“The participants characteristics, diagnoses, 
and primary outcomes were measured with a 
standardised interview” (p. 204) 
 
The outcomes are given unclear as it is not 
possible to conclude whether the outcome 
assessors were blinded or not. 
Abstinence or 
reduction of drug 
use – biochemical 
test 
Unclear * 
Abstinence or 
reduction of drug 
use – self reported 
estimates 
Unclear * 
Abstinence or 
reduction of drug 
use – 
psychometric 
scales 
Unclear * 
Abstinence or 
reduction of drug 
Unclear * 
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use – overall 
judgement 
Social functioning 
and family 
functioning 
Not relevant Not relevant 
Education or 
vocational 
involvement 
Not relevant Not relevant 
Retention Unclear * 
Risk behaviour Not relevant Not relevant 
Other adverse 
effects 
Not relevant Not relevant 
Incomplete 
outcome data 
addressed? 
 "Of the 600 adolescents randomised, one or 
more follow-up interviews were completed on 
99% (n=597), including 98% at 3 months, 97% 
at 6 months, 96% at 9 months, and 94% at 12 
months." (p. 206) 
 
"(…) Analytical files were then created where 
the legitimately skipped items were recoded to 
their implied values. In order to maximize the 
available data and minimize bias to the mean 
and variance, the remaining missing items were 
replaced either within scales where there were 
sufficient data from the individual or through hot 
deck imputation." (Protocol, p. 27) 
 
Intent-to-treat was design used. (p. 206) 
 
"Days of abstinence (from cannabis, alcohol 
and other drugs) were summed across all four 
quarterly follow-up waves, using the 
adolescent's average days abstinent to fill in 
any missing values." (p. 205) 
 
Treatment completion indicated in table 3, p. 
205. Trial 2: MET/CBT5: 60%, ACRA: 61%, 
MDFT: 71%. 
 
The outcomes, other than urinalysis, are given 2 
as there is very little missing data but 
unfortunately we cannot distinguish the missing 
data between trial 1 and 2.The urinalysis is 
given 3 as this outcome has around 10 % 
missing data. 
Abstinence or 
reduction of drug 
use – biochemical 
test 
3 "Collateral interviews and urine test data were 
obtained on over 90% of the adolescents who 
were not incarcerated." (Protocol, p. 26) 
 
Abstinence or 
reduction of drug 
2 "Days of abstinence (from cannabis, alcohol 
and other drugs) were summed across all four 
quarterly follow-up waves, using the 
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use – self reported 
estimates 
adolescent's average days abstinent to fill in 
any missing data." (p.205) 
 
Recovery: "For the 6% of the adolescents who 
did not complete their 12-month interview, data 
from their previous follow-up interview was used 
to determine their recovery status." (p. 206) 
Abstinence or 
reduction of drug 
use – 
psychometric 
scales 
2 * 
Abstinence or 
reduction of drug 
use – overall 
judgement 
2 * 
Social functioning 
and family 
functioning 
Not relevant Not relevant 
Education or 
vocational 
involvement 
Not relevant Not relevant 
Retention Unclear - 
Risk behaviour Not relevant Not relevant 
Other adverse 
effects 
Not relevant Not relevant 
Free of selective 
reporting? 
 The urinalysis outcome is given 3 as the 
measurement, and thereby data collection is 
made but the results are reported 
inappropriately.  
 
Outcomes for social functioning and family 
functioning and education or vocational 
involvement are given 3 as these are mentioned 
in the protocol but not in the final study 
(apparently no data collection has been made 
for these outcomes). 
 
Other outcomes are given 1 as they are 
reported carefully. 
Abstinence or 
reduction of drug 
use – biochemical 
test 
3 The urinalysis outcomes are not explicitly 
reported - however selfreportings vs. on-site-
tests are (e.g. p. 23-24 in Protocol). 
 
Abstinence or 
reduction of drug 
use – self reported 
estimates 
1 (See p. 207-208 + appendix) 
 
Abstinence or 
reduction of drug 
1 Only reported in appendix 
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use – 
psychometric 
scales 
Abstinence or 
reduction of drug 
use – overall 
judgement 
1 * 
Social functioning 
and family 
functioning 
3 (See p. 207-208 + appendix) 
 
The study protocol mentions emotional 
problems, behavioural problems, and family 
problems as outcomes but they are not 
considered in the final study. 
Education or 
vocational 
involvement 
3 The study protocol mentions school problems 
as an outcome but this outcome is not 
considered in the final study. 
 
Retention 1 (See table 3, p. 205) 
 
Risk behaviour 3 The study protocol mentions legal problems and 
victimization as outcomes but these outcomes 
are not considered in the final study. 
 
Other adverse 
effects 
Not relevant Not relevant 
Free of other 
bias? 
1  
A priori protocol? Yes (Protocol: Dennis ID 853) 
A priori analysis 
plan? 
Yes "Following the Consolidated Standards of 
Reporting Trials (…), all analyses were 
conducted with an "intent-to-treat" approach. 
Thus all adolescents were included in analyses 
as assigned, including approximately 5% who 
did not actually receive any treatment." (p. 206) 
 
The protocol mentions the outcomes for 
analysis and the intended design of the 
analyses. 
* Denotes that support for judgement is described in the general risk of bias category field above.   
 
Table 14.2: Godley et al., 2010 
Bias Author’s judgement 
 
Support for judgement 
Sequence 
generation 
Low risk "(…) participants were (…) assigned to one of 
four conditions based on a randomization log, 
which was generated by the project manager 
and consisted of alternating blocks of six 
assignment slots to the MET/CBT7 intervention 
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(due to closed groups) or CBOP. A coin was 
flipped to determine which treatment condition 
would be the initial outpatient condition. Within 
each block of a treatment assignment, there 
were alternating assignments to the continuing 
care conditions, with the first continuing care 
condition in each block also determined by a 
coin toss. Thus each participant was 
simultaneously assigned to one of the outpatient 
treatments and one of the continuing care 
conditions." (p. 48) 
Allocation 
concealment 
Low risk "(…) a randomization log, which was generated 
by the project manager. (…)The randomization 
log was stored in a locked file cabinet in the 
office of research staff." (p. 48) 
Blinding – 
outcome 
assessors? 
 "It was not possible to blind staff to condition; 
however, research staff with no connection to 
the conditions administered all follow-up 
interviews." (p. 48) 
 
"It was not possible to blind the research staff 
who collected follow-up data to participants' 
study condition assignment; however, separate 
staff were used for research interviews and 
treatment." (p.52) 
 
"Follow-up interviews (...) were administered by 
research staff with bachelor's or master's 
degrees. Training in the study assessments 
included formal training sessions, observation, 
feedback on audiotaped administrations until 
certification was achieved, and on-going 
monitoring with scheduled reviews of additional 
audiotapes." (p. 48) 
 
The outcomes, other than retention, are given 3 
as the study separated the outcome assessors 
from treatment assistants. However, they were 
not blinded. 
Abstinence or 
reduction of drug 
use – biochemical 
test 
Unclear Not reported 
Abstinence or 
reduction of drug 
use – self reported 
estimates 
3 * 
Abstinence or 
reduction of drug 
use – 
psychometric 
scales 
3 * 
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Abstinence or 
reduction of drug 
use – overall 
judgement 
3 * 
Social functioning 
and family 
functioning 
Not relevant Not relevant 
Education or 
vocational 
involvement 
Not relevant Not relevant 
 
Retention 4 "Clinicians recorded which therapy or case 
management procedure(s) were conducted with 
which participant, when, and the duration." (p. 
49) 
 
Risk behaviour Not relevant Not relevant 
Other adverse 
effects 
Not relevant Not relevant 
Incomplete 
outcome data 
addressed? 
- "There was very little missing data (i.e., less 
than 10% of the participants missed any given 
interview wave and less than 4% had missing 
data on any one variable), and any missing data 
were addressed with the mixed effects 
analyses, which generated estimates using 
restricted (by condition) maximum likelihood (...) 
When differences from more than one group 
were analysed, Cohen's effect-size f-index was 
calculated as the average of the absolute value 
of the difference between each group mean and 
the grand mean." (p. 49) 
 
"Follow-up rates were 97%, 96%, 93%, and 
91% for each respective follow-up wave and 
were above 90% for each condition by wave." 
(p. 48) 
 
ITT-design used (p. 49) 
 
The outcomes are given 1 as the authors clearly 
state the number of missing data, which is 
between 4-10 %. Furthermore, they use an ITT-
design where the missing values were 
addressed properly. 
Abstinence or 
reduction of drug 
use – biochemical 
test 
1 * 
Abstinence or 
reduction of drug 
use – self reported 
estimates 
1 * 
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Abstinence or 
reduction of drug 
use – 
psychometric 
scales 
1 * 
Abstinence or 
reduction of drug 
use – overall 
judgement 
1 * 
Social functioning 
and family 
functioning 
Not relevant Not relevant 
Education or 
vocational 
involvement 
Not relevant Not relevant 
Retention Unclear - 
Risk behaviour Not relevant Not relevant 
Other adverse 
effects 
Not relevant Not relevant 
Free of selective 
reporting? 
 The urinalysis outcome is given 3 as the 
measurement, and thereby data collection is 
made but the results are reported 
inappropriately. 
 
Other outcomes are given 1 as they are 
reported carefully. 
Abstinence or 
reduction of drug 
use – biochemical 
test 
3 "Urine samples were collected (…), and when 
an adolescent reported being in recovery, but 
the urine test result suggested a false-negative 
self-report, data were re-coded to show the 
adolescent as not being in recovery." (p. 49) 
(Note: results from urinalysis are however not 
explicitly reported although the false-negative 
rates are). 
Abstinence or 
reduction of drug 
use – self reported 
estimates 
1 (reported in table 3) 
 
(recovery status rates for the individual 
conditions are reported at p. 51) 
 
Abstinence or 
reduction of drug 
use – 
psychometric 
scales 
1 (reported in table 3) 
 
Abstinence or 
reduction of drug 
use – overall 
judgement 
1 * 
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Social functioning 
and family 
functioning 
Not relevant Not relevant 
Education or 
vocational 
involvement 
Not relevant Not relevant 
 
Retention 1 (reported in table 2) 
 
Risk behaviour Not relevant Not relevant 
Other adverse 
effects 
Not relevant Not relevant 
Free of other bias? 2 "(…) some adolescents participated in other 
mental health treatment (e.g. counseling and/or 
medication management)." (p. 48) 
A priori protocol? Yes This study was registered at clinicaltrials.gov 
with a description of the interventions, the 
outcomes and the eligible participants (no 
description of analysis plan). 
A priori analysis 
plan? 
Unclear Intent-to-treat analysis (p. 45). 
The protocol mentions the outcomes but not the 
analyses plans. 
* Denotes that support for judgement is described in the general risk of bias category field above.   
 
Table 14.3: Hendriks et al., 2011 
Bias Author’s judgement 
 
Support for judgement 
Sequence 
generation 
Low risk "(…) eligible patients were randomly allocated 
(1:1) by our research group to outpatient CBT 
(control group; n = 54) or MDFT (experimental 
group; n = 55) by using a computer-generated 
randomization list. Randomization (…) was 
prestratified for age, gender, ethnicity and 
frequency of cannabis use, using blocks of two 
patients." (p. 65) 
Allocation 
concealment 
Low risk "Randomization was concealed (…)" (p. 65) 
Blinding – 
outcome 
assessors? 
 "Study assessments were conducted by trained 
research assistents who used standardized 
instruments to minimize information bias." (p. 
65) 
From Rigter et al. (2011): 
“Questionnaires were self-administered by the 
adolescent or the parent, or if required 
completed with the assistance of a researcher, 
who had been trained by INCANT project staff 
and was working under the guidance of three 
instruction manuals." (p. 28) 
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"Research staff were unaware of treatment 
condition when carrying out assessments and 
analysing outcomes." (p. 4 in journal edition) 
 
The outcome, other than retention, are given 1 
as it is clear from the text that outcome 
assessors were blinded 
Abstinence or 
reduction of drug 
use – biochemical 
test 
Unclear "Questionnaires were self-administered by the 
adolescent or the parent, or if required 
completed with the assistance of a researcher, 
who had been trained by INCANT project staff 
and was working under the guidance of three 
instruction manuals." (p. 28) 
 
"Research staff were unaware of treatment 
condition when carrying out assessments and 
analysing outcomes." (p. 4 in journal edition) 
 
The outcome, other than retention, are given 1 
as it is clear from the text that outcome 
assessors were blinded. 
Abstinence or 
reduction of drug 
use – self reported 
estimates 
1 * 
Abstinence or 
reduction of drug 
use – 
psychometric 
scales 
1 * 
Abstinence or 
reduction of drug 
use – overall 
judgement 
1 * 
Social functioning 
and family 
functioning 
1 * 
Education or 
vocational 
involvement 
1 * 
Retention 4 For one of the retention measures it is clearly 
stated: "Treatment completion as defined by 
therapist" (Table 3, p. 69). 
Risk behaviour 1 * 
Other adverse 
effects 
Not relevant Not relevant 
Incomplete 
outcome data 
addressed? 
  
"Missing data at month 3, 6, and 12 were 
estimated by means of multiple imputation 
procedure, using five imputed datasets." (p. 66). 
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MDFT: 1 did not start treatment - 3 lost to 
follow-up at month 12 - 44 completed 
intervention (26 in planned treatment period). 
CBT: 7 did not start treatment - 3 lost to follow-
up at month 12 - 16 completed treatment (5 in 
planned treatment period). (p. 66) 
 
The outcomes are given 2 as the number of 
missing data is small except month 9 where 
there is dissimilarities between groups. 
Abstinence or 
reduction of drug 
use – biochemical 
test 
2 * 
Abstinence or 
reduction of drug 
use – self reported 
estimates 
2 "Efficacy of MDFT vs. CBT in terms of the 
primary outcome measure was analysed by 
means of a 2 (treatment: MDFT vs. CBT) x 2 
(time: Baseline vs. Month 12) repeated 
measures MANOVA, using the baseline and 
imputed month 12 datasets. Difference in 
percentage treatment responders between the 
study groups at month 12 was analysed in a 
logistic regression model, with treatment group 
as independent variable and response (imputed 
dataset) as outcome variable. The same 
approach was used for analyzing the difference 
in percentage of recovered adolesecnts at 
month 12" (p. 66). 
Abstinence or 
reduction of drug 
use – 
psychometric 
scales 
Not relevant Not relevant  
Abstinence or 
reduction of drug 
use – overall 
judgement 
2 * 
Social functioning 
and family 
functioning 
2 * 
Education or 
vocational 
involvement 
Not relevant Not relevant 
Retention Unclear  - 
Risk behaviour 2 "Differences in delinquency (property and 
violent crimes) between the study groups at 
month 12 were tested using the same analytical 
approach as described for the primary outcome 
measure (i.e. repeated measures MANOVA)" 
(p. 66) 
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Other adverse 
effects 
Not relevant Not relevant 
Free of selective 
reporting? 
 "Outcomes relating to the 9 month follow-up are 
not reported because of a particular low follow-
up rate in CBT" (p. 66) 
 
The urinalysis outcome is given 4 as the 
measurement, and thereby data collection, is 
made but no results reported for this outcome. 
From information in Rigter et al. 2011:Outcomes 
for self-reported and scales for the primary 
outcome are given 1, as these outcomes are 
reported carefully. 
Social functioning and family functioning and 
education or vocational involvement outcomes 
are given 3 as these outcomes are mentioned in 
the protocol but not in the final studies 
(apparently no data collection for these 
outcomes). 
 
Other outcomes (except retention which is a 
different kind of measure) are given 3 as the 
results for the 9 month follow-up are not 
reported. 
Abstinence or 
reduction of drug 
use – biochemical 
test 
4 Not reported allthough measurements are 
made. 
Abstinence or 
reduction of drug 
use – self reported 
estimates 
1 (See table 6.1 in Rigter et al., 2011) 
Abstinence or 
reduction of drug 
use – 
psychometric 
scales 
1 (see table 6.2 in Rigter et al., 2011) 
Abstinence or 
reduction of drug 
use – overall 
judgement 
1 * 
Social functioning 
and family 
functioning 
3 (see table 7.1 in Rigter et al., 2011) 
 
The protocol mentions family dysfunction as an 
outcome but this outcome is not clearly reported 
in the final study. 
Education or 
vocational 
involvement 
3 The protocol mentions school problems as an 
outcome but this outcome is not clearly reported 
in the final study. 
Retention 1 Table 3, p. 69 
Risk behaviour 1 (see table 7.2 in Rigter et al., 2011) 
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Other adverse 
effects 
Not relevant Not relevant 
Free of other 
bias? 
1   
A priori protocol? Unclear The study is part of a larger European study for 
which a priori protocol has been made but the 
study is considered as an individual study (see 
Rigter et al., 2011) 
A priori analysis 
plan? 
Unclear "Study data were analysed using an intent-to 
treat-approach, which included all patients that 
were notified about their randomised group 
allocation." (p. 66). The protocol includes 
description of outcomes and analyses plans 
* Denotes that support for judgement is described in the general risk of bias category field above.   
 
Table 14.4: Kaminer et al., 1998a, 1999 
Bias Author’s judgement 
 
Support for judgement 
Sequence 
generation 
Unclear "They were then randomly assigned to one of 
two treatment conditions: CBT or IT." (Kaminer 
ID. 1085, p. 686) 
Allocation 
concealment 
Unclear Not reported 
Blinding – 
outcome 
assessors? 
 "(…) and subjective indicators for substance 
use and substance use-related problems were 
elicited from rating scales administered at 
intake, during treatment, and at follow-up." (p. 
685) 
 
"Data were collected by a master's level 
research assistant who was not informed of the 
matching hypotheses being studied (…)" 
(Kaminer ID. 1085, p. 686) 
 
The outcomes, other than urinalysis and 
retention, are given 2 as the outcome assessors 
were not informed of the hypotheses, but still 
had the knowledge of group allocation. 
Abstinence or 
reduction of drug 
use – biochemical 
test 
Unclear Not reported 
 
"Weekly urinalysis procedure employed EZ-
screen Test Kit for cannabinoid, cocaine, and 
opiates." (p. 685) 
Abstinence or 
reduction of drug 
use – self reported 
estimates 
Not relevant Not relevant 
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Abstinence or 
reduction of drug 
use – 
psychometric 
scales 
2 * 
Abstinence or 
reduction of drug 
use – overall 
judgement 
2 * 
Social functioning 
and family 
functioning 
2 * 
Education or 
vocational 
involvement 
2 * 
Retention Unclear - 
Risk behaviour 2 * 
Other adverse 
effects 
Not relevant Not relevant 
Incomplete 
outcome data 
addressed? 
 "Among the subjects with valid baseline and 
follow-up measures on the T-ASI (N=23), the 
CBT and the IT groups did not differ significantly 
at baseline on the percent male, percent white 
ethnicity, average age, on any of the T-ASI 
measures, or on externalising, internalizing, 
major depressive disorder/dystymia, or conduct 
disorder/oppositional disorder." (Kaminer ID 
1085, p. 687) 
 
"(...) Regardless of program completion status, 
22 of the 32 original subjects completed 3 
months follow-up assessment procedures, while 
14 completed the 15 month follow up. Of the 22 
that followed up at three month, eight were not 
interviewed at 15-month follow-up because of 
incarceration (one), having moved out of state 
(three), refusal (two), and failure to locate (two). 
Data of two adoelscents who were interviewed 
at 15-months are not included in the anlaysis 
because their baseline data could not be 
retrieved." (Kaminer ID. 1044, p. 115) 
 
Intent-to-treat design used (Kaminer ID 1044, p. 
115) - but not used in analysis of follow-up as 
the N's are measured as CBT=5 and IT=7 
(Kaminer ID 1044, p. 117) 
 
The outcomes are given 3 as there is missing 
data of 20-55 % in the follow-ups. 
Abstinence or 
reduction of drug 
3 * 
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use – biochemical 
test 
Abstinence or 
reduction of drug 
use – self reported 
estimates 
Not relevant Not relevant 
Abstinence or 
reduction of drug 
use – 
psychometric 
scales 
3 * 
Abstinence or 
reduction of drug 
use – overall 
judgement 
3 * 
Social functioning 
and family 
functioning 
3 * 
Education or 
vocational 
involvement 
3 * 
Retention Unclear - 
Risk behaviour 3 * 
Other adverse 
effects 
Not relevant Not relevant 
Free of selective 
reporting? 
 The urinalysis outcome is given 3 as the 
measurement, and thereby data collection is 
made, but the results are reported 
inappropriately. The primary outcome 
(psychometric scale) is given 2 as the scale is 
split in the follow-up but not in the first study. 
Other outcomes are given 1 as they are 
reported carefully. 
Abstinence or 
reduction of drug 
use – biochemical 
test 
3 "Of those subjects with available measures, 
approximately half (16) tested positive for 
marijuana (sometime during the course of the 
treatment), whereas only two tested positive for 
cocaine and one tested positive for heroin. No 
significant differences between therapy groups 
were found." (Kaminer ID 1085, p. 688). 
(Note: The urinalyses are not numerically 
reported, furthermore it is stated that one of the 
shortcomings of the study is "lack of objective 
measures of urinalysis during the follow-up 
period.", Kaminer ID 1085, p. 689) 
Abstinence or 
reduction of drug 
use – self reported 
estimates 
Not relevant Not relevant 
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Abstinence or 
reduction of drug 
use – 
psychometric 
scales 
2 "From the analyses of each of the seven T-ASI 
scales, none of the baseline measures were 
significantly correlated with the respective 
outcome measure, but the psychiatric subscale 
showed a trend toward significance (…)" 
(Kaminer ID. 1085, p. 687) 
 
"(…) The original T-ASI substance abuse scale 
was split into an Alcohol and a Drug subscale." 
(Kaminer 1044, p. 116) 
(Note: this is NOT done in Kaminer ID. 1085) 
Abstinence or 
reduction of drug 
use – overall 
judgement 
2 * 
Social functioning 
and family 
functioning 
1 (See table 2) 
 
"The rate of change from baseline to follow-up-
up in family problems showed a trend toward 
significance as a function of therapy group (…)" 
(Kaminer ID. 1085, p. 688) 
Education or 
vocational 
involvement 
1 (See table 2) 
 
"There were no significant baseline, main , or 
interactive effects for T-ASI Drug, School, Legal 
or Family subscales." (Kaminer ID 1044, p. 116) 
Retention 1 "Of the 32 adolescents who were randomlys 
assigned to the two tretament conditions, 50% 
of the subjects (8 CBT, ( IT) completed the 
treatment program..." (p. 687) 
 
"There were no significant effects or trends for 
the rate of change difference from baseline to 
follow-up for those who completed treatment 
versus those who did not." (Kaminer ID 1085, p. 
688) 
Risk behaviour 1 (see table 2) 
 
"There were no significant baseline, main , or 
interactive effects for T-ASI Drug, School, Legal 
or Family subscales." (Kaminer ID 1044, p. 116) 
Other adverse 
effects 
Not relevant Not relevant 
Free of other 
bias? 
1  
A priori protocol? Unclear - 
A priori analysis 
plan? 
Unclear Intent-to-treat design (Kaminer, ID. 1044, p. 
115) 
 
They state it is an ITT-design but they do not 
use this analysis plan in the actual analysis, 
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where the N's are much lower than the 
randomised number of participants. 
* Denotes that support for judgement is described in the general risk of bias category field above.   
 
Table 14.5: Kaminer et al., 2002 
Bias Author’s judgement 
 
Support for judgement 
Sequence 
generation 
Unclear "Participants completed a baseline assessment 
battery and were then randomised into one of 
two closed-group conditions: CBT or PET." (p. 
738). 
Allocation 
concealment 
Unclear Not reported 
Blinding – 
outcome 
assessors? 
 "Subjective indicators for substance use and 
substance use-related problems were elicited 
from a rating scale administered by a trained 
research assistant." (p. 739) 
 
The outcomes are given unclear as it is not 
possible to conclude whether the outcome 
assessors were blinded or not. 
Abstinence or 
reduction of drug 
use – biochemical 
test 
Unclear Not reported 
 
"A trained research assistant used EZ-Screen 
Test Kit to test for cannabinoid, cocaine, and 
opiate use." (p. 739) 
Abstinence or 
reduction of drug 
use – self reported 
estimates 
Not relevant Not relevant 
Abstinence or 
reduction of drug 
use – 
psychometric 
scales 
Unclear "Subjective indicators for substance use and 
substance use-related problems were elicited 
from a rating scale administered by a trained 
research assistant." (p. 739) 
Abstinence or 
reduction of drug 
use – overall 
judgement 
Unclear * 
Social functioning 
and family 
functioning 
Unclear "Subjective indicators for substance use and 
substance use-related problems were elicited 
from a rating scale administered by a trained 
research assistant." (p. 739) 
Education or 
vocational 
involvement 
Unclear "Subjective indicators for substance use and 
substance use-related problems were elicited 
from a rating scale administered by a trained 
research assistant." (p. 739) 
Retention Unclear -  
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Risk behaviour Unclear "Subjective indicators for substance use and 
substance use-related problems were elicited 
from a rating scale administered by a trained 
research assistant." (p. 739) 
Other adverse 
effects 
Not relevant Not relevant 
Incomplete 
outcome data 
addressed? 
 "Since some subjects had follow-up data for one 
but not the other of the two follow-up periods (3 
months and 9 months), two sets of regressions 
were carried out: one for baseline versus 3 
month follow-up evaluation, and one for 
baseline versus 9 month follow-up evaluation." 
(p.740) 
 
"The treatment completion rate was 86%; the 3-
month follow-up rate was 80%; and the 9-month 
follow-up rate was 65%. No significant 
association between group and completion 
status." (p. 740) 
 
The authors do not explain what they do with 
missing values for other outcomes than urin 
tests. The N-value in the outcome table 
indicates that all subjects were included in the 
analysis. 
 
The outcomes, other than urinalysis, are given 4 
as there is missing outcome data for 20-35 % 
and because the authors do not mention the 
method used to fill in any missing values. 
However, this method is mentioned for 
urinalysis and therefore this outcome is given 3. 
Abstinence or 
reduction of drug 
use – biochemical 
test 
3 "Drug urinalysis data were analysed as intent to 
treat, with missing values filled in with the last 
valid value carried forward". (p. 740) 
Abstinence or 
reduction of drug 
use – self reported 
estimates 
Not relevant Not relevant 
Abstinence or 
reduction of drug 
use – 
psychometric 
scales 
4 * 
Abstinence or 
reduction of drug 
use – overall 
judgement 
4 * 
Social functioning 
and family 
functioning 
4 * 
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Education or 
vocational 
involvement 
4 * 
Retention Unclear  - 
Risk behaviour 4 * 
Other adverse 
effects 
Not relevant Not relevant 
Free of selective 
reporting? 
 The urinalysis outcome is given 4 as the 
measurement, and thereby data collection is 
made but no results reported for this outcome. 
Other outcomes are given 1 as they are 
reported carefully. 
Abstinence or 
reduction of drug 
use – biochemical 
test 
4 Outcomes relating to urinalysis are not reported. 
Abstinence or 
reduction of drug 
use – self reported 
estimates 
Not relevant Not relevant 
Abstinence or 
reduction of drug 
use – 
psychometric 
scales 
1 (see table 3) 
Abstinence or 
reduction of drug 
use – overall 
judgement 
1 * 
Social functioning 
and family 
functioning 
1 (see table 3) 
Education or 
vocational 
involvement 
1 (see table 3) 
Retention 1 (see table 1) 
Risk behaviour 1 (see table 3) 
Other adverse 
effects 
Not relevant Not relevant 
Free of other 
bias? 
1  
A priori protocol? Unclear  - 
A priori analysis 
plan? 
Unclear  - 
* Denotes that support for judgement is described in the general risk of bias category field above.   
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Table 14.6: Latimer et al., 2003 
Bias Author’s judgement 
 
Support for judgement 
Sequence 
generation 
Unclear "(…) 43 youths and families were randomly 
assigned to IFCBT or DHPE conditions." (p. 
306) 
Allocation 
concealment 
Unclear Not reported 
Blinding – 
outcome 
assessors? 
 "The youth and parent baseline assessments 
batteries were administered separately by pre-
doctoral graduate research assistants who 
completed extensive didactic training on the use 
of DICA, ADI and self-report tools." (p. 307) 
 
"Discharge and follow-up assessments were 
administered by staff who had no treatment 
delivery duties." (p. 308). 
 
The outcomes, other than retention, are given 3 
as the study separated the outcome assessors 
from treatment assistants. However, they were 
not blinded. 
Abstinence or 
reduction of drug 
use – biochemical 
test 
Not relevant Not relevant 
Abstinence or 
reduction of drug 
use – self reported 
estimates 
3 * 
Abstinence or 
reduction of drug 
use – 
psychometric 
scales 
3 * 
Abstinence or 
reduction of drug 
use – overall 
judgement 
3 * 
Social functioning 
and family 
functioning 
3 * 
Education or 
vocational 
involvement 
3 * 
Retention Unclear  - 
Risk behaviour Not relevant Not relevant 
Other adverse 
effects 
Not relevant Not relevant 
165  The Campbell Collaboration | www.campbellcollaboration.org 
Incomplete 
outcome data 
addressed? 
 "Out of the 43 youth and parents enrolled, 42 
completed the youth neuropsychological 
assessment battery and posttretatment 
assessments at 3- and 6-month follow-up 
points. Thirty-five of these youth also completed 
the 1-month follow-up assessment." (p. 308) 
 
"(...) Data on 1-month follow-up outcomed were 
derived from their 3-month follow-up 
assessment." (p. 310) 
 
"Intent-to-treat analyses were conducted on 
data from the 42-of-43 youth who enrolled in the 
radnomized treatment study and completed the 
baseline and follow-up assessments." (p. 310) 
 
The outcomes are given 1 as there apparently is 
no missing data in this study - only one 
participant is excluded from the analysis. 
Abstinence or 
reduction of drug 
use – biochemical 
test 
1 * 
Abstinence or 
reduction of drug 
use – self reported 
estimates 
1 * 
Abstinence or 
reduction of drug 
use – 
psychometric 
scales 
Not relevant Not relevant 
Abstinence or 
reduction of drug 
use – overall 
judgement 
1 * 
Social functioning 
and family 
functioning 
1 * 
Education or 
vocational 
involvement 
1 * 
Retention Unclear  - 
Risk behaviour Not relevant Not relevant 
Other adverse 
effects 
Not relevant Not relevant 
Free of selective 
reporting? 
 The urinalysis outcome is given 3 as the 
measurement, and thereby data collection, is 
made but the results are reported 
inappropriately. 
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Other outcomes are given 1 as they are 
reported carefully. 
Abstinence or 
reduction of drug 
use – biochemical 
test 
3 (Note: results from urinalysis are not explicitly 
reported. However it is stated that "rates of 
concordance between youth self-report of 
substance use during the past month and 
urinalysis results exceeded 95% at baseline and 
each follow-up assessment point." (p. 308)) 
Abstinence or 
reduction of drug 
use – self reported 
estimates 
1 (reported in table 4) 
Abstinence or 
reduction of drug 
use – 
psychometric 
scales 
Not relevant Not relevant 
Abstinence or 
reduction of drug 
use – overall 
judgement 
1 * 
Social functioning 
and family 
functioning 
1 (reported in table 5, 6, 7) 
Education or 
vocational 
involvement 
1 (reported in table 5) 
Retention Unclear  - 
Risk behaviour Not relevant Not relevant 
Other adverse 
effects 
Not relevant Not relevant 
Free of other 
bias? 
1  
A priori protocol? Unclear Not reported 
A priori analysis 
plan? 
Unclear "Intent-to-treat analyses were conducted on 
data from the 42-of-43 youth who were enrolled 
in the randomised treatment study and 
completed the baseline and follow-up 
assessments." (p. 310) 
* Denotes that support for judgement is described in the general risk of bias category field above.   
 
 
Table14. 7: Waldron et al., 2001 
Bias Author’s judgement 
 
Support for judgement 
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Sequence 
generation 
Low risk "An urn randomization procedure (…) was used 
to retain random allocation while balancing 
treatment condition groups on a priori continous 
and categorical variables. With this procedure, 
relative probabilities of assignment to treatment 
groups (urns) are computer adjusted on the 
basis of previous randomizations to ensure pre-
treatment group equivalence. The variables 
included in this project's urn were gender, age, 
level of substance use, ethnicity, psychiatric 
severity, and family constitution." (p. 804) 
Allocation 
concealment 
Unclear Not reported 
Blinding – 
outcome 
assessors? 
 The outcomes are given unclear as it is not 
possible to conclude whether the outcome 
assessors were blinded or not. 
Abstinence or 
reduction of drug 
use – biochemical 
test 
Unclear Not reported 
Abstinence or 
reduction of drug 
use – self reported 
estimates 
Unclear Not reported 
Abstinence or 
reduction of drug 
use – 
psychometric 
scales 
Not relevant Not relevant 
Abstinence or 
reduction of drug 
use – overall 
judgement 
Unclear * 
Social functioning 
and family 
functioning 
Not relevant Not relevant 
Education or 
vocational 
involvement 
Not relevant Not relevant 
Retention Not relevant Not relevant 
Risk behaviour Unclear Not reported 
Other adverse 
effects 
Not relevant Not relevant 
Incomplete 
outcome data 
addressed? 
 "Some of the 120 adolescents failed to 
complete measures either at the 4-month (n=8) 
or at the 7-month (n=7) assessment period. Six 
others missed both follow-up assessments; 
these 6 were removed from subsequent 
analysis, leaving 114 families. We assessed 
whether the values from remaining families 
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appeared to be missing, randomly using the 
missing completely at random (MCAR) statistics 
(...). This statistic (...) provided evidence that the 
values were not missing at random. To avoid 
possible bias from subsequent analyses (i.e., 
listwise deletion) we created estimates, for the 
missing scores. The regression plus random 
residuals MVA module in SPSS provided the 
estimates....." (p. 807-808) 
 
Intent-to-treat sample used (p. 806). 
 
The outcome is given 1 as the study has very 
little missing data. 
Abstinence or 
reduction of drug 
use – biochemical 
test 
Unclear Not reported 
Abstinence or 
reduction of drug 
use – self reported 
estimates 
1 * 
Abstinence or 
reduction of drug 
use – 
psychometric 
scales 
Not relevant Not relevant 
Abstinence or 
reduction of drug 
use – overall 
judgement 
1 * 
Social functioning 
and family 
functioning 
Not relevant Not relevant 
Education or 
vocational 
involvement 
Not relevant Not relevant 
Retention Not relevant Not relevant 
Risk behaviour Unclear Not reported 
Other adverse 
effects 
Not relevant Not relevant 
Free of selective 
reporting? 
 The urinalysis outcome is given 3 as the 
measurement, and thereby data collection is 
made but the results are reported 
inappropriately.  
Outcomes for social functioning and family 
functioning is given 3 as these are mentioned in 
a footnote but not reported explicit in the study. 
Other outcomes are given 1 as they are 
reported carefully. 
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Abstinence or 
reduction of drug 
use – biochemical 
test 
3 "Analyses of the differences in urine screen 
rates over time or between condition differences 
did not approach statistical significance." (p. 
809-810) 
(Note: the numerical outcomes (for the 
individual conditions) are however not reported) 
Abstinence or 
reduction of drug 
use – self reported 
estimates 
1 (see table 3 + French, table 2) 
Abstinence or 
reduction of drug 
use – 
psychometric 
scales 
Not relevant Not relevant 
Abstinence or 
reduction of drug 
use – overall 
judgement 
1 * 
Social functioning 
and family 
functioning 
3 "No statistically significant effects of treatment 
on either the Internalizing or the Externalizing 
Scale of the CBCL in the adolescent or primary 
caregiver family conflict scores were found." (p. 
810) 
(Note: the numerical outcomes (for the 
individual conditions) are however not reported - 
se footnote 2, p. 810) 
Education or 
vocational 
involvement 
Not relevant Not relevant 
Retention Not relevant Not relevant 
Risk behaviour 1 (This measure is reported in French - see Table 
2) 
Other adverse 
effects 
Not relevant Not relevant 
Free of other 
bias? 
1  
A priori protocol? Unclear Not reported 
A priori analysis 
plan? 
Unclear "(…) however, 10 of these completed follow-up 
assessments, and their data were included in all 
analyses as part of the full intention-to-treat 
sample." (p. 806) 
* Denotes that support for judgement is described in the general risk of bias category field above.   
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